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SUMMARY 
Despite overall improvements in breast cancer management, breast cancer continues to 
be a major health challenge worldwide, with high mortality rates. Following initially 
successful therapies, some cells are able to evade the treatment and remain in the body 
at undetectable levels (known as minimal residual disease) and could eventually lead to 
a lethal tumor recurrence. Understanding the nature of this elusive cell population is of 
a great importance in tumor eradication and relapse prevention. Nevertheless, the 
intricate mechanistic details about these processes and the nature of these cells remain 
poorly understood, mainly due to difficulties in obtaining patient material of MRD and 
being able to study them over the course of treatment.  
To characterize MRD in breast cancer, we employed an inducible TetO-MYC/TetO-
Neu/MMTV-rtTA mouse model and primary 3D cultures of mammary organoids that yield 
a correlate of MRD upon oncogene silencing. A combination of immunofluorescence, RNA 
sequencing, lipidomics and metabolomics revealed the unique nature of the residual 
cells. Despite the phenotypic similarity to the normal population, the residual cells 
exhibited a distinct transcriptional profile. This profile was also different when compared 
to the tumor, highlighting the unique properties of the residual cell population. In 
addition, lipid profiles of the residual cells were also distinguished from both normal and 
tumor populations.  
Surprisingly, despite the inactivated oncogenes and seemingly normal phenotype of the 
residual structures, the residual cells bore a metabolic resemblance to tumor cells. They 
retained some tumor metabolic hallmarks, which persevered long after the oncogenes 
were silenced and tumors had regressed. This was demonstrated in our 3D cultures and 
verified in vivo on histological sections and fresh samples of the mammary glands 
following tumor regression. Enhanced glycolysis, the urea cycle and NOS2 activity were 
the most prominent features preserved in the residual cells. As shown in correlation with 
publicly available microarray datasets of patient samples following neoadjuvant 
treatment, these traits could be particularly important in MRD of the basal-like HER2 
positive and HER2 negative breast cancer subtypes. 
In conclusion, our findings suggest vast and profound effects of the changes happening 
over the course of tumor progression, which result in an altered metabolic network even 
in the absence of oncogene signaling, implying the existence of a “metabolic memory” 
probably imprinted through the changes in the epigenetic landscape. This phenomenon, 
particularly its potential driver(s), remains to be investigated. Furthermore, enhanced 
glycolysis, urea cycle and NOS2 activity in the residual cells compared to the normal, 
could provide an opportunity to interfere with MRD, offering the potential of preventing 
tumor recurrences. 
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ZUSAMMENFASSUNG 
Trotz weitreichender Entwicklungen in der Brustkrebsbehandlung, stellt Brustkrebs, mit 
seinen hohen Todesfällen, nach wie vor eine wesentliche gesundheitliche 
Herausforderung auf globaler Ebene dar. Nach zunächst erfolgreicher Therapie schaffen 
es manche Zellen der Behandlung zu entgehen und in nicht detektierbarer Anzahl im 
Körper zu verweilen (minimale Resterkrankung (MRD) genannt). Zu einem späteren 
Zeitpunkt können sie zu einem Wiederauftreten des Tumors mit tödlichen Folgen führen. 
Daher ist es für die Tumorbeseitigung und zur Prävention der Tumorwiederkehr von 
größter Bedeutung das Verhalten dieser schwer detektierbaren Zell-Population zu 
verstehen. Gleichwohl sind die komplizierten Mechanismen dieser Prozesse sowie die 
Eigenschaften dieser Zellen nur unzureichend verstanden. Dies liegt hauptsächlich an 
Schwierigkeiten bei der Beschaffung von Patientengut sowie an den begrenzten 
Möglichkeiten dieses während des gesamten Behandlungsverlaufs zu untersuchen. 
Um MRD im Falle von Brustkrebs zu charakterisieren, verwendeten wir ein induzierbares 
TetO-MYC/TetO-Neu/MMTV-rtTA Mausmodell sowie 3D-Primärzellkulturen von Brust-
Organoiden welche nach Gen-Stilllegung eine Korrelation zu MRD bieten. 
Immunfluoreszenz in Kombination mit RNA-Sequenzierung, Lipidomik und Metabolomik 
offenbarte die einzigartige Natur der residualen Zellen. Trotz der phänotypischen 
Ähnlichkeit zur normalen Population, wiesen die residualen Zellen ein eindeutiges 
Transkriptionsprofil auf. Dieses Profil unterschied sich weiterhin von dem Tumor, was die 
einzigartigen Eigenschaften der residualen Population nochmals unterstreicht. Zusätzlich 
unterschieden sich die Lipid-Profile der residualen Zellen von denen der normalen und 
der Tumorzellen. 
Erstaunlicherweise wiesen die Residualzellen trotz der inaktivierten Onkogene und der 
scheinbar normalen Phänotypen eine metabolische Ähnlichkeit zu Krebszellen auf. So 
behielten die Residualzellen einige metabolische Kennzeichen, die sie lange nach der 
Onkogenhemmung und Turmorregression bewahrten. Dies wurde in unseren 3D-
Kulturen in vivo und anhand von histologischen Schnitten sowie frischen Proben von 
Milchdrüsen nach Tumorregression demonstriert. Eine gesteigerte Glykolyse, der 
Harnstoffzyklus sowie die NOS2-Aktivität waren die auffälligsten Merkmale, die in den 
Residualzellen erhalten blieben. Wie in Korrelation zu öffentlich zugänglichen Microarray-
Datensätzen von Patientenproben nach neoadjuvanter Therapie gezeigt, könnten diese 
Merkmale besonders wichtig für die MRD der basal-ähnlichen HER2-positven und HER2-
negativen Krebssubtypen sein. 
Zusammenfassend weisen unsere Erkenntnisse auf breite und tiefgreifende 
Auswirkungen der Änderungen, die während der Tumorfortschreitung stattfinden, hin. 
Das Ergebnis ist ein abgewandeltes metabolisches Netzwerk, das auch bei Abwesenheit 
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ZUSAMMENFASSUNG 
onkogener Signale bestehen bleibt. Dies wiederum impliziert die Existenz eines 
„Metabolomischen Gedächtnisses“, welches vermutlich durch Änderung der 
epigenetischen Landschaft imprägniert wird. Dieses Phänomen, vor allem sein 
potenzieller Antrieb bzw. seine potenziellen Antriebe müssen noch untersucht werden. 
Weiter kann die gesteigerte Glykolyse, der Harnstoffzyklus und die NOS2-Aktivität der 
residualen Zellen möglicherweise genutzt werden, um in die MRD einzugreifen. Dies 
könnte die Möglichkeit bieten das erneute Auftreten des Tumors zu unterbinden. 
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INTRODUCTION 
 
Cancer is a disease caused by the uncontrolled proliferation of abnormal cells, leading 
to the formation of a malignant mass that invades and destroys the surrounding healthy 
tissue (1). Even though, in its essence, the term “cancer” reflects a simple phenomenon, 
it encompasses a group of heterogeneous ailments with their own etiology, diverse 
features, specific risk factors and different courses of progression and treatment. This 
heterogeneity and immense complexity is what makes cancer a major health problem 
worldwide and a leading cause of death (2). According to the data from 2015, there have 
been 14 million new cases of cancer and 8,7 million of deaths (3) worldwide. Moreover, 
projections predict that the number of new cancer cases and cancer-related deaths will 
increase, due to increase in proportion of the aging population, and also increased 
exposure to environmental risk factors brought about by specific lifestyles. This includes 
unhealthy diet and physical inactivity which leads to a rise in obesity levels, alcohol and 
tobacco consumption, exposure to certain viruses such as human papillomavirus (HPV) 
and hepatitis B (HBV) and C (HCV) viruses (2).  
Despite these concerning statistics, great steps forward have been made in 
understanding cancer in particular on a molecular level, leading to the recognition of 
many different types and subtypes. This has made it possible to identify key molecular 
events and players driving tumor progression in certain subgroups and therefore develop 
more specific drugs. However, due to differences in genetic makeup and great inter- and 
intratumor heterogeneity, efficacy of the drugs and patients’ response to the treatment 
are not universal, imposing the need for better therapeutic options that are tailored for 
specific cases. Better understanding of tumor biology could eventually make this 
possible, along with the development of targeted therapies and pharmacogenomics (4).  
Overall, growing knowledge about risk factors, etiology and molecular biology of certain 
tumor types, earlier detection of the disease and better therapeutic strategies have led 
to improvements in cancer management and a decrease in overall cancer death rates 
(5). This is particularly true for breast, lung, prostate and colorectal cancer (5). 
Nonetheless, challenges still remain, mainly imposed by resistance to therapy, tumor 
recurrence and metastatic disease which remains still incurable, and is a major cause of 
cancer-related deaths. Understanding the elusive and intricate processes behind these 
phenomena is of utmost importance as it gives hope that this frightening disease could 
be managed in a more effective way. This could be by giving more efficient treatments 
and combined therapies that would prevent relapses, be more selective and exert less 
side-effects on the healthy tissues, eventually leading to longer life of cancer patients.   
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INTRODUCTION 
1.1 BREAST CANCER 
Breast cancer is a malignant tumor originating in the mammary glands.  
A simplified depiction of the breast anatomy is given in Figure 1.  
The female breast consists of:  
• 15-20 lobes of glandular tissue divided into 20-40 smaller lobules (containing 
rounded acini of milk-producing cells); 
• small milk ducts connected to the lobules, that gradually join into larger ducts 
and a duct system that opens at the nipple;  
• surrounding adipose and connective tissue (6).  
 
Figure 1: Female breast anatomy. Figure modified from (7) and (8), with permission. Abbreviations 
are explained in the List of Abbreviations. 
The basic functional unit of the mammary gland is the terminal ductal lobular unit 
(TDLU), comprised of a lobule, intralobular and extralobular duct (9). Cuboidal or 
columnar, polarized luminal epithelial cells are localized in an innermost layer around 
the lumen of the healthy ducts and acini, surrounded by an outer layer of myoepithelial 
(basal) cells. These are divided from the surrounding stroma by a basement membrane, 
which serves as an important barrier and dynamic structure composed of extracellular 
matrix proteins (10,11). 
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INTRODUCTION 
Breast cancer arises mostly from abnormal epithelial cells in the lobules (lobular 
carcinoma) or ducts (ductal carcinoma). In rare cases it can also originate from the 
structures of breast stroma (12). Following an oncogenic insult (Figure 2A), cells divide 
uncontrollably, filling up the mammary gland lumen, leading to lobular carcinoma in situ 
(LCIS) or ductal carcinoma in situ (DCIS), which correspond to the earlier stages of 
cancer (Figure 2B). At these earlier stages, the basement membrane stays intact, as 
opposed to invasive and metastatic cancer (Figure 2C,D) in which DCIS or LCIS can 
progress further.  
 
Figure 2: Tumor initiation and progression in breast lobules and ducts. A) Tumor initiation; B) LCIS 
and DCIS; C) Invasive lobular and ductal carcinoma; D) Metastatic lobular and ductal carcinoma. 
Figure modified from (8), with permission. 
Breast cancer is the most frequent cancer for females worldwide, with approximately 2,1 
million new cases per year (13). It is a heterogeneous group of diseases, with more than 
20 different histological types (14) and four intrinsic molecular subtypes (15) (Table 1). 
Invasive ductal carcinoma (IDC) is the most common type of breast cancer, seen in 80% 
of cases (14). Although breast cancer can occur in the male population, it is quite rare, 
accounting for less than 1% of all breast cancer cases (16). 
Advanced diagnostics tools have enabled earlier detection and classification in some 
cases. This has resulted in a better outlook for breast cancer patients, which has also 
been helped by improvements in managing these subtypes by identifying some of the 
key drivers in breast tumorigenesis and developing appropriate therapeutic options. 
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INTRODUCTION 
Knowledge about the implicated oncogenes and pathways paved the way to the 
development of targeted therapies that directly interfere with the oncoproteins of 
interest. Phenomenon known as “oncogene addiction” - where tumor maintenance is 
dependent on the action of a single or a few oncogenes (17), has allowed tailored 
therapies to be developed that inhibit the driver oncogene signaling. 
Table 1: Four intrinsic molecular subtypes of breast cancer and their main general features. The 
table summarizes data reported by (18–22). Abbreviations are explained in the List of 
Abbreviations. 
Molecular subtype 
Receptor 
status 
Ki-67 
status 
Histologic 
grade 
Prognosis Prevalence 
10-year 
recurrence 
risk 
Targeted 
therapy 
Luminal A 
ER+ and/or 
PR+, HER2- 
low 
levels 
low-
grade 
very good ~50-60 %  12,5 %  +  
Luminal B 
ER+ and/or 
PR+, 
HER2+/- 
high 
levels 
high-
grade 
poorer 
DFS 
~40 % 23,4 % + 
Triple 
negative/basal-
like 
triple 
negative/ER, 
PR-, HER2+  
high 
levels 
high-
grade  
poor ~10-30 % 30% +/- 
HER2-enriched 
ER-, PR-, 
HER2+ 
high 
levels 
high-
grade  
poorer 
than 
luminal 
~15-20 %  26,6 %  +  
 
Certain features of different molecular subtypes in breast cancer have been exploited by 
developing drugs that target them specifically (Table 2). However, triple negative breast 
cancer (TNBC), a particularly aggressive subtype, remains a challenge, as it lacks the 
commonly targeted receptors. Even though epidermal growth factor receptor (EGFR) is 
often overexpressed in TNBC, existing therapies targeting EGFR were unsuccessful (23). 
Because of this, it is mainly treated by chemotherapy, and still yields poor outcomes. 
This leads to an urgent need to identify druggable targets such as poly ADP ribose 
polymerase (PARP) which proved successful in clinical trials (23). 
With the exception of the TNBC subtype (where only a small subset of patients responds 
to currently available drugs against EGFR and PARP), targeted therapies show a great 
efficacy in clinical practices, usually leading to fast tumor regression. In breast cancer 
types dependent on estrogen, inhibition of tumor growth is achieved through application 
of selective estrogen receptor modulators (SERM) that obstruct estrogen action or by 
aromatase inhibitors (AI) that block the key enzyme in androgens biosynthesis, leading 
to reduction of estrogen levels (24). The Human epidermal growth factor receptor 2 
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(HER2) is a member of the HER family of transmembrane proteins that respond to 
extracellular ligands by dimerization and transphosphorylation of their intracellular 
domains, activating various signaling pathways in the cell (25). As these pathways are 
also involved in cell proliferation and survival, HER2 serves as a particularly strong 
target. Several therapies have been developed for HER2-enriched tumors (Figure 3) and 
have successfully led to dramatically improved prognoses, increasing the overall survival 
of Her2 positive patients (26). All these efforts led to improvements in breast cancer 
management, which is well reflected in the rise of the 5 year-relative survival rate, which 
currently reaches up to 89,7% (27). This is especially true for developed countries, such 
as the United States, where women who have survived breast cancer represent the 
majority of cancer survivors (28). 
Table 2: Available targeted therapies in breast cancer. The table summarizes data reported by 
(23,24,29). Abbreviations are explained in the List of Abbreviations. 
Breast cancer 
types according to 
receptor status 
Percentage (in all 
breast cancer 
cases) 
Target Available targeted therapies 
ER positive 75 % ER 
SERM (tamoxifen, raloxifene, lasofoxifene),          
AI (anastrozole, letrozole, exemestane) 
HER-2 positive 25-30 % 
HER2; HER 
and EGFR 
pathways 
Recombinant monoclonal antibodies 
(trastuzumab, pertuzumab), dual tyrosine 
kinase inhibitor (lapatinib), conjugated 
monoclonal antibody TDM1 
Triple negative 10-30 % EGFR, PARP 
EGFR TKI, anti-EGFR mAbs (effective for only 
a small subset of breast cancer patients), 
olaparib (the first approved PARP inhibitor) 
 
Despite these successes and encouraging achievements, breast cancer still represents a 
significant health threat, as mortality rates remain high worldwide. According to the 
World Health Organization (WHO) report, more than 500 000 women died from breast 
cancer in 2018 (13). In underdeveloped countries, limited access to health care and 
adequate treatment largely contributes to this problem. However, another major cause 
is tumor heterogeneity and drug resistance, both of which pose a challenge even in the 
most advanced clinical settings.  
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INTRODUCTION 
 
Figure 3: Therapies targeting HER2. A) Trastuzumab inhibits HER2 overexpression effects; B) 
Lapatinib is tyrosine kinase inhibitor interrupting HER2 and EGFR pathways; C) Pertuzumab 
inhibits HER2 dimerization with other HER receptors; D) T-DM1 (Trastuzumab emtansine) is a 
conjugated antibody containing trastuzumab and emtansine which is a cytotoxic agent. Figure 
modified from (30). Abbreviations are explained in the List of Abbreviation. 
Ideally, the therapy of choice should eradicate all of the cancer cells, but this is often 
not the case. Some tumor cells can evade these treatments and survive in the body 
below detectable levels (Figure 4). This small population of surviving cells is referred to 
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INTRODUCTION 
as minimal residual disease and is one of the main hindrances in decreasing the breast 
cancer burden.   
 
Figure 4: Model of ideal treatment compared to actual clinical outcome that leads to tumor 
regression. Left: eradication of all cancer cells by therapy; right: remaining residual cell population 
that can subsequently lead to a relapse. Figure modified from (31). 
1.2 MINIMAL RESIDUAL DISEASE 
The term “minimal residual disease”, first coined in 1980s, refers to the cells that evaded 
or survived therapeutic intervention but are below detectable levels in the body. This 
makes the disease asymptomatic, appearing as though the patients have achieved 
complete remission (32). Conventional diagnostic methods and laboratory tests cannot 
detect the presence of the remaining cells (32). This surviving residual cell population 
poses a great threat as it can subsequently drive tumor recurrence which happens in up 
to 40% of the cases in breast cancer patients (33). A smaller percentage (10-20%) 
comes back as isolated locoregional relapses, while 60-70% appear as metastases in 
distant organs or multiple distant sites (33). Even though patients undergo surgery and 
receive adjuvant therapy in order to minimize the chances of recurrence, many of them 
still relapse and die (32). Recurrences can occur over a period from 2-3 years, when the 
risk is highest (33), up to decades (34) following initially successful therapy.   
1.2.1 The three faces of minimal residual disease 
Minimal residual disease can be present in three different forms (Figure 5): 
• locally found residual cells,  
• circulating tumor cells (CTCs), 
• disseminated tumor cells (DTCs). 
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Figure 5: Three forms of minimal residual disease. A) CTCs; B) DTCs; C) Repopulation of the 
original tumor site; D) MRD can lead to local and regional relapse or metastatic cancer. 
Abbreviations are explained in the List of Abbreviation. 
Locally present residual cells could be cells that were not successfully removed by 
surgery. This could be the case after breast-conserving surgery when margins were 
positive or too close; if the tumor was multi-focal or if the cancer cells already invaded 
deeply into pectoral fascia. However, even a whole mastectomy does not completely 
remove this risk, as at the time of surgery tumor cells could have been in the chest wall 
or already reached the regional lymph nodes and metastasized. Above mentioned factors 
and some other parameters (age, tumor size, grade, molecular subtype) are associated 
with the local recurrence (35). According to a newly proposed concept, local relapse 
could be also caused by the disseminated cells that repopulate the original site (36). 
Circulating tumor cells are breast cancer cells found in the bloodstream. They shed away 
initially from the primary tumor or metastasize at later stages and enter the circulatory 
system (37). Even though a large amount of these cells are present in the patient body, 
around 106 CTCs per gram of primary tumor are detached and entering circulation on a 
daily basis (38). It is very difficult to detect them in the blood, because they are present 
in a very low number in the circulation, as the majority are eliminated by the action of 
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the immune system (39). When these cells manage to invade and infiltrate into other 
tissues, they are termed as DTCs. However, from the beginning of their travel through 
the circulation, up to the homing to other distant sites, cells escaping the primary tumor 
are coping with numerous stress conditions. Research in animal models showed that only 
a small fraction of these cells (2,5%) are able to survive and adapt to the new tissue 
microenvironment, while 0,01% could eventually trigger the formation of macro-
metastases (37).  
Disseminated tumor cells are found at distant sites and invade different organs. The 
most common site of metastases in breast cancer patients are bone and visceral organs 
such as the lungs, brain and liver (40). Metastases are incurable and “breast cancer thus 
remains the most common cause of cancer-related death in women.” (33). 
1.2.2 Mechanisms behind minimal residual disease 
What are the selective advantages of residual cells? What gives them the ability to 
escape and evade treatment? Mechanisms driving MRD and subsequent tumor relapse 
remain largely unknown.  
Different hypotheses have been established to attempt to explain the survival of these 
cells (Figure 6).  
One of the proposed mechanisms of survival assumes the existence of “cancer stem 
cells” (CSCs) that are more resilient to therapy through drug-efflux pumps, epithelial-
mesenchymal transition (EMT), quiescence and enhanced resistance to pro-apoptotic 
signals (41). Residual cells often express ATP-binding cassette (ABC) transporters (42) 
that can pump out many different compounds, which they use to reduce intracellular 
drug levels. Tumor cells can survive even targeted therapy, as other mutations can occur 
in the gene encoding the targeted oncoprotein, or alternative pathways emerge to 
circumvent therapy and enable survival (43). These secondary mutations can lead to 
substitution of amino acids in the kinase domain of these proteins, changing the 
structure of the targeted region and thus preventing the binding of the original drug, 
such as EGFR inhibitors. Another mechanism of resistance involves amplification of the 
target gene, such as dihydrofolate reductase gene (DHFR) which results in the 
production of its oncoproteins in an amount larger than are able to be targeted by 
methotrexate (44). Activation of new pathways are nicely illustrated by the example of 
acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors through the 
activation of the insulin-like growth factor 1 receptor (IGF1R) pathway (43). The role of 
epigenetic mechanisms in resistance is also being explored, as many epigenetic changes 
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take place in tumor cells, allowing them to evolve quickly and evade the therapy (45). 
For instance, it has been demonstrated that demethylation of ATP-binding cassette 
subfamily C member 1 gene (ABCC1) in cancer cell lines reduces intracellular drug levels 
(44). Polyploidy of residual cells has also been recently shown to play a role in 
chemoresistance and initiation of tumors in vivo. Namely, these cells avoid 
chemotherapy aimed at proliferating cells by infrequent cell divisions and they have also 
evolved budding and bursting as a special mechanism to produce their progeny which is 
more resilient to stressful conditions (46).  
 
Figure 6: Mechanisms enabling survival of residual cells and tumor recurrence. A) Heterogeneity 
and adaptations in the primary tumor; B) Residual cells in dormancy; C) Awakening and 
progression to tumor recurrence. Abbreviations are explained in the List of Abbreviations. 
Other studies have shown that residual cells survive through rewiring of their metabolic 
networks and switching to programs such as autophagy (47). For instance, resistance to 
a widely used chemotherapeutic drug, Gemcitabine was explored in hormone-
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independent prostate cancer (HIPC) cell lines, where it was demonstrated that 
autophagy decreased sensitivity to the drug (48). 
Studies in acute lymphoblastic leukemia (ALL) showed that dissociation of dormant cells 
from their environment make them exit this state, becoming proliferative and sensitive 
to therapy (49). Thus, a significant role in influencing the response of tumor cells to the 
chosen therapy is attributed to the tumor microenvironment (TME), which comprises a 
multitude of factors including: levels of available nutrients and oxygen, interactions with 
neighboring cells, presence of immune cells, proximity of blood vessels and different 
factors secreted from the environment and many others. For instance, certain factors 
secreted by stromal cells, such as the hepatocyte growth factor (HGF) can help tumor 
cells survive the drug treatment, as shown in case of BRAF-mutant melanoma, where 
stromal HGF re-activated MAPK and PI(3)K-AKT signaling pathways, leading to 
resistance to RAF inhibition (50). Microenvironmental conditions can induce multidrug 
resistance through different mechanisms, for instance by increasing expression of the 
epidermal growth factor-like domain 7 (EGFL7) protein and the amount of multi-drug 
resistance P-glycoprotein under hypoxia in non-small-cell lung carcinoma (NSCLC) cells 
(51). This can be also achieved by switching metabolic flux towards enhanced glycolysis 
to obtain energy, as shown in human breast and ovarian cancer cells (52). Through 
modulating the microenvironment and inducing immunosuppression (53), residual cells 
can escape from immune-surveillance, survive and eventually drive tumor recurrence. 
“Self-seeding” is a paradigm by Comen and Norton (36) which proposes that cancer cells 
have the ability to move multi-directionally. Hence, they are competent to infiltrate not 
only distant and regional sites, but also return back to the primary tumor site. This was 
already experimentally shown in models of some carcinomas, such as breast, colon and 
melanoma (54). Disseminated cells are attracted by tissue specific factors, inflammatory 
cytokines, leaky vasculature and microenvironmental conditions that enabled their 
migration in the first place (36). This view also tries to explain the existence of small, 
but aggressive cancers, as even such barely detectable tumors can cause metastases as 
seen in many human malignancies (55). Thus, the cells coming from these cancers could 
be poor self-seeders, but good distant seeders (36). It would be of utmost importance 
to reveal specific gene signature of cells able to self-seed, as well as to populate other 
sites, as this could open a new therapeutic window aimed at the seeding ability of tumor 
cells. 
The “seed and soil” hypothesis, originally proposed by Paget (56), attempts to explain 
the preference of CTCs/DTCs for certain organs. It assumes that these cells cannot 
survive microenvironmental conditions in other tissues. What directs these cells to the 
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preferred sites of metastasis? There have been reports that CTCs express certain 
proteins and chemokine receptors that drive them to preferred sites, while chemokines 
produced at the specific site of their dissemination also play a role in their survival in the 
newly invaded environment (37).  
Although the gain of invasive, metastatic properties was before considered as a later 
event in tumor progression, a study in a mouse model of HER2-driven cancer found that 
about 80% of metastases were a result of the early dissemination (57). Early 
dissemination has been also seen in a mouse model of pancreatic cancer. Lineage tracing 
showed that some cells from pre-invasive pancreatic intraepithelial neoplasia (PanIN) 
lesions went through EMT acquiring a mesenchymal phenotype and stem cell features 
and disseminated into the liver (58). This ability of cells to migrate even in the early 
stages of primary tumor progression can explain tumor recurrences after removal of 
primary tumors that were small in size and appeared non-invasive, as well as CUP 
syndrome (cancer of unknown primary) which happens in 3-5% of all cancer cases (59).  
The above-mentioned concepts aim to elucidate survival mechanisms of residual cells 
and have been probed in experimental models. However, they also lack to explain all 
the observed phenomena concerning MRD and disease progression as they are observed 
in the clinic (Table 3). 
Considering tumor heterogeneity and the influence of tumor microenvironment, as well 
as the whole organism on a systemic level, it is most likely that all of the proposed 
mechanisms provide a plausible rationale in a specific context. Namely, while some of 
the proposed concepts might be true for certain populations of residual cells within a 
specific tumor subtype and under particular microenvironmental conditions, they might 
not be applicable for another. In addition, multiple mechanisms could be at work at the 
same time in a given tumor.  
Nevertheless, one apparently universal feature of residual cells seems to be their 
dormant state. Before progressing to a clinically detectable tumor relapse/metastasis, 
residual cells can stay in dormancy for decades, such as is the case with dormant breast 
cancer cells in bone marrow (60).  
 
 
 14 
 
INTRODUCTION 
Table 3: Some proposed concepts aiming to explain the mechanisms behind MRD. Abbreviations 
are explained in the List of Abbreviations. 
Concept Pros + Cons - 
Drug insensitivity 
resistance to initially 
successful therapy, e.g. 
erlotinib/gefitinib in lung 
cancer patients (61) 
subset of patients with relapse 
responding to repeated initial 
treatment (61) 
Different levels of 
cell damage by the 
drug caused by its 
partial delivery 
subset of patients with 
relapse responding to 
repeated initial treatment 
(61) 
mouse model for BRCA1-deficient 
breast cancer showed surviving 
cells despite repeated treatments 
(61) 
Existence of cancer 
stem cells which are 
more resistant to 
therapy 
CSCs are found in small 
numbers in the bulk of 
tumor, and only a small 
subset of cells exhibit the 
ability to cause tumor 
development when 
transplanted into 
immunocompromised mice; 
CSCs possess escape 
mechanisms such as up-
regulation of drug efflux 
pumps, increased DNA 
repair, quiescence, evasion 
of apoptosis, EMT; CSC 
model explains some 
cancers such as mouse 
acute myeloid leukemias 
(61) 
not tested in many cancers and 
some of these features are also 
found in some other cancer 
resistant cells that are not 
considered CSC (61) according to 
the current criteria (established 
markers, tumor initiation); 
question whether transplanted 
CSCs can recapitulate the original 
tumor heterogeneity from which 
they come still remains, as (this is 
typically tested based only on a 
few surface markers); lack of 
interaction with immune system in 
immune-compromised mouse 
models; the CSC model potentially 
rationalizes a subset of cancers, 
not all (62) 
Protection from 
tumor 
microenvironment 
interaction of cells with the 
TME can be beneficial for 
their survival, e.g. secretion 
of HGF from surrounding 
stromal cells saves cancer 
cells from therapy (61) 
even though the tumor cells are 
able to modulate TME to favor their 
growth and survival, they can also 
be eliminated through the action of 
the immune system or hostile 
conditions in the surrounding 
stroma (62) 
Clonal evolution 
could explain tumor 
heterogeneity and existence 
of several clones by gradual 
acquisition of genomic and 
epigenetic alterations (63) 
some new models have challenged 
the idea of gradual changes in 
cancer cells - later mutations seem 
to play only a small part in 
providing selective advantage to 
tumor cells (64) 
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1.2.3 Tumor dormancy 
Tumor dormancy is a phenomenon observed in clinical practices which refers to a 
temporary halt in tumor progression, with a prolonged latency (this results in a disease-
free survival period after therapy and is manifested by remission of the primary tumor 
as well as absence of clinically detectable tumor recurrence) (65). Dormancy can extend 
over a long period of time followed by a relapse. In breast or prostate cancer patients, 
the recurrence can happen decades after initial treatment (66). Late recurrences have 
been also frequently observed in melanoma and renal cell carcinomas, 10-15 years after 
the treatment (67). 
Tumor dormancy can refer to both tumor mass dormancy and cellular dormancy. Tumor 
mass dormancy happens due to the factors that constrain tumor expansion despite cell 
proliferation. The balance between cell division and apoptosis is achieved through the 
conditions in the microenvironment, be it the lack of nutrients and oxygen or immune 
system responses that efficiently eliminate the tumor cells (68). Another reason for 
tumor dormancy is a true mitotic arrest in the tumor cells, a phenomenon known as 
cellular dormancy (69). MRD is likely to be a result of both processes. 
The drivers of cellular dormancy and the molecular entities that push cells in and out of 
dormancy are not yet fully identified. One of the mechanisms driving cellular dormancy 
could be senescence, a cellular program that becomes activated as a way to cope against 
oncogenic stress (66) in normal cells. Even though senescence signatures have been 
seen in neoplastic cells, it is not clear if this phenomenon could push cells towards 
relapse, since senescence was considered to be an irreversible process. However, it has 
recently been demonstrated that the process of senescence could also be reversed, 
leaving the possibility for its potential role in tumor recurrence (70).  
Another more plausible mechanism behind the dormancy could be quiescence. This is 
characterized by arrest in GO-G1 phase, a state in which most adult cells are and a 
reversible feature of stem cells, or cells exposed to unfavorable microenvironmental 
conditions and temporary constraints (66).  
Features of senescent and quiescent cells are summarized in Table 4. 
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Table 4: Differences between quiescence and senescence. Abbreviations are explained in the List 
of Abbreviations. 
Dormancy program Quiescence Senescence 
Cause 
environmental stress and nutrient 
limitation (71) 
replicative or oncogenic stress 
(71) 
Metabolism 
in general, low activity, with some 
exceptions such as quiescent primary 
human fibroblasts (71) 
normal metabolic activity (71) 
Reversibility reversible (71) mechanism-dependent (71) 
Some studied 
markers 
cyclin D1 downregulation (72); p27 
and p21 upregulated or stabilized 
(73,74); CAF-1 strongly 
downregulated (75) 
upregulation of p16 and 
senescence associated GLB1; p53 
activation; senescence-associated 
heterochromatic foci (71) 
1.2.4 Detection of minimal residual disease 
In leukemia, certain markers of MRD have been established and some sensitive 
molecular tools have been developed enabling its detection through blood sampling. 
However, in solid tumors this is not the case. Lack of standardized methods and markers 
for reliable detection of MRD currently make it largely undetectable. To overcome the 
risk of residual disease and relapse, the majority of patients receive adjuvant therapy, 
but not all of the patients benefit from it (76) and some treatments are also associated 
with toxicity (77).  
There have been some improvements in detection of MRD through isolation of CTCs and 
DTCs, although their abundance still represents a great hurdle. In breast cancer the ratio 
is 1 tumor cell in the background of 106 to 107 mononuclear cells (78). Still, a recent 
study by Beaver et al. (79) offers the exciting hope that MRD could be routinely 
monitored through plasma tumor DNA (ptDNA) which, albeit present in a very small 
fraction, can be detected with high specificity and sensitivity by droplet digital PCR 
(ddPCR) (80). Even though the method was applied in preliminary study on patients 
bearing PI3KCA mutations, it holds a great promise and hope for monitoring MRD. 
1.2.5 Importance of studying minimal residual disease 
MRD poses a great threat as remaining cells can lead to tumor recurrence in a form of 
local and regional relapse, or a distant metastasis. It is estimated, in the case of breast 
cancer, that around 30% of women diagnosed with the localized tumor (which 
corresponds to the earlier stages of the disease) and 75% of patients with lymph node 
involvement will eventually relapse (81). These recurrent tumors can be more aggressive 
and non-responsive to initial therapies, making these relapses life-threatening (82). This 
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highlights the importance of studying and understanding features of MRD in order to 
prevent recurrence by eradicating residual cells or keeping them dormant, following the 
patients' status, individualizing the treatments and choosing the best therapeutic options 
available. 
In order to survive, tumor cells need to adapt to oncogene activity, new energy demands, 
constantly changing or new microenvironmental conditions. For this they need to adjust 
and rewire their metabolism all the time during the course of tumor induction and 
treatment. In this regard, identifying metabolic dependencies in residual cells and 
specific metabolic switches they rely on could reveal potential therapeutic targets and 
bring novel opportunities in the prevention and delay of tumor recurrence.  
1.3 TARGETING CANCER METABOLISM – A NEW THERAPEUTIC 
OPPORTUNITY? 
Since the pioneering work of Otto Warburg (83), metabolism has been explored in the 
context of cancer, as proliferating cells need to rewire their metabolism in order to meet 
their energy needs. A specialized cancer cell metabolism also ensures the production of 
sufficient building blocks for biomass increase and needs to respond to changing 
conditions and environmental challenges.  
1.3.1 Altered metabolism as a hallmark of cancer  
In their seminal review, Hanahan and Weinberg introduced the concept of cancer 
hallmarks (84), to better describe the main features that are crucial in the maintenance 
of a malignant phenotype. This attempt aimed to reduce the immense complexity of 
cancer when it comes to molecular heterogeneity of different subtypes/tissues and 
highlighted the most prominent phenotypic, biochemical and cellular interaction traits 
that distinguish a cancer tissue from normal cells. These properties are shared between 
many distinct cancer types, as the core molecular machinery of different mammalian 
cells types regulating these features is, in its essence, the same. Originally proposed 
cancer hallmarks were: “self-sufficiency in growth signals, insensitivity to growth-
inhibitory (antigrowth) signals, evasion of programmed cell death (apoptosis), limitless 
replicative potential, sustained angiogenesis and tissue invasion and metastasis” (84). 
As the body of knowledge on cancer grew, these hallmarks have been revisited and 
extended to several novel characteristics such as: tumor-promoting inflammation, 
evasion of immune response, genome instability and dysregulated cellular energetics 
(85). Changes in cellular energetics proved widespread in cancer. Although originally 
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thought of as a mere consequence of active proliferation-supporting oncogenic 
pathways, new discoveries of activating mutations in certain metabolic enzymes show 
that metabolic changes can initiate oncogenesis (86). Nowadays, altered metabolism 
has found its place among the accepted and well-studied cancer phenomena, 
establishing itself as one of the hallmarks of cancer, tightly interconnected with all the 
other processes that are taking place in a neoplastic cell (Figure 7).    
 
Figure 7: Metabolism as one of the hallmarks of cancer. Abbreviations are explained in the List of 
Abbreviations. Figure modified from (85,87,88), with permission. 
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Some of the examples of these relations are also seen from Figure 7. Namely, 
proliferation requires energy and material for biosynthesis, which is provided through 
rewiring of metabolic pathways that would meet this demand. Defects in p53 that enable 
enhanced replication also exhibit effects on energy metabolism, such as inhibition of 
oxidative phosphorylation (OXPHOS) and upregulation of glycolysis. Modifications of 
glycan structures in cancer promote cancer-related inflammation that is important in 
shaping the microenvironment and driving cancer progression. Perturbed glycosylation 
enables the evasion of immune response and promotes angiogenesis (growth of blood 
vessels for supplying tumor with oxygen and nutrients). Pathological levels of some 
metabolites such as fumarate and succinate can affect the activity of certain enzymes 
such as prolyl 4-hydroxylases, important in sensing cellular O2. This can induce hypoxia, 
which affects cell adhesion, facilitating detachment and metastasis. Switch to glycolysis 
render the cancer cells independent of O2, helping them evade tumor growth 
suppression. Excreted lactate enables the evasion of immune response.  
 
Pavlova and Thompson further define six hallmarks of altered metabolism in cancer cells. 
These are: 
• “… deregulated uptake of glucose and amino acids, 
• use of opportunistic modes of nutrient acquisition, 
• use of glycolysis/tricarboxylic acid (TCA) cycle intermediates for biosynthesis 
and NADPH production, 
• increased demand for nitrogen, 
• alterations in metabolite-driven gene regulation, and 
• metabolic interactions with the microenvironment”. (86) 
Each of the above-mentioned six hallmarks enable metabolic adaptations of cancer cells 
and their survival, which results in the tumor growth, progression and invasion. 
1.3.1.1 Deregulation in the uptake of nutrients 
While division of normal cells and their uptake of metabolites is regulated by growth 
factors, proliferation of cancer cells is enabled through deregulation of signaling 
pathways that renders them independent (89). Nutrients might be scarce, but tumor 
cells are still able to find the means to use them and satisfy their demands by engaging 
alternative pathways. To meet the demands of proliferation, cancer cells (as well as 
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normal mammalian proliferating cells) display anabolic metabolism (89). As glucose and 
glutamine are the main components supporting biosynthesis and maintaining cellular 
redox homeostasis, their uptake is particularly increased; however, many other 
metabolites such as methionine, cysteine, choline, essential fatty acids and 
micronutrients, play various roles in tumor maintenance and progression and their 
function is yet to be understood (86). While glucose is the main molecule for catabolism 
and anabolism of carbohydrates, glutamine is used for de novo synthesis of proteins and 
nucleotides or non-essential amino acids via glutamate (90). Glutamate can enter the 
TCA cycle as -ketoglutarate and thus support OXPHOS and lipid biosynthesis, generate 
NADPH and replenish intermediates (90). Through conversion into glutathione, 
glutamate also plays role in dealing with the oxidative stress (90). Since glutamine plays 
a role in so many processes supporting cancer cells, its uptake is particularly increased 
in many cancers, which is often termed “glutamine addiction”. 
1.3.1.2 Acquisition of nutrients by engaging alternative opportunistic pathways 
As tumor cells proliferate and the growing tumor mass gets further away from the blood 
vessels, supply with oxygen and nutrients might become critical. Cancer cells also 
experience hypoxia and nutrient scarcity in the new microenvironment where they 
metastasize to. Certain therapies, modulation in the diet, calorie restriction and changes 
on the systemic level in the organism can lead to a lack of certain compounds important 
in tumor metabolism. In order to survive starvation periods and to overcome these 
unfavorable conditions, cancer cells engage alternative mechanisms that enable them to 
seize the necessary material and energy from different, normally unexpected sources. 
These opportunistic modes are illustrated by micropinocytosis of extracellular 
macromolecules and their further degradation, entosis of entire cells, phagocytosis of 
apoptotic bodies and self-catabolism through autophagy (86). Cancer cells also engage 
both arms of pentose phosphate pathway (PPP) – oxidative (used by normal cells) and 
non-oxidative, to ensure components for nucleotides when nutrients are scarce. Further, 
cancer cells manage oxidative stress and induce angiogenesis (91), building a route for 
obtaining their supplies, which leads to further tumor growth.  In order to ensure lipid 
supply, they also often enhance de novo fatty acid synthesis (91). Another pathway 
frequently increased to provide material for biosynthesis and energy is fatty acid 
oxidation (FAO) that yields acetyl CoA, NADH, FADH and ATP (91). This whole spectrum 
of adaptations and diverse metabolic solution is made possible through the action of 
certain oncogenes and their impact on different cellular processes such as actin 
cytoskeleton remodeling or capability of cells to invade the cytoplasm of other 
neighboring cells (86). 
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1.3.1.3 Generation of important intermediates through engagement of glycolysis and 
TCA cycle 
While non-proliferating, differentiated cells switch to enhanced lactate production only 
in anaerobic conditions, cancer cell increase lactate levels irrespective of the O2 
availability which is a phenomenon known as the Warburg effect or aerobic glycolysis 
(89). Even though less effective in terms of energy production, proliferative cancer cells 
favor this metabolic pathway probably because ATP itself is not a limiting factor most of 
the time and the cancer cells’ need for reducing equivalents and building blocks 
originating from glycolytic intermediates overcomes their need for a greater ATP yield 
(89). In order to compensate for the lower efficacy of ATP production, cancer cells 
overexpress glucose transporters to increase glucose uptake (91). Overexpression is 
also seen in many glycolytic enzymes. In addition, cancer cells often engage usage of 
alternative enzyme isoforms, such as pyruvate kinase muscle isozyme M2 (PKM2), 
embryonic isoform of pyruvate kinase which is frequently expressed and responsible for 
shunting glycolytic metabolites for biosynthesis of glycine and serine (83). Metabolic 
intermediates coming from glycolysis are used for anabolic processes such as 
biosynthesis of nucleotides, amino-acids and biological macromolecules. Shunting 
metabolites to the PPP also results in production of NADPH which is the major reducing 
agent used in maintenance of cellular redox homeostasis (91). 
Besides ensuring a faster metabolic rate and proliferation, glycolysis can also provide a 
fuel for mitochondrial OXPHOS through excess lactate (89). Lactate secreted in the 
microenvironment could be consumed by the cancer cells that are near blood vessels 
and have oxidative metabolism (83). Contrary to the misconception that cancer cells do 
not use mitochondrial OXPHOS, emerging evidence shows that a significant portion of 
ATP is being produced through this pathway (92) – in some cancer cell lines 50 to 70% 
(83). In other cell lines, only 10% of ATP is produced this way (83) and mitochondrial 
enzymes are dominantly utilized for generating precursors that would be used in 
biosynthetic processes (92). This is done via the TCA cycle which provides intermediates 
that are important for biosynthesis, such as: oxaloacetate that generates aspartate 
further involved in pyrimidine synthesis, citrate for lipid biosynthesis and acetylation and 
α-ketoglutarate for biosynthesis of amino acids, nucleotides, hexosamines and 
glutathione (93). In addition, enhanced mitochondrial activity ensures control over Ca2+ 
concentration and overall cellular redox homeostasis (91). Increased glucose uptake and 
glycolysis, as well as glucose carbon flux into anabolic pathways require functional 
mitochondria. This increase is often triggered through activation of the PI3K/Akt pathway 
that is a very frequent event in human cancers (92). 
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1.3.1.4 Increased requirement for nitrogen 
Besides carbon, cancer cells exhibit an increased requirement for nitrogen for their 
biosynthetic processes. Nitrogen is released when amino acids are broken down, as a 
result of protein catabolism. The main source of reduced nitrogen is glutamine, which is 
also rate-limiting factor, since it is required for progression of the cell cycle and utilized 
in the biosynthesis of nucleotides and non-essential amino acids (86). Nitrogen in the 
cell is often present in the form of ammonia, which was recently discovered to be more 
than just a waste product. Namely, breast cancer cells are able to recycle ammonia into 
central amino acid metabolism, supporting the growth of tumor biomass (94). The 
interest in the role of nitrogen is growing and, while alterations in nitrogen metabolism 
in cancer are still not largely explored, recent studies highlight its importance for cancer 
progression, mainly through production of polyamines (86) or dysregulation in urea cycle 
enzymes (95). The latter has been found to correlate with tumor invasiveness and 
reduced survival of the patients (95). 
1.3.1.5 Changes in gene expression through metabolic networks 
Metabolic reprogramming is a result of oncogenic signaling, but at the same time it can 
drive oncogenic changes, mainly through an action of regulatory enzymes that can 
further shape the cell’s epigenetic profile and thus affect gene expression (86). Some of 
the known metabolites involved in epigenetic alterations are (86):  
• cytosolic acetyl-CoA – has a role in histone acetylation, as a substrate of 
histone acetylases that renders the genome more accessible for 
transcriptional enzymes; 
• crotonyl-CoA – a substrate of p300 histone acetyltransferase that activates 
gene expression; 
• S-adenosylmethionine (SAM) – has a role in methylation, as a donor of methyl 
groups; 
• NAD+ – has a role in de-acetylation of histones and non-histone proteins, as 
a cofactor of sirtuins (class of deacetylases); 
• α-ketoglutarate – has a role in post-translational modifications, through α-
ketoglutarate-dependent dioxygenases; 
• succinate and fumarate – have an inhibitory effect on α-ketoglutarate-
dependent dioxygenases. 
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1.3.1.6 Metabolic reprogramming through dynamic interaction with the tumor 
microenvironment 
Tumor cells have the ability to change their microenvironment and use it to meet their 
needs, fueling the tumor growth. For instance, they can ensure survival through this 
type of “metabolic symbiosis” by consuming the products of metabolically altered 
stroma. Tumor cells exhibit effects on normal neighboring cells, surrounding stromal 
cells and vasculature, as well as the components of the immune system by 
reprogramming them through secretion of growth factors and dynamic changes of the 
extracellular matrix (ECM) (86). A well-known consequence of an increased glucose and 
glutamine uptake and lactate secretion by cancer cells is the acidification of the 
microenvironment that results in immunosuppression, generation of the new blood 
vessels (angiogenesis) and tumor invasion (86). Another example of microenvironmental 
effects on the tumor concerns stromal cells that had lost caveolin-1 (CAV1); these cells 
enhance glycolysis and secrete the metabolites that cancer cells consume as a fuel for 
their mitochondrial metabolism, which is a phenomenon known as a “reverse Warburg 
effect” (96). Similarly, molecules secreted from cancer associated fibroblasts (CAFs) as 
well as physical barriers of a rich stroma in pancreatic ductal adenocarcinoma (PDAC) 
contribute to chemoresistance (97). 
The relationship between cancer cells and their environment is bidirectional. Metabolic 
stress can induce dormancy in cancer cells in different ways: through chronic hypoxia 
(98), cell cannibalism (99) and increased activity of certain pathways that enhance 
compensatory metabolic routes (100). This enables the survival in a hostile environment. 
Hypoxic conditions, through activating hypoxia-inducible factor 1-alpha (HIF1-α), can 
also lead to EMT. EMT results in the loss of polarity and cell-cell adhesion, giving the 
tumor invasive properties (101). Conditions in their microenvironment thus also affect 
tumor cells, challenging them to find the best metabolic solution, shaping their metabolic 
network (86). 
Previously described metabolic changes – from increased nutrient uptake, over 
engagement of opportunistic pathways, generation of important intermediates through 
upregulation of key pathways, and metabolic crosstalk with the environment reflect a 
metabolic plasticity of tumor cells. Extensive metabolic reprogramming that takes part 
in cancer cells gives them a selective advantage and enables their survival in harsh 
environmental conditions, eventually driving tumor progression through invasion of 
surrounding tissue and metastasis. 
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1.3.2 Metabolic reprogramming in cancer – more than just an epiphenomenon 
of oncogenic signaling and uncontrolled proliferation? 
Traditionally, cancer has been thought of as a disorder of aberrant, uncontrolled 
proliferation. In addition, as the role of altered metabolic pathways behind many 
oncogenic processes is becoming apparent, this view is expanding and metabolic aspects 
of this disease start to receive attention (83).  
Cancer metabolism is characterized by increased glucose uptake and glycolysis, lactate 
production and export, enhanced PPP, upregulated fatty acid synthesis and lipid 
metabolism, higher glutamine uptake and glutaminolysis, mitochondrial biogenesis, FAO 
increase, alterations in the TCA cycle, reactions in electron-transport chain (ETC) and an 
increase in overall anabolic processes for generating energy and supporting biomass 
production. A global metabolic landscape of cancer cells is illustrated in Figure 8. 
Overexpressed oncogenes (gain of function) or missing tumor suppressors (loss of 
function) affect not only cell cycle/proliferation, but also induce changes in metabolism 
through aberrant signaling (Figure 9). For instance, MYC, HIF-1α and AKT upregulate 
the expression of key glycolytic enzymes enhancing glycolysis, while p53 exhibits the 
opposite effect by inhibiting the expression of glucose transporters. 
V-myc avian myelocytomatosis viral oncogene homolog (c-MYC or MYC) is a particularly 
important proto-oncogene, a master regulator of metabolism. This gene encodes a 
transcription factor (TF) which, through regulation of microRNAs (miRNAs) and 
thousands of genes, controls many cellular processes, integrating them with cellular 
metabolism (102). Besides driving cell proliferation, oncogenic MYC shapes the cancer 
metabolic network by increasing glucose uptake, glycolysis and mitochondrial 
biogenesis, glutaminolysis and other anabolic pathways (Figure 10). The MYC protein is 
also involved in sensing the cells nutrient status and response to hypoxic conditions, as 
hypoxia reduces its levels, turning the switch from mitochondrial metabolism towards 
glycolysis (102). 
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Figure 8: Global metabolic landscape of cancer cell with key metabolic changes summarized. Figure 
modified from (91). Abbreviations are explained in the List of Abbreviations. 
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Figure 9: Changes in central carbon metabolism resulting from dysregulated oncogenes (AKT, 
MYC, HIF) and tumor suppressors (p53). Activation of certain enzymes in indicated in arrows, 
inhibition in lines. Figure modified from (83). Abbreviations explained in the List of Abbreviations. 
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Figure 10: Metabolic pathways under regulation of MYC in cancer metabolism. Figure modified 
from (103). Abbreviations are explained in the List of Abbreviations. 
Nevertheless, cancer metabolism is not just an epiphenomenon, a result of altered gene 
expression and aberrant oncogenic pathways, but an active player in oncogenesis (104). 
Metabolites are substrates or cofactors of enzymes catalyzing chemical modifications of 
chromatin. Changes in the abundance of cellular metabolites also affect nutrient-
sensitive posttranslational modifications (104). Oncometabolites, such as 2-
hydroxyglutarate (2HG), change gene expression through their effect on chromatin 
organization (104). The role of altered metabolic pathways and effect of changes in 
abundance of metabolites in modulating and shaping the cells’ epigenetic profile is being 
acknowledged and intensively explored. Discovery of oncometabolites resulting from 
mutations in genes encoding enzymes in some cancer types such as glioma, 
demonstrated the active role of altered metabolic pathways in tumorigenesis and cancer 
progression. One such example are mutations in isocitrate dehydrogenases (IDH1 and 
IDH2). In normal cells, normal variants of IDH1 and IDH2 catalyze reactions producing 
NADPH and α-ketoglutarate, which have a prominent role in many metabolic processes. 
Instead of α-ketoglutarate (α-KG), mutant forms of IDH1 and IDH2 catalyze the reaction 
that converts it to its structural analog 2-hydroxyglutarate (2HG) which is only present 
in low concentrations in normal cells (below detection), while it accumulates in tumor 
cells (104). 2HG is considered an oncometabolite because it binds to the enzymes that 
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normally require α-KG as a cofactor and thus inhibits their action. Since many of these 
enzymes are involved in shaping an epigenetic landscape, 2HG drives epigenetic changes 
through inhibition of Jumonji-C domain histone demethylases (JHDMs) and TET (Ten-
eleven translocation) enzymes involved in DNA demethylation (104). A similar 
phenomenon is seen in other cancer types where mutations in succinate dehydrogenase 
(SDH) and fumarate hydratase (FH) lead to the pathological accumulation of these two 
metabolites. Fumarate and succinate thus become oncometabolites that also inhibit α-
KG-dependent enzymes, further driving a range of other effects such as promoting HIF1 
action and causing epigenetic alterations (104). 
Products of metabolism previously considered to be a cellular toxic waste, keep emerging 
as players in tumor progression. One of them is ammonia, recently shown to support 
tumor growth in breast cancer (94). Lactate is another metabolite that plays an 
important part in tumor progression, mainly through inducing changes in the tumor 
microenvironment through acidification or serving as a fuel for a subset of cancer cells 
that appear to be addicted to mitochondrial metabolism (104). 
Besides glycolysis and mitochondrial metabolism, which have been pathways of great 
interest in cancer research since the discovery of the Warburg effect, other metabolic 
pathways and their implications in tumor maintenance are being comprehensively 
explored. One such example is one-carbon metabolism which is connected with the main 
anabolic pathways and, along with affecting metabolic processes and redox homeostasis, 
has been linked to epigenetic changes in tumor cells (104). 
Epigenetic modifications such as methylation and acetylation are influenced by metabolic 
changes (Figure 11), as the abundance of methyl donors, glucose or acetyl CoA can have 
an effect on their regulation and thus impact gene expression (104). Similarly, altered 
expression levels of deacetylases which are dependent on NAD+ (sirtuins) have been 
demonstrated in many diseases, including cancer where loss of certain sirtuins promoted 
neoplastic transformation through various mechanisms. Low levels of certain sirtuins 
have been associated with increased DNA damage or ineffective DNA repair. In 
particular, sirtuin 1 (SIRT1) downregulation has been found in breast cancer, especially 
associated with breast cancer 1, early onset gene (BRCA1) mutations (104).  
While oncogenic signaling affects and regulates many metabolic pathways, the opposite 
is also true. Dynamic exchange between the cancer cell and their microenvironment, 
their exposure to external cues and factors of the surrounding stroma and physiological 
conditions affecting the cellular metabolic state result in the changes of metabolite 
abundance. This subsequently alters the cells epigenetic landscape and gene expression 
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patterns. Together, oncogenic signaling and perturbed metabolism further shape the 
cancer cells’ phenotype. Thus, altered metabolism is not just a mere byproduct, but a 
prominent player in tumorigenesis worth exploring as a potent source of many 
therapeutic targets. 
 
Figure 11: Epigenetic control as a link between metabolism and gene expression profiles in cancer. 
Abbreviations are explained in the List of Abbreviations. 
1.3.3 Metabolic changes – clinical implications and therapeutic targets 
Metabolic profiling of cancer cells holds a promise for new approaches in treating cancer. 
Its exploration is aimed at identifying novel biomarkers for various cancer subtypes and 
the development of new metabolic drugs. With the improvement of existing 
metabolomics techniques for the precise and fast detection of a broad range of 
metabolites, the body of knowledge in the field of cancer metabolism is growing. This 
knowledge has already found some practical application in a clinical setting. One of the 
fine examples is 2-[18F] fluoro-2-deoxy-D-glucose positron-emission tomography (FDG-
PET) scan – an imaging technique that detects tumors which exhibit the Warburg effect 
employing radiolabeled glucose analogues used to visualize the process of an increased 
glucose uptake, revealing the tumor sites (105). Non-invasive techniques such as 
magnetic resonance imaging (MRI) and magnetic resonance spectroscopy imaging 
(MRSI) have been used in diagnosis of cancers as well as monitoring and assessment of 
the treatment (105). Application of MRI and MRSI led to significant improvements in 
breast cancer management – while mammography and MRI displayed better sensitivity 
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and accuracy compared to mammography alone, detection of choline by MRSI displayed 
a 100% sensitivity distinguishing between benign and malignant breast tumors (105).  
Besides metabolic biomarkers used in imaging, there are many metabolites that could 
be measured in the samples which could be obtained in a relatively non-invasive and 
easy way. Metabolites could be measured in breath, saliva, serum, plasma and urine. 
These markers could be used in monitoring cancer progression and assessing the cancer 
stage, as they have been found to correlate with cancer aggressiveness (105). For 
example, three phosphatidylinositols were found to be reduced in the plasma of 
pancreatic cancer patients; lysophosphatidylcholines were decreased in the blood of lung 
and liver cancer patients; lysophosphatidic acid was elevated in ovarian cancer (105). 
Employing metabolic biomarkers in clinical practice has a lot of potential, but requires 
optimization, reproducibility and standardization of specific and sensitive laboratory 
tests. 
Observed changes in cancer metabolism are also finding their way to a clinical setting, 
in terms of extensive searching for the novel targets that could be hit with a specific 
therapy while sparing the normal cells. Even though tumor heterogeneity exists also on 
metabolic level, it is still a more efficient way compared to targeting diverse genetic 
features – there are certain common metabolic dependencies seen in many tumors. One 
of the common metabolic pathways upregulated in cancer cells is glycolysis, so glycolytic 
enzymes and transporters emerged as an interesting option for targeting. This is 
especially true for glucose transporters and hexokinases (enzymes that catalyze the first 
step of glycolysis) as they are frequently over-expressed and studies on several mouse 
models on different cancer types show that their inhibition slows the tumor growth (90). 
To target 6-phosphofructo-1-kinase (PFK1) which is often upregulated in cancer and is 
an enzyme in the upper part of the glycolytic pathway, small inhibitors of 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase  isoform 3 (PFKFB3) are being 
developed, as PFKFB3 inhibition prevents the formation of a potent allosteric activator 
of PFK1 and slows down cancer proliferation (90). Interfering with the end part of 
glycolysis through pyruvate dehydrogenase kinase (PDHK) inhibition increases pyruvate 
dehydrogenase (PDH) activity, disrupting aerobic glycolysis and leading to cell death in 
vitro and a better outlook in animal models (90). PDHK is frequently overexpressed in 
cancer cells and its inhibitor, dichloroacetate (DCA), is being intensively explored in the 
clinics (90). 
Increased uptake of glutamine is another property of cancer cells, particularly of the 
ones driven by oncogenic MYC. Glutamine transporters: solute carrier family 1 member 
5 (SLC1A5) and large neutral amino acids transporter small subunit 1 (LAT1) are 
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frequently overexpressed and their inhibition slowed tumor growth and induced 
autophagy; decreased proliferation and cell death was also shown when glutaminase 
(GLS) was inhibited (90). Another interesting target is glutamine dehydrogenase (GDH) 
whose inhibition blocks the entrance of glutamine in the TCA cycle and thus prevents 
OXPHOS, replenishment of important intermediates and lipid synthesis – however, there 
is a need for more specific inhibitors (90). 
Certain success has also been seen in targeting some parts of a deregulated TCA cycle 
– a small molecule inhibitor aimed at mutant IDH reversed the cancer phenotype towards 
a more normal one by reducing 2HG generation (90). 
Altered lipid metabolism in cancer has also received attention – targeting de novo fatty 
acid synthesis through interference with fatty acid synthase (FASN) using available 
obesity drug Orlistat or by utilizing inhibitors of ATP citrate lyase (ACLY) represents 
another therapeutic opportunity (90). 
Despite the challenges imposed by metabolic flexibility and plasticity of cancer cells, 
potential side-effects, suboptimal specificity and toxicity, drugs targeting metabolism are 
a subject of extensive research and hold a promise for more efficient treatments as new 
and improved generations of therapeutics are being developed. Identifying metabolic 
specificities of residual cells that could be targeted, while leaving metabolism of normal 
cells functional, would be a crucial step towards finding a therapeutic window in treating 
MRD and preventing tumor recurrence. 
1.3.4 Exploring metabolic characteristics of MRD 
Many specific metabolic traits and adaptations of tumor cells are being revealed and 
cancer metabolism emerges as an important player driving oncogenesis. But what is 
known about metabolism of dormant residual cells? How similar it is to the primary 
tumor? How different it is from the normal cell?  
Studying this population still poses a challenge due to our inability to follow their fate 
and evolution in patients. Cells coming from relapses/metastatic disease already exited 
dormancy and could have acquired additional genetic insults, as most metastases appear 
to be driven by mutations different than the ones maintaining the primary tumor 
(106,107).  
One of the ways to study residual cell populations is through samples obtained after 
neoadjuvant treatments whose purpose is to make some locally advanced tumors 
operable. The treatment leads to tumor regression which is often incomplete – a resistant 
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cell population survives, representing MRD (108). Cells from the primary tumor that 
entered the circulation (CTCs), sampled after neoadjuvant therapy in breast cancer 
patients, showed cancer-stem like features associated with resistance (109). Cancer 
stem cells (CSCs) or CSC-like – tumor initiating cells (TICs) are the cells that have been 
implicated in aggressiveness of cancer and its poor prognosis (110,111) and thus 
assumed to be responsible for drug-resistance and subsequent tumor recurrence. Being 
stem cells, they are able of self-renewal dividing asymmetrically, yet they are slow-
cycling (112). Because of their restricted proliferation and differentiation, they are 
usually refractory to standard chemotherapy aimed at proliferating cells. Alterations in 
metabolic programs emerge as important in the survival and resistance to therapy (113). 
As many parallels can be drawn between tumor dormancy and CSC models (114), 
studying the metabolic characteristics of CSCs/CSC-like dormant cell population provides 
important cues about metabolic properties of MRD. 
Scientists are employing additional ways and novel platforms for studying the residual, 
dormant population. Three-dimensional cell cultures with matrix of different physical 
properties that regulate dormancy (115), in vitro model of tumor dormancy and 
recurrence after short-term chemotherapy that enriches for therapy resistant, slow-
cycling cells (116) and platforms that induce dormancy through encapsulation of the 
cells in the special nondegradable gels (117) are some of the tools that will expand our 
knowledge about MRD. 
Another interesting opportunity to closely follow tumor regression and the surviving 
residual population comes from the inducible mouse models and employment of the 
corresponding 3D cultures which enable detailed insights in these cells. They have been 
shown to drive relapse and thus represent a correlate of MRD (118,119). So far, our 
previous study on the residual cells in breast cancer model revealed enhanced fatty acid 
metabolism as a striking feature associated with oxidative stress that renders them 
susceptible to DNA mutation and subsequent relapse, that was also verified in MRD 
samples obtained from different cancer subtypes (119). Further exploration of residual 
cells on a metabolic level could reveal additional interesting metabolic targets or 
biomarkers of clinical importance in prevention of tumor relapses and metastatic spread. 
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The current knowledge on MRD in breast cancer is limited, as most samples available 
from clinics are either primary tumors or relapses, where many intricate changes have 
already taken place. Studying MRD in breast cancer is limited by the availability of 
patient samples and by the difficulty to obtain residual cells, which leaves them largely 
unexplored.  
It is clear that knowledge of this elusive cell population would be valuable, as its features 
could potentially be exploited as targets for better interference against tumor 
recurrences. The overall goal of this thesis is to characterize this cell population, 
employing a tractable mouse model of MRD. Understanding the metabolic traits 
of MRD would be particularly important, as this could provide valuable information on 
the potential metabolic dependencies and vulnerabilities of the residual cells. 
2.1 HYPOTHESIS 
Since altered metabolism is one of the hallmarks of cancer, it is likely to be of great 
importance in the context of MRD. One oncogenic insult can lead to the dysregulation of 
multiple pathways. Metabolic reprogramming in cancer is an extensive and profound 
process that happens as a consequence of oncogenic signaling and defects in the function 
of tumor suppressors, but also as a result of the exposure of cancer cells to different 
cues and conditions and their dynamic interaction with the environment. Altered 
metabolism is not just a byproduct of these processes, but emerges as an active player 
that could drive further changes in tumor progression, leading the cells to evolve new 
features. Changes in gene expression and metabolic pathways during tumor progression 
could eventually leave a fundamental imprint on the cellular metabolic network, which 
would remain altered despite the inactivation of the driver oncogenes. These alterations 
could have a vast, intense and lasting effect on the rewiring of the cancer cell.   
Metabolic reprogramming of cancer cells could have a more permanent effect 
on the biochemical phenotype of the cell, persisting as a metabolic memory in 
the dormant residual cells. 
Identifying metabolic features specific for the residual cell population could bring us 
closer to the information on the phenotype of these cells as it would reflect their 
biochemical characteristics. Narrowing the immense tumor heterogeneity to a finite 
number of metabolic solutions could pave a way towards new targets and therapeutic 
opportunities in the prevention of tumor recurrences.  
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In this thesis, the following questions will be answered: 
• What are the overall characteristics of surviving residual cells following oncogene 
inactivation? 
• Is there the lasting metabolic imprint following extensive metabolic rewiring 
during tumorigenesis on the residual cells after oncogene inactivation? Are there 
oncogenic remaining features preserved in the absence of oncogenic signaling? 
• Can we identify specific metabolic features – potential metabolic targets of the 
residual cell population, that set them apart from healthy cells? 
• Can we identify a time-point during tumor progression where irreversible changes 
take place; find the “point of no return”? 
• What could be a mechanism behind potential metabolic memory? 
 
2.2 AIMS 
The knowledge on residual cells would be obtained through the following aims: 
• in depth characterization of a 3D culture system that yields a correlate of MRD; 
• a multi-omics approach and set up of metabolic methods to obtain the metabolic 
landscape of the residual cell population; 
• verification of the most prominent findings in the mouse models in vivo and in 
correlation with datasets from breast cancer patients; 
• following the kinetics of oncogenesis and regression as a mean to identify a 
potential time-period when the “metabolic memory” is established. 
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CONTRIBUTIONS 
This thesis contains experiments performed in collaboration with the groups of Dr. Kiran 
Patil, Dr. Theodore Alexandrov (both Structural and Computational Biology Unit, EMBL 
Heidelberg) and the group of Prof. Britta Brügger (BZH Heidelberg, University of 
Heidelberg).  
I designed the experiments, optimized and characterized the 3D culture system. I 
genotyped the animals and performed in vitro experiments: phenotype characterization 
through bright-field and confocal microscopy, immunofluorescence, Real-Time qPCR, 
Western blot, RNA collections and extractions over timepoints during oncogenesis and 
regression, DNA and protein collections and extractions, intracellular and extracellular 
metabolite collections, extractions and runs on GCMS and Q-Exactive MS; collections of 
the extracellular and intracellular samples for the shotgun lipidomics. I did the 
conceptual integration of the transcriptomics, lipidomics and metabolomics data, Over 
Representation Analysis (ORA), identification and selection of the most prominent 
targets. I validated selected targets and most prominent findings through in vivo 
experiments: maintained the mouse colony, collected mammary gland tissues, 
performed IHC and IF stainings on FFPE tissue sections, performed and ran metabolic 
experiments in vivo (GCMS metabolic measurements, measurements of 13C glucose 
labelling, NOS and BCA assays). I analyzed NOS assay data and the in vivo fluorescence 
staining data at the Tissue-gnostic microscope with the help of Dr. Yuanyuan Chen 
(group of Dr. Sotillo, DKFZ Heidelberg). I set up the methods for IMS on mammary gland 
tissues and performed the cryo-sectioning, prepared and ran the samples for IMS. 
Eleni Kafkia (Patil group, Structural and Computational Biology Unit, EMBL Heidelberg) 
set up metabolic protocols, optimized GCMS for data acquisition and analyzed GCMS 
data, contributing also to its interpretation. Eleni contributed also to harvesting and 
collecting of the in vivo metabolite samples, and NOS and BCA assays experiments. 
Katharina Zirngibl (Patil group, Structural and Computational Biology Unit, EMBL 
Heidelberg) did bioinformatic analysis and integration of RNA-sequencing data (GO 
enrichment, KEGG reactions and metabolite predictions), as well as correlation of mouse 
and patients’ (publicly available) datasets. 
Ashna Alladin (Jechlinger group, Cell Biology and Biophysics Unit, EMBL Heidelberg) 
contributed to the optimization of TetO-Myc/TetO-Neu/MMTV-rtTA system and its 
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characterization: doxycycline titration experiments, IF stainings, collection and 
extraction of RNA during oncogenesis and regression. Ashna Alladin, Savannah Jackson, 
Matthew Boucher and Marta Garcia Montero further maintaining the mouse colony and 
contributed to collecting the tissues to be used for in vivo analysis. 
Sylwia Gawrzak analyzed the data for the Kaplan-Meier curve.  
Marta Garcia Montero provided technical assistance with histology.  
Federico Villa contributed to the in vitro setup of metabolic methods out of the 3D culture 
matrix.  
Dr. Daniel Sevin (GSK Cellzome, Heidelberg) ran and analyzed Q-Exactive MS data from 
untargeted metabolomics experiments performed at Cellzome, GSK Heidelberg. 
Christian Lüchtenborg (Brügger group, BZH Heidelberg, University of Heidleberg) 
performed lipid extractions from collected samples and shotgun lipidomics together with 
data analysis on these experiments. 
RNA sequencing and bisulfite-free DNA sequencing were performed at the Genomic Core 
Facility at EMBL. Andrew Palmer (Alexandrov group, Structural and Computational 
Biology Unit, EMBL Heidelberg) assisted to setting up the methods for IMS on mammary 
gland tissues. 
Dr. Martin Jechlinger supervised the project and designed experiments.  
Manuscripts in preparation: 
I am co-first author of the first manuscript in preparation, along with the co-first authors 
Eleni Kafkia and Katharina Zirngibl; with Ashna Alladin, Federico Villa, Marta Garcia 
Montero, Savannah Jade Jackson, Daniel Sevin, Christian Lüchtenborg, Britta Brügger, 
Kiran Raosaheb Patil and Martin Jechlinger: In depth multi-omics analysis reveals an 
oncogenic metabolic memory in a surviving cell population in a breast cancer model of 
minimal residual disease (in preparation). 
The second manuscript in preparation will deal with the kinetics of oncogenesis and 
tumor regression – highlighting the point of no return from oncogene addiction. I will be 
co-first author of this manuscript, along with the co-first authors Ashna Alladin, Eleni 
Kafkia and yet to be determined contributing scientists that will include the lead authors 
Kiran Raosaheb Patil and Martin Jechlinger. 
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3.1 INDUCIBLE MOUSE MODELS AND THREE-DIMENSIONAL PRIMARY 
CELL CULTURES FOR STUDYING MINIMAL RESIDUAL DISEASE IN BREAST 
CANCER  
Mouse models have been of a great importance in studying many human disease related 
processes, helping us to elucidate various aspects of human biology and establishing 
themselves as a valuable tool in research, biotechnology and the pharmaceutic industry. 
Conditional mouse models, commonly used in studies exploring cancer, represent a leap 
forward in better modeling of human malignancies. In particular, tetracycline-inducible 
mouse models bring us closer to the patients’ situation, as they allow for temporal control 
of oncogene expression. Oncogenesis is induced in the adulthood in case of breast cancer 
as modeled disease.      
Experimental design and approaches to study MRD in this project are outlined in Figure 
12. We explored MRD in breast cancer utilizing inducible mouse models and primary 
mouse mammary cells grown in 3D cultures. To fully characterize MRD, we optimized 
and set up methods for a 3D culture system that enabled us to follow it in depth: from 
observation of phenotypes to the application of a multi-omics approach. To test the 
hypothesis of metabolic memory and to get a detailed, full picture on the features of 
MRD, a systems biology approach was employed, integrating obtained information from 
different layers of biological system (transcriptomic, metabolomic, lipidomic and 
methylome profiles). Key features of MRD observed in vitro were verified in mouse 
models in vivo and then correlated with available human datasets of MRD. 
As a model of MRD, we employed TetO-cMYC/TetO-Neu/MMTV-rtTA inducible mice that 
have two transgenes – oncogenes that play an important role in breast tumorigenesis: 
c-MYC (MYC) which contains human exon 2 and 3 (120) and activated rat Neu (121). 
MYC is a gene that encodes MYC protein which is a transcription factor and a master 
regulator of metabolism (122). It is also a potent proto-oncogene implicated in many 
tumor types. While it represents a primary oncogene in some human cancers (for 
instance, Burkitt’s lymphoma), in other types MYC is more often an “early-response” 
gene that is downstream of other activated oncogenic pathways and signaling from 
ligand-receptor complexes (122). Neu (Her2) encodes HER2 – human epidermal growth 
factor receptor that plays a role in regulation of many cellular processes, mainly cell 
proliferation,  differentiation and survival (123). Her2 gene overexpression is seen in 
around 15-30% of primary breast cancer cases (121). When these two oncogenes are 
overexpressed together, which is a common case in breast cancer, prognosis is 
particularly poor and tumors are aggressive (124).  
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Figure 12: Experimental design to study MRD  
Mouse mammary tumor virus long terminal repeat (MMTV-LTR) sequence enables spatial 
control of these transgenes; their specific expression in the mammary gland (120). 
Reverse tetracycline-dependent transcriptional activator (rtTA) regulates temporal 
expression of the oncogenes which are under control of the tetracycline-dependent 
minimal promoter (120). The system is regulated by doxycycline (antibiotic from 
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tetracycline class). Upon doxycycline (Dox) administration, rtTA binds to tetracycline 
operator (TetO) sequences, driving oncogene transcription and inducing tumorigenesis 
(120) (Figure 13A). Doxycycline removal from the system results in very fast inactivation 
of oncogenes. They are “switched off”; their expression is not detectable anymore 
(120,121). The system mimics the phenomenon of oncogene addiction, where tumor 
maintenance is dependent on the action of one or a few oncogenes (17). Switching off 
the oncogenes by doxycycline withdrawal resembles perfect targeted therapy aimed at 
the driver oncogenes. 
In order to follow the complex dynamics of tumorigenesis and regression, as well as to 
model MRD, we employed a 3D culture system, obtained from the mouse mammary 
epithelial cells, as previously established in our group (118). Mammary glands from adult 
virgin female mice were dissected and dissociated to single cells placed in 2D collagen-
coated plates for selection of epithelial cells (Figure 13B). Epithelial cells were then 
seeded in 3D spheres of Matrigel-collagen mixture which represented the elements of 
the microenvironment and enabled the growth of the cells in physiological, 3D conditions, 
so they formed basic mammary gland ductal units – acini. Each acinus consisted of 
luminal epithelial cells, surrounding the lumen. Figure 13C shows a schematic 
representation of phenotypes followed in 3D culture. Normal hollow acini (termed “NI” 
from “never induced” as they were not exposed to doxycycline and thus oncogenic 
transgenes were never expressed) represent a healthy duct. When doxycycline (Dox) 
was introduced through the cell media, MYC and Neu oncogenes were activated and cells 
began to proliferate uncontrollably. After 5 days, the lumens were filled and these 
structures (termed “tumor” or designated “DOX”) acted as an experimental tumor 
correlate. From the previous research in our group, it is known that, upon switching off 
the oncogenes, the majority of these cells die yet the surviving rim remains (119). These 
residual structures (designated “OFF”) represent a model of MRD, as some of the cells 
bear tumorigenic potential and were able to drive relapse (118,119). Studying MRD in 
this model first required its characterization and optimization, as well as the set-up of 
new protocols for obtaining different types of material from 3D cell cultures (Figure 13D). 
This clear and synchronous culture represents a reductionist, clean system without noise 
and complexity one would encounter in vivo, enabling also more controlled experiments 
and an overall shorter time-frame for oncogenesis and regression. An additional 
advantage of our 3D culture system lies in the fact that, while recapitulating 3D cellular 
organization in vivo and interactions with extracellular matrix components, we can still 
closely follow the structures, monitor their phenotypes throughout different stages of 
oncogenesis and regression, and collect the material for various types of analyses.  
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Figure 13: Studying MRD in a breast cancer model. A) Tetracycline inducible mouse models; B) 
3D culture system enabled primary mammary mouse epithelial cells to grow and form basic ductal 
functional unit – acinus; C) Schematic representation of the phenotypes at the most critical 
timepoints: healthy, never induced (NI) structure, tumor (DOX) and residual (OFF). D) Setting up 
methods and obtaining information from 3D culture system. 
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Through collaboration with the Patil group, bioinformatic models were built and 
developed to help us gain a further understanding of processes that were taking place 
in the residual cell population in vitro (Figure 14A). For in vivo validation of metabolic 
memory and the most prominent features found in 3D model of MRD, regressed 
mammary gland tissue at the timepoint of 9 weeks after doxycycline withdrawal was 
used, along with the corresponding age-matched controls (Figure 14B). Namely, mice 
were fed with doxycycline food until they reached the full-blown tumors (4-6 weeks on 
Dox). When the tumor burden was large, they were put off doxycycline food and taken 
when tumors were regressed and non-palpable (9 weeks off Dox). Age-matched controls 
that were wild type, non-inducible mice, were treated in the same manner, being put on 
and off Dox food at the same time as animals with tumors. In this way, comparison 
between these different states was possible. 
 
Figure 14: Data integration, validation and interpretation. A) Multi-omics approach for global 
overview of the system; B) In vivo validation of the most prominent findings from 3D culture; C) 
Correlation of main findings with human datasets obtained samples after neoadjuvant treatment 
and healthy controls. 
While mouse models still represent an invaluable tool in exploring human diseases, as 
regulation of genome seems to be very similar between the two species, there are certain 
differences, particularly in metabolic processes. To check if the identified metabolic 
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features could have some relevance in human breast cancer, findings from the mouse 
model were overlaid and compared to the human datasets. Namely, relevance of the 
observations verified in vivo was further assessed through correlation with available 
databases from patients that were undergone neo-adjuvant treatment (Figure 14C). 
Following neoadjuvant treatment, often given to make large tumors operable, residual 
cells can remain as a result of resistance to therapy. Publicly available gene expression 
profiles of residual cells were compared with the ones from healthy control samples 
obtained from women who had reduction mammoplasty.  
3.2 Phenotypic characterization and optimization of TetO-cMYC/TetO-
Neu/MMTV-rtTA 3D culture system  
Our 3D culture system faithfully recapitulates the dynamics of tumorigenesis and 
regression, as shown in comparison to mammary gland biopsies taken from TetO-
cMYC/TetO-Neu/MMTV-rtTA transgenic mice (119) (Figure 15). 
  
Figure 15: Model of tumorigenesis and regression, immunohistochemistry (IHC) on MYC protein. 
A) Upper panel: in vitro images - 3D culture, from left to right: never induced structures; 
structures 5 days on doxycycline (Dox) (tumor correlate); structures 7 days off doxycycline 
(residual structures). Lower panel: in vivo images - mammary gland biopsies, from left to right: 
tissue section showing duct from a healthy gland, tumor, regressed gland. Scale bar: 50 µm. B) 
Expression of transgenes: human MYC and rat Neu at 5 days on Dox and 7 days off Dox (β-actin 
used as a reference). Error bars represent the standard error of the mean (±SEM). Figure taken 
and adapted from (119). 
In our TetO-cMYC/TetO-Neu/MMTV-rtTA 3D cultures, several days during growth in 3D 
culture, cells form acinar-looking, polarized structures with the lumen (Figure 15A, upper 
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panel, left), resembling and mimicking basic ductal units of mammary glands, 
representing normal structures without oncogene expression (Figure 15A, lower panel, 
left). Upon induction with the doxycycline, cells start proliferating in an uncontrolled 
manner, filling up the lumen of the duct (Figure 15A, middle) and expressing the 
oncogenes (MYC stain shown in Figure 15A, middle; MYC and Neu mRNA expression 
shown in B). Doxycycline withdrawal results in a rapid regression and clearance of the 
lumen (Figure 15A, right) and loss of oncogene expression (absence of MYC in Figure 
15A, right; low mRNA expression of MYC and Neu in B), but not in the complete tumor 
eradication, as the surviving rim remains. 
One of the first things that needed to be assessed and optimized in our 3D culture system 
was the appropriate concentration of doxycycline for induction of the oncogenes: human 
MYC and rat Neu. Doxycycline belongs to tetracyclines, antibiotics that bind to the small 
subunit of ribosomes of prokaryotes, thus interfering with their protein synthesis (125). 
Since mitochondria resemble prokaryotic cells in their ribosome subunits, doxycycline 
could also affect mitochondrial protein synthesis (125). This is why several doxycycline 
concentrations were assessed, whereby a potential effect on the phenotype was 
examined in vitro and in vivo (Figure 16). In the 3D cultures, same structures were 
followed over time, using bright field microscopy, starting from their normal, never 
induced phenotype (time 0) (Figure 16A). Some 24 hours upon induction, structures 
became thicker. Proliferation continued and structures were getting larger. Proliferating 
cells were filling up the lumen and at 5 days on doxycycline, structures represented a 
correlate of a full blown-tumor, while uninduced structures remained normal, 
representing a healthy phenotype. In both commonly used doxycycline concentration of 
1000 ng/ml (Figure 16A, middle panel) and the lowest tested concentration of 150 ng/ml 
(Figure 16A, lower panel) there were no differences in the induction kinetics. Lower 
concentrations of doxycycline did not affect oncogenesis and the tumor phenotype of the 
induced structures. In addition, structures at lower doxycycline concentration appeared 
healthier, as not much cell death was observed around them.  
Efficiency of different dosage of doxycycline on oncogene activation was also assessed 
through counting the number of induced structures in 3D culture, expressed in 
percentage (Figure 16B). While the percentage of induced structures was the highest at 
1000 ng/ml (90-95%), it remained high even at the lowest doxycycline concentration 
tested (77-87%). The percentage of induced structures was higher at a slightly higher 
doxycycline concentration of 200 ng/ml (81-94%), almost reaching the percentage seen 
at 1000 ng/ml.  
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Figure 16: Examining the effect of doxycycline concentration on phenotype, oncogene expression 
and mitochondrial function. A) Bright-field (BF) images of 3D cultures at indicated timepoints and 
Dox concentrations (ng/mL); B) Percentage of induced structures in vitro (5 days on Dox) at the 
indicated Dox concentrations; C) Expression of the transgenes in vitro at the indicated timepoints 
and Dox concentrations: left – human MYC, right – rat Neu; D) Western blot on MT-CO1 protein 
in vitro (5 days on Dox) at the indicated Dox concentrations; E) IHC on MT-CO1 protein in vivo 
(from left to right: control, tumor at 3 weeks on Dox, regressed gland at 2 weeks off Dox).  
Error bars represent the standard error of the mean (±SEM). Scale bar: 100 µm. 
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Next, we employed qPCR to measure the mRNA expression of human MYC and rat Neu 
oncogenes in the cells harvested from 3D culture. The analysis showed approximately 
1,7 times lower MYC expression over 24 and 48 hours upon induction at the lower 
doxycycline concentration compared to the 1000 ng/ml. Nevertheless, on the endpoint 
of fifth day on doxycycline, the expression was actually approximately 1,7 times higher 
than the one at 1000 ng/ml doxycycline, which could be explained by potential apoptotic 
effect of high MYC expression (Figure 16C, left). As for the Neu oncogene, its expression 
at the lower concentration of doxycycline at 24 hours was around 1,4 times lower than 
at 1000 ng/ml. At 48 hours and 5 days the expression was about 2 times lower than at 
1000 ng/ml (Figure 16C, right). 
Mitochondrially-encoded cytochrome C oxidase 1 (MT-CO1) protein, which is a part of 
the respiratory complex IV, was used for assessing the potential effect of doxycycline on 
mitochondrial function in 3D cultures (Figure 16D) and in vivo (Figure 16E). Western 
blots were conducted on protein lysates from 3D cultures. Relative blotting band 
intensity of MT-CO1 compared to tubulin showed some effect of doxycycline on MT-CO1, 
as a decrease of intensity (from 1 down to 0,8) was observed in the samples treated 
with doxycycline in comparison to never induced controls (Figure 16D). However, this 
was not significant (One-Way ANOVA, F=1,49, p=0,25 at CL=95%). In addition, IHC 
staining for MT-CO1 was performed on the FFPE tissue sections obtained from mice with 
tumors (3 weeks on Dox food), mice with regressed mammary glands (2 weeks off Dox 
food) and age-matched controls (Figure 16E). The staining showed that there was no 
dramatic effect of doxycycline on MT-CO1 expression at the commonly used 
concentrations of 625 mg/kg, supplemented in the food of the experimental mice for 
inducing fully palpable tumors. 
Overall, lowering doxycycline concentration did not affect the induction of oncogenes or 
tumor phenotype. Based on these experiments, we decided that a doxycycline 
concentration of 200 ng/ml would be used for oncogene induction, as it was high enough 
to induce oncogenesis, yet could be potentially safer for metabolomics experiments, 
regarding the effect of doxycycline on the mitochondria. 
To further investigate gene expression profiles and obtain full transcriptomic picture of 
the residual cells, protocols for RNA sequencing were tested. The established RNA 
isolation protocol using the mirVana kit proved highly effective for obtaining high quality 
RNA for deep sequencing employed for obtaining transcriptomics datasets. 
Immunofluorescence protocols were successfully modified and optimized for in vitro and 
in vivo material, which enabled full phenotypic characterization of the respective 
structures in a normal, physiological state, and during tumorigenesis and regression.  
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3.3 Residual population exhibits transcriptional profile distinctive from tumor 
and normal physiological state 
We employed immunofluorescence (IF) staining and confocal microscopy on 3D cultures 
to observe and compare the phenotypes of normal (never induced), tumor (5 days on 
doxycycline) and residual (7 days off doxycycline) structures in greater detail. IF staining 
for polarity markers and the MYC oncogene (Figure 17A) showed that tumor structures 
lost their lumen and polarity (upper panel, middle), as opposed to normal which 
exhibited a clear lumen and a single, polarized rim (upper panel, left). In normal 
condition, alpha-6 integrin (ITGA6, shown in red) had a basal localization; Zonula 
Occludens (ZO-1, shown in green) was apical, staining occludins at the tight junctions; 
Golgi matrix protein (GM-130, shown in magenta) was restricted to apical part of the 
cell, marking Golgi. This was not the case in the tumor, where the expression of these 
markers was less consistent. However, a great phenotypic similarity was observed 
between normal and residual structures, as they regressed back to polarized single rim 
with the lumen (upper panel, right). Immunofluorescence staining for transgenic MYC 
showed its expression in tumor cells (lower panel, middle; in green) and its absence in 
the regressed cells (lower panel, right) similarly to the controls (lower panel, left). 
 
Figure 17: Comparison of phenotypes and transcriptional profiles between normal, tumor and 
residual structures. A) Upper panel: ITGA6 (red), ZO-1 (green), GM-130 (magenta). Lower panel: 
human MYC oncogene (green); E-cadherin (CDH1, in red) as a counterstain. From left to right: 
normal, tumor and residual structures. Scale bar: 50 µm. B) PCA plot based on transcriptional 
profiles from RNA sequencing data of normal (NI), tumor (DOX) and residual (OFF) structures. 
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Despite this similarity, it was demonstrated that the residual structures exhibited a 
specific gene expression profile, observed from microarray data in our previous study 
(119). To further obtain the in-depth picture of the whole transcriptome, we performed 
RNA sequencing on material collected from 3D cultures. This confirmed that the residual 
cell population (OFF, shown in blue) indeed had a distinctive transcriptional profile that 
distinguished it from both tumor (DOX, shown in red) and normal (NI, shown in green), 
as seen in the Principal Component Analysis (PCA) (Figure 17B). The first and the second 
principal components accounted for 45% and 17% of the variance, respectively. 
Centroids were calculated based on two principal components and showed the center of 
each sample group (control, tumor, residual) represented on the PCA plot. Distance was 
calculated considering all principal components, as Euclidean distance between the 
centroids of the samples. In this regard, residual structures (OFF) were closer to the 
normal (NI) ones (distance between them was 63,7). The distance between residual 
structures (OFF) and tumors (DOX) was larger (82,6). The largest distance was seen 
between tumor (DOX) and normal (NI) cells (95,3). The confidence interval of a 
multivariate normal distribution is represented in the ellipses (CI = 0,95).  
To gain an understanding of the affected pathways, 1925 differentially expressed genes 
in residual cells (compared to never induced control, q value<0,05) were taken for GO 
(Gene Ontology) Enrichment Analysis. GO terms obtained from genes with lower 
expression showed downregulation of processes mostly connected to cell division, which 
reflected the dormant state of the residual population (Figure 18A). GO terms coming 
from upregulated genes reveal activation of the cell surface receptor signaling pathway, 
cell adhesion and locomotion, probably reflecting cellular movements towards 
integration into the single rim, establishment of contact with the basement membrane 
and restoration of polarity. Interestingly, metabolic processes such as ATP generation, 
nucleotide phosphorylation and glycolysis were seen upregulated in residual cells (Figure 
18B) despite their non-proliferative state, hinting at the potential significance of 
metabolism in the MRD. To check for altered pathways in tumor cells, GO enrichment of 
the 5274 differentially expressed genes in comparison to the control (padj<0,1, 
Bonferroni correction for multiple testing) was also performed (Figure 19). In contrast 
to the residual cell population, cell adhesion, motility and cell communication were 
downregulated in tumor cells compared to the control (Figure 19A), while cell division 
was upregulated (Figure 19B). This was expected for the proliferating cells that did not 
have contact with the extracellular matrix anymore and lost contact inhibition, filling up 
the lumen. In addition, many metabolic and biosynthetic processes were enhanced in 
the tumor state, which is unsurprising, considering that these cells have high demands 
for energy and support of proliferation.  
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Figure 18: Altered biological processes in residual population compared to normal (Fisher classic 
test; p-value shown in the legend). A) GO terms: top 30 (p<0,01) downregulated processes in 
residual (OFF) compared to control (NI) population. B) GO terms: top 30 (p<0,01) upregulated 
processes in residual (OFF) compared to control (NI) population.  
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Figure 19: Altered biological processes in tumor population compared to normal (Fisher classic 
test; p-value shown in the legend). A) GO terms: top 30 (p<0,01) downregulated processes in 
tumor (DOX) compared to control (NI) population. B) GO terms: top 30 (p<0,01) upregulated 
processes in tumor (DOX) compared to control (NI) population.  
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3.4 METABOLIC FEATURES OF RESIDUAL CELL POPULATION 
3.4.1  Establishment of metabolomics methods for studying TetO-cMYC/TetO-
Neu/MMTV-rtTA 3D culture system 
Seeing the changes on the transcriptional level (described in Chapter 3.3) that pointed 
out to the alterations in metabolic processes happening in the residual cells (shown in 
Figure 18B), we wanted to further examine these findings on the metabolic level. In 
addition, acknowledging altered metabolism as one of the hallmarks of cancer, we 
wanted to explore it in the context of MRD. The goal was to obtain a metabolic landscape 
that acts as a “signature” of MRD, and also to explore the impact that metabolic rewiring 
could have on the residual cells.   
Measuring metabolites also brings us closer to the cellular phenotype, as it reflects real-
time processes taking place in the cell and is a direct read-out of its biochemistry. For 
this purpose, we employed untargeted, high-throughput metabolomics using high-
resolving mass spectrometer (flow injection Q-Exactive MS) that enables detection of up 
to 10 000 ions and profiling of thousands of metabolites. This approach was untargeted, 
allowing detection of changes across wide range of molecules, which yielded global 
profiles of our normal, tumor and residual population. However, it was semi-quantitative 
with putative metabolite annotations based on accurate mass and isotope distribution, 
without the possibility to resolve isomers. Thus, as a more precise method we employed 
gas chromatography-mass spectrometry (GCMS). GCMS provided retention time and 
mass that, along with the specific fragment pattern, allowed for precise metabolite 
identification and quantification. We took advantage of both untargeted metabolomics 
and GCMS features to characterize our 3D cultures on a global level and at the same 
time gain insights into more specific metabolic changes.  
Employing metabolic methods in vitro first required establishment of metabolic methods 
for our 3D culture system. The great challenge was imposed by the fact that the 
structures were growing in the Matrigel and initially the Matrigel signal was too strong 
in the GCMS profile, making it impossible to see other metabolites. Since there were no 
established protocols for 3D cultures in Matrigel, we firstly needed to set up the methods 
for efficient quenching and collecting of the metabolites. Several approaches were tried 
and eventually 1,5-hour long digestion of Matrigel using collagenase and liberase was 
shown to be the most successful in freeing the structures from the Matrigel, without 
interference from the Matrigel signal. We also had to try different strategies regarding 
cell number that would give a good signal, but also to tackle growth conditions and 
regularity of media changes. Eventually, we chose to change media every day at the 
 54 
 
RESULTS 
same time. This strategy was very important as it did not dilute and affect good signal 
from metabolites (which could have been potential problem especially in case of 
extracellular metabolites) and did not additionally stress the cells, as they had enough 
nutrients. Experiments were designed in such a way that the metabolites from different 
states (normal, tumor, residual) were collected and processed at the same time. Before 
harvesting intracellular metabolites, extracellular metabolites were also collected. After 
fast washing the structures in PBS, metabolites were quenched with absolute cold 
methanol and stored at -80oC. Upon assessing and deciding on solvents concentrations 
to be used during extraction, samples were further processed - extraction of metabolites 
was successful using a methanol-water 1:1 extraction protocol, with a 15-minute-long 
denaturation of cellular proteins at 72oC. GCMS data acquisition was optimized by fine-
tuning different concentrations of derivatization agents, split ratio, detector voltage and 
ion transitions. The established method was suitable for harvesting the metabolites for 
different metabolic analyses.  
3.4.2  Residual population is metabolically similar to tumor state, despite the 
absence of oncogene expression 
To get the wide metabolic picture across different states (control, tumor, residual), both 
intracellular and extracellular metabolites samples from 3D cultures were run using high-
throughput discovery metabolomics. Total of 7941 intracellular and 6791 extracellular 
raw ions were detected.  
Upon performing quality control and checking the consistency of raw ion detection across 
injections, ions that had been detected reproducibly were taken for further analyses 
(Appendix, Figure 52). Their number was 2832 for intracellular and 3208 for extracellular 
samples. Clustergrams were obtained by hierarchical bi-clustering of samples based on 
measured intracellular (Figure 20) or extracellular (Figure 21) ions and metabolite ion 
clusters.  
Strikingly, the clustergram of samples with measured intracellular metabolites (Figure 
20) showed that, on a metabolic level, residual population (shown in blue) clustered with 
tumor samples (shown in red), suggesting that it retained some metabolic features 
acquired in the tumor state. Analysis also included metabolites taken from cells of wild 
type (WT), non-inducible animals (shown in dark green). These cells were treated with 
media containing doxycycline, as an important control of its potential effect on metabolic 
profiles. Clustering of these samples with normal (NI) controls (shown in green) showed 
that this clustergram pattern did not come from the treatment with doxycycline.  
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Figure 20: Clustergram of normal (NI, WT), tumor (DOX) and residual (OFF) cell culture samples, 
based on measured (Q-Exactive MS) intracellular ions and metabolite ion clusters (C1-C10), 
obtained by unsupervised hierarchical bi-clustering and Manhattan distances.  
Bi-clustering of extracellular metabolites showed that the separation of the samples 
based on their condition (normal, tumor, residual) was not really clear (Figure 21). This 
was probably due to the detection of many more non-significant metabolites in the 
media. 
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Figure 21: Clustergram of normal (NI, WT), tumor (DOX) and residual (OFF) cell culture samples, 
based on measured (Q-Exactive MS) extracellular ions and metabolite ion clusters (C1-C10), 
obtained by unsupervised hierarchical bi-clustering and Manhattan distances. 
For intracellular samples, 813 ions were annotated as metabolites. Number of unique 
metabolites (without double/several annotations) was 2235. Metabolites in clusters were 
used in metabolic pathway enrichment analysis (left-tail hypergeometric test), where p-
values marked the probability that having up to a certain number of metabolites in a 
certain pathway was more than expected by chance. Enrichment analysis was conducted 
using KEGG metabolic pathway definitions. Metabolites that were not detected have been 
removed before the analysis and ambiguous annotations were counted individually. In 
 57 
 
RESULTS 
five clusters (2, 3, 5, 8 and 9) there were no significant changes with respect to a higher 
number of metabolites appearing in 85 metabolic pathways. Significant enrichment was 
seen in: tyrosine and tryptophan metabolism in cluster 1; fructose and mannose 
metabolism, beta-alanine metabolism and amino sugar and nucleotide sugar metabolism 
in cluster 4; phenylalanine metabolism in cluster 6; pentose and glucuronate 
interconversions, purine metabolism; valine, leucine, isoleucine biosynthesis, D-
glutamate and D-glutamine metabolism and glyoxylate and dicarboxylate metabolism in 
cluster 7; histidine metabolism, tryptophan metabolism and vitamin B6 metabolism and 
folate biosynthesis in cluster 10.  
For extracellular samples, 1039 ions were annotated as metabolites and 2501 were 
unique metabolites. Consistent with unclear separation of the extracellular samples on 
clustergram, metabolic pathway enrichment analysis of metabolites in clusters did not 
reveal any significantly upregulated pathway.  
Analysis of intracellular ions (unpaired t-test) was further performed to assess which 
metabolites could be differentiating residual from the normal population. Some of the 
highest log2 fold changes (FC) of residual versus normal values were observed in ions 
that could not be annotated, with log2 FC reaching up to 5,3; p<0,05, as well as certain 
dipeptides with log2 FC reaching up to 4,3; p<0,05. Besides dipeptides, annotated ions 
contributing significantly (p<0,05) to the differences between the two populations could 
be corresponding to metabolites such as the ones presented in Figure 22 (residual 
population shown as boxplots in blue; normal in green; tumor in red). These examples 
included leucine (m/z 130.087; log2 FC=0,82), proline (m/z 114.056; log2 FC=1,06), 
succinic acid (m/z 117.019; log2 FC=1,48), methionine (m/z 148.044; log2FC=1,50) 
and adenosine monophosphate (AMP) (m/z=346.056; log2 FC=1,95) that were present 
in higher levels in the residual cells (and tumor); 5,10-methenyltetrahydrofolic acid 
(m/z=227.072; log2 FC=-1,11) was found in lower amounts. Elevated metabolites were 
also observed to be significantly higher in the tumor cells (boxplots in red) compared to 
the normal: leucine (log2 FC=0,75), proline (log2 FC=1,73), succinic acid (log2 
FC=0,94), methionine (log2 FC=1,52) and AMP (log2 FC=2,35). Ions corresponding to 
5,10-methenyltetrahydrofolic acid were also recorded significantly lower in the tumor 
samples (log2 FC=-1,0). In addition, significantly higher levels of glutathione (m/z 
306.077) and oxidized glutathione (m/z 305.069) were found in the residual (log2 
FC=0,95; log2 FC=0,97, respectively) and tumor (log2 FC=2,54; log2 FC=1,54, 
respectively) cells. Changes were also seen in beta-alanine (m/z 88.041; residual log2 
FC=0,88; tumor log2FC=1,35), lysine (m/z 145.098; residual log2 FC=0,64; tumor log2 
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FC=0,70), tyrosine (m/z 180.067; residual log 2FC=0,66; tumor log2 FC=1,0) and 
various other metabolites.  
 
Figure 22: Selected intracellular ions significantly different (unpaired t-test; p<0,05) between 
residual (OFF) and normal (NI) cells, measured by Q-Exactive MS. 
The same analysis was performed to compare residual with tumor samples. Of the 
annotated ions, some with the significantly changed levels correspond to metabolites 
shown in Figure 23. 
Glutathione (log2 FC=-1,6), 5’-methylthioadenosine (m/z 296.082; log2 FC=-0,78) and 
diguanosine triphosphate (m/z 393.03; log2 FC=-1,6) were found in lower amount in 
the residual compared to the tumor cells, but still higher than in the controls. Pantothenic 
acid (m/z 218.103) was found in significantly lower amount in residual cells compared 
to the tumor (log2 FC=-0,86), but also to the control (log2 FC=-0,6). Glutamine (m/z 
145.062) was significantly higher in residual cells compared to tumor (log2 FC=0,66), 
as well as anserine (m/z 241.12), found higher than in the tumor (log2FC=1,75) and 
control (log2 FC=1,30). In addition, around 30 ions without annotations and several 
dipeptides with log2 FC ranging from 2 to 4,6 were significantly different between 
residual and tumor cells. 
 59 
 
RESULTS 
 
Figure 23: Selected intracellular ions significantly different (unpaired t-test; p<0,05) between 
residual (OFF) and tumor (DOX) cells, measured by Q-Exactive MS. 
Analysis of extracellular ions showed that some of the metabolites contributing to 
differences between the residual population and control were (Figure 24): lactic acid, 
ornithine, arginine, glutamine, methionine and ribose 1,5-bisphosphate. 
Lactic acid (m/z 89.025, log2 FC=1,09) and ornithine (log2 FC=1,57) were found in 
significantly higher amounts in residual cells, while arginine (m/z 173.104; log2 FC=-
2,07) was found in lower amounts. In the tumor cells, compared to the control, 
extracellularly located lactic acid (log2 FC=0,90) and ornithine (log2 FC=1,36) were also 
significantly higher. Arginine was also significantly lower extracellularly in tumor cells 
compared to the control (log2 FC=-2,99). Additionally, levels of extracellular glutamine 
were significantly lower in the tumor population compared to both residual (log2 FC=-
1,19) and normal (log2 FC=-1,11), which could be due to the proliferative state of tumor 
cells as opposed to non-proliferative residual and normal cells. The same was observed 
in the case of extracellular methionine (m/z 148.044) which was significantly lower in 
the tumor compared to residual (log2 FC=-1,68) and normal (log2 FC=-0,55) cells. 
Ribose 1,5-bisphosphate (m/z 308.979) was found to be significantly lower in residual 
cells compared to normal samples (log2 FC=-3,55). 
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Figure 24: Selected extracellular ions significantly different (unpaired t-test; p<0,05) between 
residual (OFF), tumor (DOX) and normal (NI) cells, measured by Q-Exactive MS. 
All the described significant changes in intracellular and extracellular ions shown in 
figures 22-24, were not found to be significantly different in the wild-type samples 
between the never induced (NI) state compared with the doxycycline treated (DOX, OFF) 
cases. 
Taken together, untargeted metabolomics revealed a metabolic resemblance of residual 
and tumor population. We further confirmed this observed similarity by performing 
GCMS analysis on the cell culture samples of the three respective states (normal, tumor, 
residual). PCA plot based on GCMS measurement of intracellular (Figure 25A) and 
extracellular (Figure 25B) metabolites demonstrated again the clustering of residual 
population (shown in blue) closer to tumor (shown in red) with a Euclidean distance of 
5,6 (for the intracellular metabolites plot) and 4,4 (for the extracellular metabolites plot). 
Both populations were clearly distinctive from normal (NI, WT shown in green and dark 
green, respectively), with a Euclidean distance of 8,8 (for both NI-OFF and NI-DOX on 
intracellular metabolites plot) and 8,7 (for both NI-OFF and NI-DOX on extracellular 
metabolites plot). Centroids for both PCA plots were calculated based on two principal 
components, indicating the center of each sample group. The first principal component 
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in the plot of intracellular metabolites explained 37% of variance and the second18 %, 
while the first principal component in plot of extracellular metabolites explained 68% of 
variance and the second 11%. Ellipses indicate the confidence interval of a multivariate 
normal distribution (CI = 0,95).  
 
Figure 25: PCA plots from GCMS measurement of the respective states: residual (OFF), tumor 
(DOX) and controls (NI, WT). A) intracellular and B) extracellular metabolites.  
Seeing the metabolic changes and comparing PCA plots of metabolic and transcriptomic 
profiles, we speculated whether the distinct transcriptomic profile of residual cells could 
be attributed to changes in non-metabolic genes. To see if their transcriptomic profile 
would come closer to tumor if we exclude non-metabolic genes, we performed a PCA 
only on metabolic genes. However, this did not affect the transcriptomic profile pattern 
(Appendix, Figure 53), indicating that transcriptional differences in genes encoding 
metabolic enzymes do exist between the tumor, residual and normal populations. To 
have an insight into what gene expression changes could potentially underlie clustering 
residual cells closer to tumor, we performed the PCA on the subset of genes differentially 
expressed in both tumor and residual cells compared to normal, which resulted in the 
transcriptional clustering more similar to what we observe on metabolic level 
(communication with Katharina Zirngibl).  
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3.4.3  One third of detected intracellular metabolites is specifically changed in 
residual and tumor population 
From the heatmap corresponding to 54 intracellular metabolites detected by GCMS, it 
was clear that the residual (OFF) and tumor (DOX) samples showed metabolic similarity, 
separating distinctly as one huge cluster away from the normal samples (NI, WT) (Figure 
26).  
 
Figure 26: Heatmap of all intracellular metabolites measured by GCMS across the three 
populations – normal (NI), tumor (DOX) and residual (OFF). 
From this number, about one third of intracellular metabolites were at least more than 
1-log2 fold change (FC) significantly different (limma linear regression model, Benjamini-
Hochberg padj<0,01) between the three populations (Figure 27). Both residual and tumor 
cells exhibited higher levels of malic, succinic, N-acetylaspartic and lactic acid, 
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tryptophan, histidine, uracil, proline and beta-alanine. Metabolites found in lower levels 
compared to the normal were: aspartic, palmitic, stearic, 2-ketoglutaric and pyruvic acid, 
inositol, glucose, taurine, glutamine, glycerol and glycerol 3-phosphate. Observed 
metabolic differences between the residual and tumor population were slight – the most 
prominent were higher levels of myristic acid (log2 FC=1,14), inositol (log2 FC=0,79) 
and glucose (log2 FC=1,01) in the residual samples.  
 
Figure 27: Heatmap of intracellular metabolites that were significantly changed (log2 FC>1, 
padj<0,01) in residual (OFF) and tumor (DOX) cells compared to controls (NI).  
Next, we applied Over Representation Analysis (ORA) using MetaboAnalyst 4.0, a tool 
for statistical, functional and integrative analysis of metabolomics data (126). The 
analysis, based on all the significantly changed (log2 FC>0,5; p<0,01) intracellular 
metabolites measured in the residual samples compared to normal, was performed to 
facilitate the insight into altered metabolic pathways in residual population (Figure 28). 
ORA hypergeometric test indicated that several pathways were significantly enriched: 
amino acid metabolism, ammonia recycling and urea cycle, sugar metabolism, 
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mitochondrial ETC and polyamine biosynthesis (Figure 28). Raw p-values are indicated 
in the legend. 
 
Figure 28: Over Representation Analysis (ORA) based on all significantly changed (log2 FC>0.5, 
padj<0,01) metabolites in residual population compared to the normal 
Extracellular metabolites analysis showed that around one half of metabolites were more 
than 1-log2 FC significantly different (limma linear regression model, Benjamini-
Hochberg padj<0,01) in residual and tumor cells compared to the normal (Figure 29). 
The residual population differed more from the tumor than in case of intracellular 
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metabolites, hinting at alternative pathways and decreased metabolites uptake by non-
proliferating residual cells. This is particularly visible in the case of glutamine/glutamate 
pool which was the lowest in the tumor cells, as expected, since they were highly 
proliferative and driven by the MYC oncogene that controls glutamine metabolism. 
Higher amounts of extracellular methionine, phenylalanine, isoleucine, serine and 
glucose was observed in residual cells when compared to the tumor, but it was lower in 
comparison to the normal cells. Extracellular succinic, fumaric and lactic acid, urea, 
ornithine, putrescine, proline and alanine were found to be elevated in residual 
population compared to the normal, albeit not to the extent seen in the tumor. 
 
Figure 29: Heatmap of extracellular metabolites that were significantly changed (log2 FC>1, 
padj<0,01) in residual (OFF) and tumor (DOX) cells compared to controls (NI) 
Decreased amount of extracellular glucose and high amount of extracellular lactate, as 
well as lower levels of intracellular glucose and higher levels of extracellular lactate were 
observed in both tumor (DOX; boxplots shown in red) and residual (OFF; boxplots shown 
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in blue) population compared to compared to normal (NI, WT; boxplots shown in green 
and dark green, respectively), reflecting their glycolytic phenotype (Figure 30). Urea, 
putrescine and ornithine were not significantly changed intracellularly, but have been 
found in significantly higher amounts extracellularly (Figure 30) in residual and tumor 
cells indicating their higher export from the cells and hinting at the alterations in the 
urea cycle.  
 
Figure 30: Boxplots showing the most prominent significant (padj<0,01) changes in levels of 
extracellular and intracellular metabolites between the three populations: tumor (DOX), residual 
(OFF), normal (NI). The concentration is measured as log2 (area under the curve = AUC). 
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3.4.4  Multi-omics data integration shows urea cycle and glycolysis as the 
prominent features of residual cell population 
In order to get an overall, systemic view of the changes happening in residual cells, we 
combined transcriptomic and metabolic data using bioinformatic tools. This included 
integration of datasets obtained by RNA-sequencing (described in Chapter 3.3) and 
metabolic measurements acquired by GCMS (described in Chapter 3.4.2 and 3.4.3). 
GCMS datasets were chosen because the metabolite could be precisely identified. Even 
though metabolites obtained by untargeted metabolic analysis (Q-Exactive MS, 
described in Chapter 3.4.2), were not directly integrated because of the limitations 
imposed by putative annotations, they could still be considered in the conceptual data 
integration and further hypotheses generation.  
In addition, to gain more detailed insight and information about metabolic alterations in 
tumor and residual cells, reporter metabolite analysis was performed. For this purpose, 
the Human Metabolic Reaction 2.0 (HMR2), a genome-scale metabolic model containing 
thousands of genes associated with thousands of reactions and unique metabolites 
(127), was revised. The Platform for Integrative Analysis of Omics Data (piano, an R 
package for enriched gene sets analysis) was applied (128) and the analysis was based 
on the differentially expressed genes where the q-values (p<0,05) and log 2 fold changes 
were taken to predict significantly changed metabolites (reporter metabolites).  
Analysis using the piano vignette distinct-directional class was used to obtain 
directionality of the predicted metabolite changes, by cancelling out gene sets containing 
both significantly upregulated and downregulated genes. Over Representation Analysis 
(ORA) in MetaboAnalyst 4.0 was performed on the top metabolites predicted (original 
padj <0,1, but maximally 5% of the total list of tested metabolites) to be found in higher 
levels in residual compared to the normal state. This analysis indicated changes in the 
metabolic pathways comprising sugar, nucleotide, amino sugar, amino acid, nitrogen 
and folate metabolism; mitochondrial ETC and TCA cycle; sphingolipid and glycerolipid 
metabolism; cardiolipin, phosphatidylcholine and phosphatidylethanolamine 
biosynthesis (Figure 31). Hypergeometric tests were performed to calculate the 
probability that a certain number of metabolites point to the pathway in the tested 
metabolites list. The legend indicates the raw p-values.  
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Figure 31: Over Representation Analysis (ORA) based on the top 5 % metabolites predicted to be 
upregulated in the residual cells 
Next, to visualize the global changes in the tumor and residual cells in comparison to the 
normal, an overlay of reactions inferred from transcriptomics data (see Chapter 3.3) 
with actual metabolites measured by GCMS (see Chapter 3.4.3) was made. For adding 
more information to this overall picture, reporter metabolite analysis (described above) 
was also included: this time taking 5% of changed metabolites according to the p-value 
after multiple testing adjustment (Benjamini-Hochberg). Global changes in the tumor 
cell compared to the normal are shown in the Figure 32. The inferred reactions were 
based on the genes, whose transcript levels were significantly changed. These genes 
were mapped to biochemical reactions according to the KEGG annotation of their 
encoding enzymes. When there were multiple enzymes annotated to the same reaction, 
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with a conflicting sign of change, the sign of the gene with the strongest log2 fold change 
was depicted. Measured metabolites that were significantly changed (padj<0,01; ones 
found to be elevated shown in red, lower in blue) with log2 FC>0,5 and metabolites that 
were predicted to be changed (reporter metabolites, marked with asterisk, padj <0,1) in 
the central metabolic pathways were integrated in the picture. This overlay showed that 
the tumor cells had high uptake of glucose and high glycolytic flux and redirection to 
lactate, but at the same time also the increased reactions in tricarboxylic acid (TCA) 
cycle. Alterations in intracellular abundance of some fatty acids were observed, such as 
decrease in palmitate and stearate. Intracellular cholesterol was also found in lower 
amount compared to normal. Increase in abundance of intracellular amino acids was 
seen, probably in relation to their enhanced anabolism for proliferative needs, reflecting 
changes typical for cancer metabolism. One novel interesting feature that showed up 
was an upregulated urea cycle. Extracellular urea levels, but also putrescine, were found 
to be higher in tumor cells. Urea cycle is independent, but connected to TCA cycle. The 
branch where arginosuccinate is converted to fumarate that feeds into TCA cycle was 
enhanced, with excreted fumarate found in higher amount. Another interesting 
observation were predicted changes in glutathione metabolism and indicated higher 
conversion of S-adenosyl methionine (SAM) to S-adenosyl-homocysteine (SAH) which 
could hint towards epigenetic changes. 
But what happens when we compare non-proliferative, residual cells to the non-
proliferative, normal cells? Quite surprisingly, despite their similarity to never induced 
structures, they still kept some prominent features of tumor metabolism (Figure 33). 
This was above all visible in higher glucose uptake, prominently increased glycolysis and 
lactate export and enhanced urea cycle, visible from upregulated genes but also 
metabolic measurements showing increased excretion of extracellular urea, ornithine 
and putrescine. In addition, pathway associated with nitric oxide (NO) production was 
found upregulated. Overlay also showed deregulated TCA cycle and some changes in 
metabolism of fatty and amino acids, albeit with differences compared to the tumor. One 
part of TCA cycle (from isocitrate to succinate) showed downregulation. In another part, 
succinate, fumarate and malate were accumulated. While palmitate, stearate and 
cholesterol were still low in the residual cell, we observed the increase in oleate and 
myristate. Levels of some amino acids were back to the normal, while others (leucine, 
isoleucine, tyrosine, phenylalanine, histidine and tryptophan) remained elevated. 
Changes in glutathione metabolism were also seen in residual cells, but conversion of 
serine into glycine and cystathionine was lower compared to the normal cells (while in 
tumor this was higher); however, conversion of homocysteine to cystathionine remained 
high.  
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This integration revealed the two most interesting pathways that emerged in both tumor 
and residual cells: glycolysis and urea cycle.   
 
Figure 32: Global overview of altered pathways in tumor versus normal cells. Graphical design was 
inspired by figure from (129). Abbreviations are explained in the List of Abbreviations.  
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Figure 33: Global overview of altered metabolic pathways in residual versus normal cells. Graphical 
design was inspired by figure from (129). Abbreviations are explained in the List of Abbreviations. 
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This helped us narrow down potentially interesting metabolic targets in residual cells, so 
we looked back to the RNA-Seq data, focusing on genes encoding key enzymes in these 
pathways (Figure 34).  
  
Figure 34: Genes encoding key enzymes found to be overexpressed in residual cells compared to 
controls (in red). A) Glycolysis; B) Urea cycle. Measured metabolites indicated by color. Schemes 
of the cycles modified from (130,131). Abbreviations are explained in the List of Abbreviations. 
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Apart from phosphofructokinase (Pfk), all genes encoding enzymes catalyzing steps in 
glycolysis were upregulated in the residual cells (Figure 34A). Genes encoding key 
enzymes in urea cycle: arginosuccinate synthase 1 (Ass1) and arginase 1 (Arg1) were 
also overexpressed compared to the levels of these genes in the normal cells (Figure 
34B). In addition, Citrin (Slc25A13) encoding aspartate transporter was upregulated. 
Log2 FC of the key significantly changed (padj<0,05; with the exception of Lin28a with 
original p=0,003 and padj=1) genes involved in these two pathways (glycolysis marked 
in yellow, urea cycle in green) are shown in Table 5.  
Table 5: Upregulated metabolic genes in the residual cells, encoding important enzymes in 
glycolysis and urea cycle. Abbreviations are explained in the List of Abbreviations. 
Gene Enzyme 
Log2 FC 
(residual) 
Log2 FC 
(tumor) 
Hk2 Hexokinase 2 1,60 2,00 
Gck Glucokinase 2,64 - 
Pgi Phosphoglucose isomerase 0,96 1,52 
Aldoa Aldolase A 1,23 1,28 
Tpi Triosephosphate isomerase 1,38 1,40 
Gapdh Glyceraldehyde 3-phosphate dehydrogenase 1,13 1,38 
Pgk1 Phosphoglycerate kinase 1 1,52 1,89 
Pgm1 Phosphoglucomutase 1 1,21 1,28 
Eno1 Enolase 1 0,66 1,24 
Pkm2 Pyruvate kinase  0,77 0,98 
Pdk1 Pyruvate dehydrogenase kinase 1 1,73 1,73 
Pdk4 Pyruvate dehydrogenase lipoamide kinase isozyme 4 2,31 - 
Pfkfb3 Fructose-2,6-biphosphatase 3 3,14 - 
Ldha Lactate dehydrogenase 0,58 0,91 
Mct4 Monocarboxylate transporter 4 1,55 - 
Lin28a Lin28 homolog A 3,08 9,59 
Ak4 Adenylat kinase 4 2,51 2,89 
Ass1 Arginosuccinate synthase 1 0,84 1,43 
Arg1 Arginase 1 1,26 1,65 
Slc25A13 Citrin 1,26 1,52 
iNos  Inducible nitric oxide synthase 6,67 3,36 
 
Overall data integration pinpointed at metabolic similarities between residual and tumor 
cells. It also hinted at potential metabolic vulnerabilities of residual population, revealing 
possible points of interference. Some of these genes encoding metabolic enzymes were 
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found upregulated in both tumor and residual cells and some were exclusively seen in 
the residual population. Interfering with the latter ones might represent a new 
opportunity to target significantly upregulated pathways in MRD. 
3.5 In vivo verification 
While our 3D culture system is clean and synchronous, enabling us to follow in detail 
dynamics of tumor initiation, progression and regression, while providing a reductionist 
approach without noise and complexity encountered in living organisms, it was important 
to validate these findings in vivo. This was done using tissues of the regressed mammary 
glands (animals that had full blown tumors, but these tumors regressed after Dox 
withdrawal) and their corresponding age-matched controls, whereby following 
experiments were performed: 
• obtaining extracellular metabolic profiles using GCMS measurements of 
metabolite levels excreted after culturing them for 8 hours, 
• validating the most interesting enzymes involved in glycolysis and urea cycle 
(shown in Chapter 3.4.4., Table 5) at the protein level using IF stains, 
• measuring enzyme activity of NOS in the tissues, 
• measuring flux to lactate after culturing for 8 hours in glucose- and pyruvate-free 
media supplemented with 13C glucose. 
All the age-matched controls were healthy, wild-type animals, that were also fed with 
doxycycline supplemented food, to exclude the potentially confounding effect. 
GCMS measurements of the extracellular metabolites from the regressed and healthy 
tissue confirmed our observation from 3D cultures (see Chapter 3.4.2, Figure 25B) – 
even after tumor regression, 9 weeks of doxycycline, mammary glands (Figure 35A, 
shown in blue) still clustered away in their extracellular metabolic profiles from the 
healthy glands of age-matched controls (Figure 35A, shown in green). PC1 explained 
63,6% of variance, while PC2 explained 16,9%. 
We measured 37 metabolites by GCMS. The most prominent changes (padj<0,05) were 
seen in the levels of: urea, ornithine, putrescine, proline and glycine that were higher in 
the extracellular media of the regressed glands and pyruvate that was lower (Figure 
35B). Higher levels of urea, ornithine, putrescine and proline were in concordance with 
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the extracellular profiles obtained from the 3D cultures (see Chapter 3.4.3, Figure 30), 
hinting at changes connected with urea cycle.  
 
Figure 35: Extracellular metabolic profiles from regressed and normal mammary glands measured 
by GCMS. A) PCA plot; B) Selected significantly changed metabolites (LIMMA, p<0,05). The 
concentration is measured as log2 (AUC).  
We observed a trend in the increase of extracellular lactate and decrease of extracellular 
glucose in the regressed glands compared to normal, which would be consistent with our 
findings from 3D cultures, but the sample variation in these two metabolites was quite 
large in this experiment (Appendix, Figure 54). Metabolites that were not in agreement 
with the ones measured in 3D cultures were glutamine and aspartate that were higher 
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extracellularly in the residual samples (regressed samples, Appendix, Figure 54) as 
opposed to in vitro measurements where they were lower compared to the normal 
samples (see Chapter 3.4.3, Figure 29). Other metabolites (that were not measured in 
vitro) found to be significantly higher when residual (regressed tissue) was compared to 
the normal included: 2 keto-glutaric acid, 4-hydroxyproline, asparagine, taurine and 
uracil (Appendix, Figure 54). 
Next, we wanted to validate upregulated targets (see Chapter 3.4.4, Table 5). From this 
list, 8 genes were selected to be checked on protein level by IF staining performed on 
the formalin fixed, paraffin embedded (FFPE) tissues. The choice was driven by the 
availability of specific antibodies, known roles of these proteins and their potential 
significance as targets for interference. The following targets were further tested: 
• HK2 that catalyzes the first step of glycolysis and is isoform commonly found 
overexpressed in many cancers; 
• PDK1 that phosphorylates and inhibits pyruvate dehydrogenase (PDH), thus 
preventing conversion of pyruvate to acetyl-CoA; 
• MCT4, a transporter that exports lactate from the cell; 
• AK4 that directs metabolism towards aerobic glycolysis; 
• LIN28A that acts as a glycolytic switch, favorizing aerobic glycolysis; 
• ASS1 that catalyzes conversion of aspartate to arginosuccinate; 
• ARG1 that catalyzes the last step of urea cycle, i.e. conversion of arginine into 
ornithine and urea; 
• iNOS (NOS2) that catalyzes conversion of arginine to nitric oxide. 
To get an overview of the whole section, slides were scanned using TissueFAXS. 
StrataQuest5, the corresponding program for the analysis, was used for the 
quantification of number/percentage of positive cells and the intensity of the signal in 
the selected ducts.  
From the above-mentioned targets, HK2, AK4, LIN28A and iNOS showed very slight 
differences in their levels between the regressed and healthy tissue. However, strikingly 
significant differences were observed when the levels of ARG1 were compared (Figure 
36).  
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Figure 36: Arginase1 verification on the tissues of animals 9 weeks off doxycycline (regressed 
mammary glands) compared to healthy age-matched controls. Top panel: IF stains – E-cadherin 
in red, ARG1 in green; nuclei stained with DAPI (blue). Scale bar: 50 µm. Below: Percentage (left) 
and mean intensity (right) of ARG1 positive cells. Abbreviations are explained in the List of 
Abbreviations. 
Even though ARG1 was present in the healthy tissue as well, it was obviously more 
abundant in the regressed glands, as determined by quantification: percentage of ARG1 
positive cells was significantly higher (unpaired homoscedastic one-tailed t-test, 
p<0,001) in the group of residual cells. The trend towards increased mean intensity of 
ARG1 was seen in the regressed ducts.  
IF staining of HK2 did not reveal prominent differences between the regressed and 
normal glands, but we did observe a tendency towards its slightly enhanced levels in the 
regressed glands (Figure 37). The same trend towards slightly higher levels in the 
regressed glands was observed in IF stains for LIN28A, AK4 and iNOS (Appendix, Figure 
55). Differences were not seen in the levels of PDK1 (Appendix, Figure 56A). Slight 
decrease of ASS1 was observed in the regressed glands (Appendix, Figure 56B). 
Unfortunately, it was not possible to detect the chosen MCT4 antibody on the tissue 
sections. 
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Figure 37: IF staining of HK2. CDH1 (E-cadherin) in red, HK2 in green; nuclei stained with DAPI 
(blue). Some examples of regions of interests (ROIs) are shown. Scale bar: 50 µm. Below: 
Percentage (left) and mean intensity (right) of HK2 positive cells. Abbreviations are explained in 
the List of Abbreviations. 
Since NOS2 was found strongly upregulated on the transcriptional level in the residual 
samples in vitro (see Chapter 3.4.4, Table 5) and slightly, but not significantly 
upregulated on the protein level in vivo (Appendix, Figure 55C), we additionally 
performed NOS assay to check its specific enzymatic activity. We measured significantly 
increased (unpaired homoscedastic one tailed t-test, p<0,03) NOS activity in the 
regressed samples compared to the age-matched controls (Figure 38A).  
As enzymes involved in glycolysis showed upregulation on the transcriptional level, 
starting from HK2 that catalyzes its initial step to LDHA which catalyzes end reaction 
converting pyruvate to lactate (see Chapter 3.4.4, Table 5), we wanted to verify 
increased glycolytic flux towards lactate production in the residual cells. Thus, we 
performed flux analysis using labeled 13C glucose. This experiment confirmed statistically 
higher (Wilcoxon, Mann-Whitney test; p<0,05) conversion to lactate in the regressed 
mammary glands (Figure 38B). 
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Figure 38: In vivo intracellular metabolic verifications on the regressed and healthy mammary 
glands. A) NOS enzymatic assay; B) Levels of lactate labeling by 13C glucose  
3.6 CORRELATION OF THE MAIN FINDINGS WITH HUMAN DATASETS 
After verifying the most prominent findings hinting at alterations in glycolysis and urea 
cycle/arginine metabolism in vivo, we further explored their relevance in the human 
breast cancer. This was done through the comparison of microarray datasets obtained 
from 21 patient samples (132) collected before the treatment (fine needle aspiration, 
tumor cells) and after application of neoadjuvant systemic therapy (resected after 4-6 
months, i.e. post-treatment, residual) with the normal tissues from 9 healthy women 
(133). After data preparation, its filtering and exclusion of normal-like subtype due to 
high biological variation and poor diagnostic criteria, PCA was performed (Figure 39) and 
it showed clustering that reflected the pattern previously observed in vitro, from our 
RNA-seq data (see Chapter 3.3, Figure 17B). Pre-treatment (tumor, shown in squares), 
post-treatment (residual, shown in triangles) and healthy (normal, shown in circles) 
samples clustered separately.  
Furthermore, groups that were different among each other with respect to the tumor 
type (indicated by different symbols) and treatment, still clustered together. The first 
principal component explained 14,6% of variance and the second 11,4%.  
Clustering of transcriptomic signature obtained from our mouse model with specific gene 
expression profiles from the patient samples revealed its closeness to basal HER2 
positive sample (communication with Katharina Zirngibl). We next looked into 
differentially expressed genes between post-treatment (residual) and normal samples, 
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involved in glycolysis and urea cycle, to check if the targets we identified in mice would 
be also differentially expressed in the publicly available human sample datasets of MRD.  
 
Figure 39: PCA performed on microarray datasets from breast cancer patients (pre- and 
posttreatment) and healthy women. Abbreviations are explained in the List of Abbreviations. 
Strikingly, the following genes encoding enzymes involved in urea cycle and nitric oxide 
(NO) synthesis upregulated in our mouse model were also significantly (padj<0,1) 
upregulated in the post-treatment sample of this subtype compared to the controls 
(Figure 40, log2 FC shown in colors): ASS (6.3.4.5), ARG (3.5.3.1) and NOS 
(1.14.1339).  
Besides overexpression of HK (2.7.1.1), PFK (2.7.1.11) and LDH (1.1.1.27), other 
glycolytic enzymes found upregulated in mouse were not found significantly changed 
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(Figure 41). Still, increased gene expression of these genes indicated changes in 
glycolysis and upregulation of LDH in particular hinted at redirection of glycolytic flux 
towards lactate production.  
 
Figure 40: Altered gene expression encoding enzymes involved in arginine metabolism (urea cycle, 
NO synthesis) in basal HER2 positive breast cancer subtype sample. Pathway map was adapted 
from KEGG pathway database (134). Abbreviations are explained in the List of Abbreviations. 
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Figure 41: Altered gene expression encoding enzymes involved in glycolysis in basal HER2 positive 
breast cancer subtype sample. Pathway map was adapted from KEGG pathway database (134). 
Abbreviations are explained in the List of Abbreviations. 
 83 
 
RESULTS 
However, we could not draw the conclusions about this particular subtype (basal HER2 
positive) as it was represented with only one sample in the dataset. Nevertheless, the 
next closest subtype, basal HER2 negative, showed upregulation of ASS (6.3.4.5) 
(Appendix, Figure 57) and alterations in glycolysis (Appendix, Figure 58) as well, having 
overexpressed genes encoding GAPDH (1.2.1.12), ENO (4.2.1.11) and LDH (1.1.1.27). 
As altered glycolysis was not seen in luminal A and luminal B subtypes, it could be that 
this feature was more specific for basal HER2 positive and negative breast cancer 
subtypes.   
Overall, human samples of HER2 negative and positive subtypes showed higher levels 
of enzymes involved in urea cycle/arginine metabolism: ASS, ARG, NOS. The glycolytic 
genes found overexpressed in these subtypes were: HK, PFK and LDH.  
We identified glycolysis and urea cycle as the most prominent altered pathways in the 
mouse residual cells (see Chapter 3.4.4), which we further verified in vivo through 
metabolic measurements on the mouse regressed (compared to mouse normal) tissue, 
measurement of flux towards lactate, IF stains of selected proteins and enzymatic NOS 
assay (see Chapter 3.5). Measured metabolites and flux hinted towards alterations in 
these pathways and IF stains and enzymatic assays verified the most interesting targets 
– ARG1, HK2 and iNOS being the most important ones, as they were verified on several 
levels (all three transcriptionally in vitro; all three on protein levels in vivo and NOS 
through enzymatic activity). Furthermore, the relevance of these pathways and targets 
was verified in human datasets of MRD which, for basal HER2 negative and positive 
subtypes showed changes in glycolysis and urea cycle. In this regard, basal HER2 
positive sample was particularly interesting as it showed the upregulation of ASS, ARG, 
NOS, HK and LDH that we identified, using our mouse model, as potentially important 
targets of MRD.  
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3.7 LIPIDOMICS ANALYSES REVEAL CHANGES IN LIPID COMPOSITION 
IN RESIDUAL POPULATION 
Seeing the changes in the transcriptome and metabolic profiles of residual cells, we were 
interested if this would hold true for another class of compounds – lipids. As lipid 
metabolism clearly emerged from predictions based on RNA-Seq and array data as a 
characteristic of residual population in our previous study (119), we employed lipidomics 
to validate these findings on metabolic level and to expand our picture of minimal 
residual disease.  
Metabolic method that we established for harvesting metabolites from 3D cultures 
proved successful for the subsequent lipidomics analyses. Extraction of lipids was done 
using Bleigh-Dyer protocol (chloroform-methanol-37% HCl). Membrane- and protein-
bound, as well as free lipids were detected by “shotgun lipidomics” using Qtrap 6500+ 
coupled with NanoMate. In total, 227 lipids were measured from intracellular samples. 
PCA on lipidomics data showed distinctive profile of residual population (shown in blue), 
from normal (shown in green) and tumor (shown in red), similarly as was seen on the 
transcriptomic level (Figure 42A). The first principal component explained 51% of 
variance and the second 22%. 
 
Figure 42: Differences in lipid composition between normal (NI), tumor (DOX) and residual (OFF) 
populations. A) PCA plot based on measured lipids; B) Measured lipid categories. Error bars 
represent Mean ± 1SE. Abbreviations are explained in the List of Abbreviations.  
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Based on these data, centroids were calculated, showing the center of each sample group 
on the plot. Euclidean distance between the centroids showed that the tumor and 
residual samples were still closer (DOX-OFF 14,2) than normal and residual (NI-OFF 
19,8). Confidence interval of a multivariate normal distribution is represented by the 
ellipses (CI = 0,95).  
Figure 42B shows measured lipid categories: glycerolipids (GL), glycerophospholipids 
(GP), sphingolipids (SP) and sterol lipids (ST). Statistically significant differences (t-test; 
p<0,05) between the residual and normal populations were seen in slightly lower mol 
percentage of sterol lipids in the residual cells. When compared to the tumor, residual 
cells showed significantly higher amount of glycerolipids and lower amount of 
glycerophospholipids. Comparison of tumor cells to normal showed the lower molar 
percentage of sterol lipids and glycerolipids and higher molar percentage of 
glycerophospholipids in the tumor cells.     
The measured lipid classes are shown in the Figure 43A: phosphatidylcholine (PC), 
lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), phosphatidylserine (PS),  
phosphatidylinositol (PI), phosphatidylglycerol (PG), phosphatidic acid (PA), 
diacylglycerol (DAG), ceramide (Cer), sphingomyelin (SM), hexosylceramide (HexCer), 
dihexosylceramide (Hex2Cer), cholesterol (Chol), cholesteryl ester (CE) and 
triacylglycerol (TAG). The prefix “O” indicates that there is an alkyl ether substituent in 
the marked species; “P” stands for plasmalogen substitute. A statistically significant 
(marked with asterisk) increase was observed in PG species in the residual cells when 
compared to normal. Significantly lower levels of LPC, PS, PG O-, PA, HexCer, Hex2Cer 
and cholesterol were seen in the residual population compared to normal. When 
compared to the control, tumor cells also exhibited significantly lower levels of PS, PA, 
HexCer, Hex2Cer and cholesterol, but higher TAG and PC, PE, PI and Cer (Appendix, 
Figure 59). In comparison to the tumor state, residual cells had lower levels of PC, PE, 
PI, PG O- and Cer and higher levels of PG and TAG (Appendix, Figure 60).  
When looking across all the lipid classes at the level of lipid species, we observed many 
statistically significant changes in abundance of certain lipid species. This was true also 
for the lipid species within the classes which did not show overall changes in abundance. 
For instance, we observed a shift from short to long chain fatty acids in sphingomyelin 
species (Figure 43B), which could be indicative of some changes in membrane 
composition and its stiffness/rigidity. This was also seen in the lipid species within 
ceramides. Another interesting change is the depletion of arachidonic acid species in 
phosphatidylethanolamines class (Appendix, Figure 61). 
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Figure 43: Changes in lipid composition between residual and normal population. A) Measured 
lipid classes; B) Shift from short to long chained sphingomyelin (SM) species in the residual cells. 
Error bars represent Mean ± 1SE. Abbreviations are explained in the List of Abbreviations. 
In order to further verify the most prominent lipid features and potentially interesting 
lipid biomarkers in residual population, we attempted to set up and employ imaging 
mass spectrometry (IMS). IMS is an exciting new tool for obtaining information on spatial 
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distribution of metabolites within a sample. This particular method was chosen as it 
would allow to discriminate between the signal that comes from mammary gland 
epithelial structures and the surrounding adipose and stromal tissue.  
Mammary glands were embedded in gelatin (as this material was compatible with IMS), 
snap-frozen and cut into sections that were dried in vacuum desiccator and covered with 
matrix that would assist the ionization. As the laser was moving across the sample, it 
collected the mass spectra, whereby ion intensities were plotted against the relative 
position of the analytes from the sample. Analysis was done using bioinformatic 
framework for FDR-controlled metabolite annotations for high-resolution IMS (135). 
Workflow is summarized in Figure 44A. Specific mammary gland composition, i.e. high 
percentage of fat (70-80%) and incompatibility of freezing temperatures for surrounding 
adipose tissue, ducts and embedding media proved to be a great challenge for cryo-
sectioning. This led to the suboptimal morphology of the samples (Figure 44B, upper 
panel) that could affect the final picture of metabolites’ spatial distribution. Thus, great 
efforts were invested into preparing the sample for subsequent analyses. This was 
improved through use of certain fixatives and cryoprotectants that significantly 
preserved the morphology of the ducts (Figure 44B, lower panel). The drawback to this 
was that the sample treatment negatively affected metabolite detection compared to the 
freshly frozen samples; the number of annotated metabolites at FDR 0,2 was around 
three times lower in the treated samples (Appendix, Figure 62A,B). However, for the 
purpose of targeted metabolomics, method has the potential to be further optimized 
through fine-tuning of other parameters (choice of matrix, mode, laser power etc.). As 
we were mostly focused on detecting lipid metabolites such as the ones potentially 
corresponding to stearic acid and phosphatidylserine (shown in Figure 44C) this method 
could indeed be a great target approach to validate lipid biomarkers in vivo. However, 
detection of other classes of compounds is also possible (Appendix, Figure 62C), opening 
possibility for spatial imaging of other potentially interesting targets.  
Lipidomic analyses demonstrated changes in lipid profiles of the residual cells. Future 
verification of these findings in vivo could yield novel biomarkers and provide new 
insights into the role of lipids in MRD. Since normal and regressed mammary gland 
phenotypically look very similar, with appropriate standards, normalization and relative 
quantification it would be possible to compare the abundance and spatial distribution of 
desired molecules between the two populations using IMS.  
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Figure 44: Setting-up spatial metabolomics - imaging mass spectrometry for in vivo verification of 
potential lipid biomarkers. A) Workflow; B) Comparison of morphology of snap-frozen and PFA-
treated tissue; C) Examples showing detection of metabolites corresponding to stearic acid and 
phosphatidylserine (PS) in the regressed gland. Abbreviations are given in the List of 
Abbreviations. 
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3.8 METABOLIC MEMORY IN RESIDUAL CELL POPULATION – KEEPING 
THE MAIN METABOLIC FEATURES OF TUMOR CELLS 
Since prominent features of metabolism characteristic for tumor cells were preserved in 
the residual population also in vivo even 9 weeks after oncogenes deactivation, we 
referred to them as “metabolic memory”. But when is this memory established and how 
is it kept? 
We hypothesize that there is a threshold, an early point in neoplastic transformation 
where cells still have the flexibility to return to the normal state. From our initial 
experiments of deactivating oncogenes earlier (i.e. mimicking the treatment in earlier 
stages), we noticed that there were differences in the response of the cells to doxycycline 
withdrawal when they had been kept on doxycycline for shorter time (60 hours) than 
usual 5 days: it seemed that they were not dying, but rather simply reintegrating into 
the existing rim. Thus, we hypothesize that the cells that were shortly exposed to 
oncogene action had the plasticity and capacity to restore their normal phenotype. To 
explore this further, we decided to follow the dynamics of oncogenesis (from initiation 
over progression to full blown tumor structures) and regression in detail.   
3.8.1  Phenotypes during oncogenesis and tumor regression  
In order to track the dynamics of oncogenesis and regression in our synchronously 
behaving acinar population in 3D culture, phenotypes were closely followed employing 
IF stains and confocal imaging. First, RNA was collected and extracted over 18 timepoints 
for each of the 4 biological replicates (Figure 45A). Then, another experiment was 
conducted over 17 timepoints for each of the 3 biological replicates, whereby the cells 
had shorter (60 hours) exposure to the oncogenes action (Figure 45B). Seeing the 
preliminary results of comparison between the two experiments, we decided to include 
even earlier timepoint, i.e. even shorter (36 hours) exposure to the oncogenes action, 
which would correspond to even earlier “treatment” (Figure 45C). This experiment was 
done over 15 timepoints for each of the 3 biological replicates.  
We termed the kinetics of regression as:  
• late regression (from 5 days on doxycycline up to 7 days off),  
• mid regression (from 60 hours on doxycycline up to 7 days off), and  
• early regression (from 36 hours on doxycycline up to 7 days off)  
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Figure 45: Experimental design to follow kinetics of tumorigenesis and regression. Phenotypes 
were recorded and RNA collected over shown timepoints during tumorigenesis (red) and regression 
(blue). A) Exposure to oncogenes action for 5 days and “late” regression; B) Exposure to 
oncogenes action for 60 hours and “mid” regression; C) Exposure to oncogenes action for 36 hours 
and “early” regression  
Imaging of the induced structures in comparison to the healthy ones (Figure 46A) 
showed that the structures exposed to oncogenic action for 36 hours were still limited 
to a single rim (Figure 46B, upper panel). This changed during tumor progression – at 
60 hours they started to fill up the lumen (Figure 46B, middle) and at 5 days they 
corresponded to a full-blown tumor (Figure 46B, lower panel).  
Upon oncogene deactivation (doxycycline withdrawal), the structures followed the same 
regression pattern (Figure 46C) and 7 days after they all looked phenotypically normal 
(Figure 46D).  
IF stains for polarity markers: alpha-6-integrin (shown in red), ZO-1 (shown in green) 
and GM130 (shown in magenta) showed loss of polarity in the structures going through 
the tumor progression (Figure 46B, middle and lower panel) and at the initial phases of 
the regression (Figure 46C, middle and lower panel). The regression to the single rim 
and repolarization of the structures was achieved at the end of the regression (Figure 
46D, middle and lower panel). Structures exposed shortly to the oncogenes’ expression 
did not seem to go through phenotypic changes, resembling to the normal structures in 
all the phases (Figure 46B, C, D, upper panel). 
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Figure 46: Phenotypes of the structures at the most critical time-points during tumor initiation, 
progression and regression. Polarity markers – α6-integrin (red), ZO-1 (green), GM130 
(magenta); nuclei stained by DAPI (blue). A) Normal structure (never induced); B) Structures 
during tumor initiation and progression; C) Structures during initial phases of tumor regression; 
D) Structures at the end of regression. Scale bar: 50 µm. 
Next, we performed IF staining for following the expression of human MYC oncogene 
(Figure 47, shown in green). Even though the structures looked phenotypically healthy, 
identical to normal at 36 hours on doxycycline, human MYC was expressed (Figure 47B, 
upper panel) as further during tumor progression (Figure 47, middle and lower panel). 
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Upon oncogene inactivation, human MYC expression was gone by 6-8 hours after and 
structures looked the same in early, mid and late regression (Figure 47C, D).  
 
Figure 47: MYC expression in the structures at the most critical time-points during tumor initiation, 
progression and regression; E-cadherin (red); human MYC (green). A) Normal structure (never 
induced); B) Structures during tumor initiation and progression; C) Structures during initial phases 
of tumor regression; D) Structures at the end of regression. Scale bar: 50 µm. 
Nevertheless, the stain for apoptosis using Caspase3 marker of cell-death showed that 
structures in the early and mid-regression did not seem to be dying in the response to 
oncogene withdrawal as was the case in the late-regression (Figure 48). Caspase3 was 
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absent in the healthy structure (Figure 48A). It was present in a few cells during the 
tumor progression (Figure 48B, middle and lower panel). While majority of the cells were 
dying during in the initial phases of late regression (Figure 48, lower panel) this was not 
obvious for the structures in early and mid-regression (Figure 48C, upper and middle 
panel).  
 
Figure 48: Caspase3-dependent apoptosis in the structures at the most critical time-points during 
tumor initiation, progression and regression; E-cadherin (red), Caspase3 (green). A) Normal 
structure (never induced); B) Structures during tumor initiation and progression; C) Structures 
during initial phases of tumor regression; D) Structures at the end of regression. Scale bar: 50 
µm. 
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3.8.2  Transcriptomic profiles during oncogenesis and tumor regression  
The observations on the level of phenotypes were further followed by RNA-sequencing. 
PCA plot from transcriptomics data (Figure 49) illustrates the kinetics of the changes: 
green dots represent the normal, never induced cells; red dots and red arrow indicate 
timepoints during tumor initiation and progression; blue dots and blue arrow indicate 
timepoints in the late regression; pink dots and pink arrow show timepoints during mid-
regression; finally, yellow dots and yellow arrow indicate timepoints during early 
regression. From the PCA plot it was visible that the residual cells from late and mid 
regression had a slightly different trajectory in the beginning (corresponding to the 
different time of oncogene inactivation and their different response), but later on 
clustered together, not returning to the normal state, still being profoundly changed.  
 
Figure 49: PCA showing clustering of cell populations at many time-points during tumor initiation, 
progression and late, mid and early regression.  
 95 
 
RESULTS 
Strikingly, in the early regression trajectory, cells once exposed to the oncogene action 
managed to follow back to the normal state. We identified this as the “the point of no 
return”, upon which major events that drive tumor progression happened; a threshold 
that, once being crossed, changed the cells in such a profound manner, probably shaping 
“oncogenic memory” that would be kept even though the driver oncogene was no longer 
expressed. 
 
Figure 50: Kaplan-Meier survival curve for the mice with shorter (5-10 days; “early off” group) 
and longer (4-6 weeks; “late off” group) exposure to the oncogene action. 
Our findings were reflected in the observations from the in vivo experiments. We 
compared relapse-free survival between animals exposed to oncogene action for short 
time (5-10 days; corresponding to our early regression endpoints in vitro), named “early 
off”) and standard, long time named “late-off” (4-6 weeks, corresponding to our late 
regression endpoints in vitro). The mice exposed for short time to the oncogene had a 
significantly (Log-Rank test, p<0,0001) higher relapse-free survival (less of relapses 
compared to the other group).  
 
 96 
 
 
 97 
 
 
 
 
 
 
 
DISCUSSION 
Chapter 4 
 98 
 
DISCUSSION 
4.1 A THREE-DIMENSIONAL CELL CULTURE SYSTEM AND INDUCIBLE MOUSE 
MODELS AS A CORRELATE OF MINIMAL RESIDUAL DISEASE 
Cell cultures have been of a great importance in exploring, uncovering and 
understanding intricate cellular processes, shedding the light on many biological 
questions. In vitro studies of metabolism have provided new insights into how its 
reprogramming helps cell growth and proliferation, which nutrients are extensively 
utilized and which pathways are altered. Three-dimensional culture systems provided an 
additional step forward, as they represented a transition between commonly used 
classical 2D cultures and multicellular structures grown in more appropriate 3D 
organization which mimick organ architecture and function.  
The system we employ to culture primary luminal epithelial cells harvested from the 
mammary glands of TetO-MYC/TetO-Neu/MMTV-rtTA mice in 3D, provided the following: 
matrigel that represents exogenous extracellular matrix (ECM) supported the growth of 
primary mammary cells in 3D, physiological conditions, allowing them communication, 
correct signaling, cell-to-cell- and cell-to-matrix interactions, more faithful diffusion of 
nutrients and proper cellular adhesion. All these features together enable polarized cell-
cell communication and gene expression patterns which would otherwise be absent or 
altered in 2D cultures (136). Compared to in vivo experiments, which represent the 
current “gold standard” with respect to modeling complex physiological cell behavior, 
experiments using 3D cultures enabled more controlled conditions, better reproducibility 
and require a shorter time to be conducted, while preserving the hallmarks of tissue 
architecture and phenotypic readout.  
Employing an inducible system (described in Chapter 3.1) that allowed us to express 
oncogenes specifically in the epithelium of a mature mammary gland (mimicking 
oncogenesis in adulthood) and switching them off (specifically, as they would be aimed 
at by the targeted therapy), brought us closer to the human patient situation. Selection 
of primary epithelial cells enabled working with this relatively homogenous, clean and 
synchronous system, in the absence of many confounding factors coming from the 
complexity and heterogeneity encountered in vivo. These primary cells are not 
genotypically or phenotypically changed by immortalization (137). 
Having an extract of basement membrane (Matrigel) with collagen has been crucial to 
propagate proliferating single cells, which would later dispose their own ECM 
components. Some 36 hours after seeding single cells, colonies of 6-8 cells were formed. 
Their growth and division in the following days resulted in the formation of a hollow ball-
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shaped acinus (spheroid). Lumen was formed by epithelial cells, which are organized in 
a single layer. This acinus corresponded to the TDLU in the mammary gland. These cells 
exhibited contact inhibition and were polarized, which meant that the specific proteins 
and lipids would be asymmetrically distributed, giving apical-basal polarity (138). When 
cells are polarized, specific molecules are found on the surface of the apical domain 
(oriented towards the lumen). Along with this, complexes are also present here that 
allow for the exchange of nutrients and other molecules. The basolateral part is 
composed of cadherins which enable interaction with neighboring cells and the ECM, 
attaching the cells to the basement membrane (138).  
Studying oncogenesis and regression driven by two oncogenes – c-MYC and Her2/Neu – 
reduced the tumor complexity and allowed us to observe the tumor initiation, 
progression and the phenomenon of addiction to the driver oncogenes. In addition, it 
allowed us to study the characteristics of the cells that escape from oncogene addiction. 
Upon oncogene induction, cells in these acini proliferated in a disorganized fashion, filling 
up the lumen in the absence of contact with the basement membrane, which reflected 
its nature as carcinoma. As the cells uncontrollably divided, their polarity was also 
gradually lost. GM130, which is a marker for Golgi, was not anymore restricted to its 
apical location within the cells; ZO-1, a marker for intercellular tight junctions which 
separate membrane components between apical and basal domains, was majorly 
reduced; alpha-6-integrin, a transmembrane protein responsible for anchoring the basal 
part and interpreting the signals from the microenvironment was not anymore restricted 
to basal domain.  
However, upon oncogene withdrawal, the majority of the cells died but a certain subset 
survived. In another inducible system TetO-cMYC/TetO-Kras/MMTV-rtTA it was shown 
that a large fraction of the cells without a matrix attachment lost their mitochondrial 
potential and died (118). Even though the mechanism behind the survival of these cells 
remains unknown, it is likely that re-establishing the contact with the basement 
membrane is also crucial; similar was found in MCF10A cells where proapoptotic protein 
Bim is inhibited by integrin β1- and EGFR signaling, preventing anoikis (118). 
Surviving cells reorganized and regressed back to the single rim. These residual 
structures exhibited a hollow lumen, phenotypically looking very similar to the controls. 
However, microarray data (119) and RNA-Seq analysis revealed that these cells were 
transcriptionally different from both tumor- and control populations (described in 
Chapter 3.3). This residual population is dormant, which was previously demonstrated 
by low Ki67 (a proliferation marker) stain positivity (119) and also reflected in the 
downregulated pathways that reflect cell division processes. 
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Moreover, spontaneous in vitro relapses, in the absence of doxycycline, were detected 
when organoids derived from residual structures were reseeded, which was not the case 
for the cells coming from the normal, healthy structures (119). Thus, this system 
represents a good correlate of MRD that enabled us to characterize it in depth, employing 
a variety of methods – immunofluorescence and confocal microscopy for following the 
changes in phenotype, RNA collection for obtaining transcriptomic profiles, metabolites 
harvesting for revealing its metabolic landscape and DNA harvest for assessing 
methylome profiles and nature of preserved metabolic memory (approach described in 
Chapter 3.2). Moreover, our 3D cultures faithfully recapitulate in vivo dynamics. 
Although the 3D culture models represent an immensely valuable tool for studying MRD 
we are also aware of its limitations. Acini in 3D are isolated structures whereas in the 
mammary glands they are branching, connected with the ducts and under the influence 
of many physiological processes such as hormonal changes and tissue remodeling during 
various stages of the estrous cycle (137). This is also a monoculture model, which lacks 
other types of cells, primarily the outer myoepithelial layer. While in the 3D model 
luminal epithelial cells are in direct contact with the basement membrane, in vivo they 
would be mostly in contact with myoepithelial layer, connected to the basement 
membrane only through punctual contacts (137).  
Immune responses, other types of cells in the microenvironment and the systemic 
effects of the organism as a whole are also missing. Moreover, metabolic choices of 
cancer cells are heavily influenced by the available nutrients and thus might not reflect 
the real scenario, as there is a discordance between the abundance, ratio and presence 
of different nutrients in the cell culture media and in the body (139). Although better 
than in 2D, nutrient diffusion in 3D models might not be a faithful recapitulation of 
diffusion in vivo. Additional complexity brought in in vivo conditions comes from the 
dynamic interaction of tumor cells with their environment, their normal counterparts, 
other cell types and tissues and the effect that the whole-body metabolic changes have 
on the cancer (139).   
Despite certain constraints, 3D cultures still represent a great tool for research; they 
have been able to faithfully reflect many key biological phenomena found in vivo (137), 
especially in terms of increased nutrient uptake, flux through glycolysis, protein turnover 
and lipid catabolism (139). 3D cultures continue to be utilized in numerous scientific and 
pharmacological studies, tissue engineering and regenerative medicine. Limitations can 
be overcome through subsequent validation of the prominent findings in murine models 
in vivo, which is an approach we took.  
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In vivo validation of the key findings was performed through experiments on inducible 
mice models which were fed with doxycycline supplemented food to express the 
oncogenes. Inducible mouse models significantly improved research in the field of 
cancer, harboring key oncogenes identified in human tumors and enabling their fast 
induction in the tissues of interest as well as their rapid de-induction. This possibility to 
switch the desired oncogenes on and off gives them a great advantage over constitutive 
models. Characterization of our 3D models through many time-points during 
tumorigenesis and regression, showed that the MYC oncogene was induced as early as 
one hour after doxycycline administration and was no longer detectable 6-8 hours upon 
doxycycline withdrawal. The mouse mammary tumor virus long terminal repeat (MMTV) 
sequence enabled tightly regulated and homogeneous expression of oncogenes 
specifically in the mammary gland tissues (140). One aspect that still needs to be 
improved is that the oncogenes are induced in the majority of cells, which does not 
reflect the real state where neoplastic transformation starts in one cell. Some new 
murine models where this issue is being addressed are being developed (141).  
Our previous research showed that the oncogene activation in TetO-cMYC/TetO-
Neu/MMTV-rtTA mice led to the rapid onset of invasive mammary carcinomas (119). 
When animals developed full-blown tumors with a large tumor burden (10% of body 
weight maximum expansion), they were put on the normal diet, thus silencing the 
oncogene expression and allowing for tumor regression to a nonpalpable state. Complete 
regression happens due to the strong oncogene dependence. However, tumors reoccur 
after a long dormancy period, usually six months after oncogene deactivation (119).  
Recurrences were also previously demonstrated in another MMTV-rtTA regulated mouse 
model with the same activated Neu transgene, where its expression remained 
undetected in relapses, indicating the independence of a residual population on Neu 
overexpression (121). In another mouse model with inducible MYC, the authors showed 
that the re-activation of the tumor initiating oncogene happened through somatic 
mutation in the MMTV-rtTA that rendered it independent of doxycycline activation (142). 
Since this subset of surviving cells is known to subsequently drive tumor relapses, it 
allowed us to verify findings from our 3D culture system also in vivo, on the population 
that more faithfully represented residual cells; these cells serve as a correlate of MRD. 
Furthermore, we were interested how the findings from the mouse models correlated to 
the human situation. 
Mouse mammary carcinomas are heterogeneous, with around 17 distinct subtypes 
characterized based on their specific transcriptomic profiles (143). They harbor different 
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driver mutations, but some also show intra-model variation (143). Besides existing 
subtypes in mice and humans, defined based on their histopathology and molecular 
profiles, identification of novel biomarkers keeps revealing new subgroups, with many 
distinct but also overlapping features. When compared to the human breast cancers 
according to their transcriptomic profiles, murine models with MYC amplification were 
linked to human basal-like breast cancer (143).  
Although MMTV-Neu mouse models surprisingly resembled more to the luminal A tumors 
(143), another study also showed their clustering to a proportion of HER+ human 
cancers (144). Residual cell population from our mouse models clustered closely with 
the basal subtype, sharing some of the key altered pathways such as glycolysis or the 
urea cycle/arginine metabolism in basal Her2+/- samples. This was not surprising, given 
the fact that the oncogenesis in our system was driven by MYC and Neu oncogenes and 
considering their previously established link with human breast cancer subtypes. 
Mouse mammary glands exhibit a certain difference from human breast architecture. In 
terms of their structure, nulliparous mammary glands are simpler and their lobules 
develop and expand only during pregnancy – after involution, the glands remodel back, 
resembling a nulliparous state (145). While in human breast lobules can have a different 
estrogen or progesterone status, in mouse glands, large regions of estrogen positive and 
progesterone positive luminal cells are rare (145). Another difference is observed in the 
stroma, which is predominantly composed of adipose tissue in mice, containing only 
small amounts of fibrous tissue that is more dominant in the human breast (146). While 
primary metastatic sites of breast cancer cells in humans are the bone, brain and lungs, 
cancer cells in mice metastasize primarily to the lungs, which likely comes from certain 
differences in predominant vascular routes (141). 
Nonetheless, mouse and human mammary glands still display many similarities. Their 
basic structural and functional characteristics were found to be very similar: luminal 
epithelial cells and the myoepithelial layer, expressing specific markers, lay on the 
basement membrane that separates them from stromal components. Besides 
correlations found in this study, other analyses of mouse and human transcriptomes 
showed conservation of many genes and pathways, validating the utilization of mouse 
models in studying human breast cancer (147). 
Tetracycline-regulated mouse models are widely used. Besides enabling fast and 
reversible oncogene expression, they are commercially available, easy to use and have 
minimal toxicity (140). Upon de-induction, tumors regress to a nonpalpable state, 
reflecting the oncogene addiction that is observed in many human cancers in the clinics, 
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as well as the escape from therapy, survival and regression, which was also 
demonstrated in our mouse model (119). This feature makes it especially valuable as a 
tool to study MRD, with potential novel markers that could be further verified in 
samples/databases from human patients and potentially translated a clinical setting.  
4.2 A MULTI-OMICS APPROACH FOR STUDYING MINIMAL RESIDUAL 
DISEASE 
Development of high-throughput methods and advanced bioinformatic tools have offered 
exciting possibilities to explore many different aspects of cancer. Recent technological 
advancements have resulted in the rapid generation of large, multivariant and complex 
datasets followed by the emergence of different -omics disciplines (aiming for the 
analysis of “all constituents considered collectively”, i.e. “ome”) (148). Besides 
established fields like genomics, transcriptomics, proteomics and metabolomics, new 
subdisciplines such as lipidomics, fluxomics, secretomics and pharmacogenomics keep 
unfolding, leading to more specific datasets and growing complexity. Interpretation and 
integration of the –omics data thus requires engagement and collaboration of different 
experts from their respective areas. 
As no single –omics approach can give us a full picture and understanding of the 
complicated biological system as a whole, thus employing a multi-omics approach yields 
an overall systemic grasp of key processes underlying such complexity. Linking multi-
omics datasets together is greatly helped by the existence of publicly available, curated 
databases which allow mapping the findings from various –omics disciplines back to 
annotated genes that have been greatly characterized and described, along with their 
biological function.  
A need for integrative approaches is imposed by the fact that the cell/organism is an 
integrated system and should be observed as such. 
Changes in cancer occur on many different levels: genetic, transcriptional, protein, 
metabolic and interactions of the whole molecular network. This makes cancer a highly 
complex disease, with multiple different molecular systems at play. Therefore, this 
requires a holistic view and a multi-omics approach (149). This is why efforts to 
understand cancer include engagement of different –omics technologies that are widely 
applied in the fundamental research of cancer. Similarly, this is now also applied in a 
clinical setting, from the discovery of differentially expressed genes important in 
tumorigenesis to a range of biomarkers and drug targets (149).  
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Residual cells in MRD are also entities that needs to be looked as a system. In attempt 
to reveal its potential vulnerabilities and uncover its elusive features, we looked at its 
transcriptome, metabolome, lipidome and methylome. We took the same approach in 
characterizing normal and tumor cells for the comparison. This resulted in generating 
the following datasets for residual (OFF), tumor (DOX) and normal (NI) cell populations:  
• RNA-sequencing data, 
• metabolic profiles from untargeted metabolomics (ions and tentative 
annotations) acquired through LCMS, 
• metabolic profiles (precisely identified metabolites) acquired through GCMS, 
• lipid profiles (lipid categories, classes and species) acquired through shotgun 
lipidomics, 
• DNA-methylation profiles acquired through bisulfite-free sequencing. 
However, integrating –omics datasets is a challenging task as currently there are no 
routine and organized methods for integration, analysis and interpretation of multi-omics 
data. The integration is mainly achieved through interdisciplinary approaches and 
collaboration between biologists and bioinformaticians. While gene expression profiles 
provide easier interpretation, as transcriptomics established itself as one of the oldest 
and well-explored –omics disciplines, understanding the metabolome is more difficult. 
Challenges in interpretation and analysis of metabolic datasets are posed by the fact 
that metabolomics is still a relatively new discipline, with a lack of annotated metabolites 
in publicly available databases that would enable mapping them and also an absence of 
tools that provide a direct link between each metabolite and transcript. Integrating these 
big datasets is a challenging work, but also rewarding, as it identifies interesting and 
invaluable pieces of puzzle in uncovering many biological questions.  
To get an idea of the global profiles of residual and tumor states, as well their relation 
to each other and the controls in terms of differences or similarities, we employed 
Principal Component Analysis and hierarchical clustering. Pathways characteristic for 
MRD and primary tumor in comparison to the normal state, were revealed through 
enrichment analyses. We looked at the datasets conceptually, analyzing the 
transcriptome and metabolome individually, then comparing the obtained information 
and interpreting them together for a system overview. While the value of this approach 
comes from getting the details from different levels of information, there is a risk that 
some associations might be missed if the different datasets are not analyzed together 
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(150). This can be overcome by employing statistical analysis of multi-omics data, i.e. 
using methods that look for statistical associations between components of different –
omics datasets (150). 
We extended our analyses to examining lipid profiles in the residual cells, with the goal 
of gaining additional knowledge about the system. Namely, lipids have role in many 
cellular processes and are also implicated in major diseases. Although lipidomics 
emerges as a valuable approach, especially with the development of high-throughput 
platforms, challenges in interpreting lipidomic datasets remain, as it is one of the 
youngest disciplines still in development. Further advancement of bioinformatic tools for 
interpretation of this specific datasets holds a promise for better understanding of many 
biological processes involving lipid molecules. 
Looking at the metabolome brought us closer to biochemistry of the cell, while 
transcriptome and metabolite predictions provided a more detailed overview, giving us 
a full picture of gene expression changes and potential targets in MRD. In addition, 
lipidomic analyses extended our knowledge on the characteristics of the residual cells, 
while assessing DNA methylation profiles will help us in preliminary testing of our 
hypothesis regarding the molecular mechanism driving metabolic memory. Overall, 
exploring MRD from different angles was a powerful combination that provided us with 
complementary information and a global map of changes in our biological system. 
Employing this approach allowed us to obtain a comprehensive metabolic landscape of 
MRD and identify metabolic vulnerabilities of potential significance in eradication or 
prevention of recurrent tumors. 
4.3 THE METABOLIC LANDSCAPE OF THE RESIDUAL CELL POPULATION 
Residual cells that remain in the body in undetectable levels, representing MRD, have 
the potential to eventually give rise to tumor recurrence which can be lethal. Even though 
it is clear that understanding their biology and revealing their vulnerabilities is of utmost 
importance, difficulties to obtain and follow them limit our knowledge. Thus, to 
characterize this elusive cell population, we employed inducible mouse models of breast 
cancer and primary 3D cultures of mammary organoids, which allowed us to study the 
residual cells upon oncogene inactivation. As we knew that these residual cells were able 
to drive relapses (119) and our microarray data suggested that altered metabolism could 
be at play, we hypothesized that metabolic reprogramming established during 
oncogenesis could be carried over into residual cells, leaving them with metabolic 
features that set them apart from normal mammary epithelial cells. This would possibly 
 106 
 
DISCUSSION 
prime them with a tumorigenic potential and lead to subsequent recurrences, but could 
be also used as a target that could be selectively hit. We showed that, despite the 
phenotypic similarity to the normal cell population, the residual cells exhibited a distinct 
transcriptional and lipid profile that distinguishes them from normal, but also from the 
tumor cells (described in Chapter 3.3 and 3.7). Strikingly, their metabolic profiles were 
similar to tumors, despite apparent normal, repolarized and non-proliferative 
phenotypes, and the absence of oncogene expression (described in Chapter 3.4). We 
identified increased flux through glycolysis, the urea cycle and increase NOS activity as 
the main metabolic hallmarks present in the tumor and preserved in the residual cells, 
also verified in vivo. Furthermore, we found that these alterations seem to be a feature 
of a basal-like HER2 negative and positive breast cancer subtypes, based on the 
comparison of microarray datasets from the residual cells of the patients undergone 
neoadjuvant treatment and normal tissue from the healthy women (described in Chapter 
3.6).    
4.3.1  Despite phenotypic similarities, the residual population is different from 
its normal counterpart in its transcriptional and lipid profile 
In order to characterize the residual structures starting from their appearance to their 
gene expression profiles, we employed immunofluorescence and RNA-sequencing. This 
showed us that the residual cell population was phenotypically very similar to the control: 
structures regressed back to the monolayered acinus, repolarizing and establishing the 
contact with the basement membrane. Cells were non-proliferative, in the state of 
dormancy, as was shown by low Ki67 positivity (119) and downregulated cell division 
processes seen from the GO Enrichment terms. Moreover, the driver oncogenes, MYC 
and Her2/Neu were inactivated, as was demonstrated at the MYC protein level and 
through gene expression profiles for both of the oncogenes. 
Despite the phenotypic similarity to the normal structures, transcriptionally, residual 
cells exhibited a distinct profile, that distinguished them from both the tumor and normal 
populations. In addition, PCA based on lipidomic data obtained from normal, tumor and 
residual cells, revealed differences in their lipid profiles. The clustering of these three 
groups was strikingly similar to the clustering observed on the transcriptomic level.  
GO enrichment analysis based on transcriptomics data showed that residual cells differ 
from normal cells mostly in the downregulation of cell division and cell cycle, signaling, 
response to stimuli and cell communication, as well as the upregulation of cell adhesion, 
regulation of localization, locomotion, activation of cell surface receptor signaling- and 
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immune-response related pathways, glycolysis, nucleoside metabolism, nucleotide 
phosphorylation and metabolic processes related to ATP generation.  
The upregulation of locomotion, cell adhesion and epithelial cell differentiation in the 
residual population probably reflects the movements of the cells during tumor 
regression, their reintegration into the single rim, repolarization and restoration of 
contacts with the basement membrane (extracellular matrix). Residual cells apparently 
need to re-establish these contacts for their survival, as they lost oncogenic activity that 
could otherwise prevent anoikis.  
Interestingly, despite this reintegration into a phenotypically normal-looking rim, cell 
communication was still downregulated, as in tumor cells. Absence of cell-cell 
communication or its dysregulation is also observed in many human cancer cells and is 
indicative of aberrations in intracellular signaling pathways (151) and possible alterations 
in the composition of the cell membrane. Indeed, GO enrichment of downregulated 
processes indicating cellular compartment revealed changes impinging on the plasma 
membrane and cell periphery contacts. Thus, further exploring changed or aberrant 
communication patterns in the residual cell layer would be needed, as it could be 
important in the later progression of MRD to tumor recurrence.  
Surprisingly, certain metabolic processes were also upregulated in the residual cells, 
indicating higher flux through glycolysis, purine metabolism, nucleotide phosphorylation 
and ATP generation. While glycolysis is usually upregulated in the proliferating cells 
mostly for the generation of intermediates for biosynthesis, residual cells are non-
proliferative so it is not likely to remain enhanced for this particular reason. Purine 
metabolism is also important for the production of building blocks, but also generation 
of co-factors which promote cell survival, which could be its potential role in the residual 
cells (152). As research in acute lymphoblastic leukemia shows that purine biosynthesis 
plays an important role in drug resistance and relapse (153), it would be interesting to 
explore it further in the context of MRD in breast cancer. Nucleotide phosphorylation 
could be potentially important in signaling events that would enable the survival or 
adaptation of residual cells in response to the deactivation of oncogene signaling. 
Increased ATP metabolism could be a consequence of enhanced flux through glycolysis. 
Overall, altered biological processes obtained from RNA-Seq data of residual and tumor 
cells compared to the normal cells, pointed out to some key differences between the 
residual and tumor population. Moreover, residual cell populations, compared to tumor 
cells, display large phenotypic differences: while tumor structures have a filled lumen as 
a result of uncontrolled proliferation, residual structures have their lumen cleared upon 
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regression. Additionally, they are repolarized, dormant and in contact with the basement 
membrane. Besides this, the most important distinction is the lack of oncogene 
expression in the residual cells after oncogene inactivation. This is consistent with the 
TetO-MYC/TetO-KrasG12D/MMTV-rtTA model (118). The rapid regression of the tumor 
reflects the phenomenon of oncogene dependence, described in mouse models, but also 
seen in the clinical setting, where interference with the single driver oncogene represents 
the basis of targeted therapies, such as is the case with EGFR inhibition in NSCLC (17). 
Survival of the residual cells means that they were able to escape oncogene addiction, 
establishing pro-survival signals despite the absence of oncogene signaling. Regression 
to a single rim and the establishment of communication with the basement membrane 
could be crucial for survival, as a study on the TetO-MYC/TetO-KrasG12D/MMTV-rtTA 
system shows that most of the internal cells lose their mitochondrial potential, which 
leads to caspase-3-dependent apoptosis; this, however, does not seem to affect cells 
that are directly attached to the matrix (118).   
Although residual structures regress back to a single rim and seemingly restore their 
polarity, as seen from the immunofluorescent stains and transcriptionally upregulated 
pathways related to cell-adhesion, lipidomics data suggest that this restoration might 
not be fully back to the normal state, as their lipid– and, thus, possibly membrane 
composition is different. At the level of lipid species, many differences were observed, 
even within classes that were not altered between the residual, normal and tumor cells. 
Particularly interesting features include a shift from short to long chained fatty acids in 
sphingomyelin and ceramide species and depletion of arachidonic acid species in the 
phosphatidylethanolamine class. In addition, genes encoding some of the enzymes 
involved in these processes showed high overexpression levels in comparison to the 
residual cells. It could be that the similar pattern in transcriptomic and lipidomic PCA 
plots reflects alterations in specific genes that could lead to changes in the lipid 
composition. The observed alterations in the length of fatty acids might indicate changes 
in membrane fluidity. 
4.3.2  Despite phenotypic differences and absence of oncogene signaling, 
residual population shows similarity to the tumor in its metabolic profile 
Strikingly, despite obvious differences between tumor and residual cells (in their 
phenotype, proliferative state and oncogene expression), untargeted, broad 
metabolomics (Q-Exactive MS) demonstrated a similarity in their metabolic profiles. 
These two populations showed clear clustering from the normal cells based on the 
hierarchical bi-clustering of detected intracellular ions. Potential effects that doxycycline 
could have had on this clustering was excluded, as the wild type controls (non-inducible 
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cells, lacking the rtTA inducer, treated by doxycycline) clustered together with the 
normal, never induced cells. Metabolic enrichment analysis based on intracellular ions 
revealed significant enrichment in sugar and amino-acid metabolism.  
The separation of the three states (normal, tumor and residual) based on hierarchical 
bi-clustering was not clear in case of measured extracellular ions, probably due to the 
fact that many non-significant metabolites in the media were detected which did not 
necessarily reflect true biology of the samples and contributed to the extracellular noise. 
This was also reflected in the metabolic enrichment, as there were no significantly 
changed pathways.  
Our observation of the metabolic similarity between residual and tumor cells was further 
confirmed by GCMS, which is generally referred to as a more precise method. PCA 
plotting and the heatmap based on 54 measured intracellular metabolites showed co-
clustering of the residual cell population with the tumor, reflecting some kind of 
metabolic memory in the residual cells. Similar results were observed from the PCA plot 
and a heatmap done on the 30 measured extracellular metabolites, where the residual 
population was closer to the tumor than to normal cells, but still exhibited a distinct 
profile. This could be a result of other metabolic differences, alternative metabolic routes 
and fuels, and the proliferative status of the cell.  
To our knowledge, this is the first study that showed overall metabolic similarities 
between tumor and residual cells, hinting to some kind of metabolic memory. Data from 
experiments in vivo back up the idea that this is not simply a transient phenomenon. 
Regressed glands, 9 weeks after oncogene inactivation, displayed differences in 
comparison with the healthy glands from age-matched control animals. In this context 
it is important to mention that the cells in the mammary gland undergo hormonal 
stimulus induced proliferation and remodeling every 5 days (duration of the hormonal 
cycle in a female mouse). Therefore, the metabolic similarity of residual disease to the 
tumor state was preserved despite several cycles of tissue remodeling in vivo. 
Taken together, we propose that the metabolic changes, arising from the initial 
oncogenic signaling, might establish another layer of regulation that could even surpass 
the initial oncogene addiction, rendering the cell dependent on the metabolic network. 
4.3.3  Metabolic changes in the residual cells 
Untargeted metabolomics revealed metabolic differences between residual, normal and 
tumor cells. While some ions could not be annotated and many dipeptides found, the 
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most significantly changed intracellular ions in residual cells were annotated to the 
following metabolites: leucine, proline, succinic acid, methionine and AMP found in higher 
levels and 5,10-methenyltetrahydrofolic acid found in lower levels in residual (as well as 
tumor) cells compared to the control. Increased levels of proline, succinic acid and 
methionine might indicate epigenetic changes. Proline can serve as an alternative energy 
source in the times of stressful conditions as its specific degradation generates ATP and 
ROS that can lead to epigenetic reprogramming (154). Besides being an intermediate 
metabolism of TCA cycle, succinate emerges as an interesting oncometabolite as, when 
found in pathologically higher amount, can drive tumorigenesis and epigenetic changes 
(155).  
Extracellular levels of lactic acid were elevated in the residual and tumor cells, indicating 
a glycolytic flux towards lactate production instead of pyruvate. Low levels of arginine 
and high levels of ornithine in residual and tumor cells hint towards alterations in arginine 
metabolism and the urea cycle. In addition, among the significantly changed metabolites 
we also found ribose 1,5-bisphosphate, one of the pentose phosphate pathway 
metabolites, which was, interestingly, much lower in the residual cells compared to both 
tumor and normal, indicating potential relevance of this pathway in the residual cells. 
Indeed, microarray data from our residual cells pointed to the upregulation of this 
pathway (119) and reliance of residual cells on the enhanced PPP was also observed in 
epithelial ovarian CSCs (156). Since residual cells in our system show elevated levels of 
ROS (119), the significance of upregulated PPP could be due to the generation of NADPH 
which is needed for coping with the oxidative stress.  
The advantage of employing untargeted metabolomics was that we could obtain a wide 
picture and global profiles as there were thousands of measured ions. However, the 
limitation was that these metabolites could not be precisely identified as the method 
generates tentative annotations. Thus, measurements obtained from untargeted 
metabolomics hold a potential for exploring these changes in the future, with the high-
throughput platforms and growing datasets that will enable better metabolite 
identification. This could eventually reveal novel metabolic biomarkers, as we identified 
many dramatic changes in the ions that could not be annotated. Putative annotations 
made interpretation of these data difficult, but this is where additional measurements 
by the GCMS and the transcriptome profiles obtained from RNA-Seq data could help gain 
a better understanding of the observed metabolic changes.  
Trying to put the altered metabolite levels into perspective by exploring the literature 
and conceptually looking at the potentially relevant genes from RNA-Seq data revealed 
that in some cases, the observed metabolic change could be linked with the specific gene 
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changes in both residual and tumor cells. For instance, a higher amount of adenosine 
monophosphate (AMP) was found in both residual and tumor cells as compared to the 
normal. A study exploring potential metabolic biomarkers using cancer cell lines 
identified AMP as one of the six most prominent, significantly upregulated metabolites 
in cancer cells (157). On a transcriptional level, we observed alterations in AMP metabolic 
processes, especially in the expression of Ak4, Ak3 and 5'-nucleotidase genes (Nt5e) in 
both tumor and residual cells. However, in other cases, the change in a specific 
metabolite observed both in tumor and residual cells could be linked to the upregulated 
genes only in the tumor cells. Naturally, there are many limitations in this approach, as 
it is impossible to have a complete overview of many genes that could be driving changes 
in many alternative pathways leading to the same result. While this is the most obvious 
explanation, it is also interesting to remember the differences in transcriptomic profiles 
between the two populations, even when the PCA was based only on the metabolic 
genes. While on the transcriptional level, residual cells exhibit a unique profile that 
differentiates them from the tumor and control, on the metabolic level, they are closer 
to the tumor. Several reasons could be the reason for this observation. Most 
transcriptomic differences could probably be attributed to the activation of the MYC and 
Neu oncogenes (MYC alone exerts 10,6 times higher gene expression) and their 
downstream genes. The extent of the gene expression changes in the tumor is thus 
much greater than in the residual cells, which lack the oncogene signaling. The 
expression of around 5000 genes was changed exclusively in the tumor, and doing the 
PCA only on this subset of genes results in the same clustering as compared to when all 
the genes are taken into account (from communication with Katharina Zirngibl, PhD 
candidate, Patil group, EMBL, University of Heidelberg), which provides quite a strong 
argument for this explanation. Furthermore, residual cells restore normal expression of 
portion of genes after the driver signal is gone. For example, the residual structures are 
able to repolarize, re-establish signaling, and re-establish contact with the basement 
membrane and ECM. Therefore, reintegrating in the surviving rim and restoring 
expression of genes regulating these processes could be largely responsible for clustering 
of residual cells away from tumor in the PCA comparison. To test this assumption, we 
plan to do the PCA on the subset of such genes. Some of the genes were changed only 
in the residual cells (communication with Katharina Zirngibl), setting them apart from 
both tumor and normal. This signature is probably a reflection of engaging alternative 
pathways and survival adaptations or stress following silencing of the oncogenes and 
reflecting the resulting “oncogenic shock” (oncogene withdrawal). Another explanation 
for the distinctive transcriptional, yet similar metabolic profiles of the tumor and residual 
cells, could come from the fact that, among the genes changed in both the residual and 
tumor cells, expression levels were much more dramatically altered in the tumor for 
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metabolic signaling pathways. However, even less pronounced changes in the 
transcriptome of the residual cells could lead to similar changes in the enzymes that 
bring forward an altered metabolic network, compared to the normal cells. As a result, 
residual and tumor cells would display similarly dysregulated metabolic networks that 
could arise from the portion of genes that were epigenetically changed during 
tumorgenesis and remained differentially expressed, despite the absence of oncogenes, 
thus exerting some kind of a “memory”. When the PCA analysis is performed taking the 
genes that are found differentially expressed both in tumor and residual cells, the 
residual population clusters closer to the tumor, but still independently (communication 
with Katharina Zirngibl). This shows that the residual population, while still exhibiting a 
specific transcriptional profile, does preserve the subset of changes established in the 
transcriptome from the tumor state. This could contribute to the similarity in some main 
metabolic features. Furthermore, the established metabolic network could drive further 
changes and represent another layer of regulation.  
The heatmap of 54 measured intracellular metabolites by GCMS showed that tumor and 
residual cells formed an obvious cluster distinguishing themselves from the healthy 
controls (never induces and wild-type cells treated with doxycycline). Around one third 
of detected intracellular metabolites were changed in the residual and tumor population 
compared to the normal cells. The Over-Representation Analysis on these changed 
metabolites revealed that the observed changes could reflect alterations mostly in sugar- 
and amino acid metabolism, but also in metabolism of certain lipids. From the 30 
detected extracellular metabolites, half of them were significantly changed between the 
three populations – here, residual cells exhibited a more distinctive profile with 
metabolite levels somewhere in between tumor and normal. This is probably a result of 
the previously discussed differences about the levels of the changed enzymes, 
inactivation of the oncogene signaling and thus decreased uptake of certain metabolites 
such as glutamine, which are not needed to that extent as there is no need to support 
proliferation. 
Although GCMS measurements hinted at the most probable metabolic alterations, the 
limitation of this approach is that these metabolite levels are just a “shot” in time, making 
it difficult to assume the possible fluxes and dynamic changes. Still, looking at the levels 
of the key metabolites intra- and extracellularly, gave us ideas about the consumed and 
secreted metabolites: levels of extracellular glucose were much lower in residual and 
tumor cells compared to the controls and levels of intracellular glucose were also lower, 
indicating its higher uptake and utilization. Levels of lactate were high both intra- and 
extracellularly in tumor and residual cells, highlighting its production from glycolysis and 
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excretion from the cell. The same was observed for proline, ornithine and urea. 
Putrescine, a polyamine that is normally produced in small amount in the normal cells, 
was found to be lower intracellularly, but in higher amount extracellularly in the tumor 
and residual cells, which probably reflects its increased export.   
Overall, these metabolic changes indicated that the alterations in the residual cells 
mainly happen in the glycolysis and urea cycle. To explore this hypothesis further, we 
combined transcriptomic and metabolic datasets with metabolite predictions that 
generated an overview of dysregulated processes, allowing the comparison of residual 
cell features with the normal and tumor cells. 
4.3.4  Data integration reveals enhanced glycolysis, urea cycle and NOS2 activity 
as the main metabolic features preserved in the residual cells 
Overlay of the KEGG reactions and metabolic predictions inferred from RNA-Seq data 
with the actual measured metabolites revealed metabolic changes in the tumor cells in 
compared to normal reflected metabolic features typical of cancer: enhanced glycolytic 
flux towards lactate, upregulated TCA cycle, alterations in fatty- and amino acid 
metabolism. Upregulated glycolysis provides tumor cells with the intermediates for 
biosynthesis. Enhanced TCA cycle ensures that these cells meet their energy demands. 
Decreased levels of palmitate and stearate could be the result of the upregulated fatty 
acid oxidation as alternative source of energy. Increased levels of many amino acids 
reflect anabolic metabolism. The upregulation of urea cycle was a surprising, novel 
finding. In addition, changes in glutathione and methionine metabolism and SAM to SAH 
conversion could indicate epigenetic changes.  
The same overlay done on the residual cells revealed that, despite inactivation of the 
oncogene and their non-proliferative state, residual cells still preserve enhanced 
glycolysis and urea cycle. In addition, they exhibit metabolic alterations in TCA cycle, 
amino acid-, lipid and glutathione metabolism in comparison to the normal cells. 
Increased uptake of glucose, upregulated flux through glycolytic pathway and higher 
excretion of lactate found both in tumor and residual cells highlight the Warburg effect 
(aerobic glycolysis). Aerobic glycolysis is important and not surprising feature of many 
tumor cells – it fuels their growth and proliferation, as it provides many important 
intermediates for biosynthesis and maintenance of redox homeostasis (83,91). However, 
residual cells are non-proliferative, without these demands. What could then be a benefit 
and significance of Warburg effect in MRD and do all residual cells exhibit it?  
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Reports on residual cells’ metabolism have been mainly based on research done on 
cancer stem cells (CSCs) that, besides being slow cycling and having self-renewing 
capacities, exhibit high resistance to therapy and thus are considered to be a main 
“reservoir” of MRD. The Warburg effect is not a universal feature of the residual cell 
population. Quite the contrary, CSCs appear to rely more on mitochondrial metabolism- 
consuming more O2, displaying increased mitochondrial mass, membrane potential and 
high mitochondrial ROS levels (158). The breast CSC populations characterized by a high 
mitochondrial mass are more efficient in the formation of mammospheres, tumor 
initiation in vivo and resistance to paclitaxel (159). Increase in mitochondrial mass was 
also shown in primary human breast CSCs from metastatic breast cancer samples or a 
patient derived xenograft (PDX) (159). An active antioxidant response seems to keep 
the levels of ROS in control (158). 
Highly active mitochondrial metabolism is also seen in lung cancer, glioblastoma (160) 
and colon cancer stem cells (161). Its importance for survival is demonstrated in the 
model of PDAC upon oncogene ablation. This residual dormant cell population displayed 
dependence on OXPHOS and autophagy that enabled their survival  in an unfavorable 
microenvironment (162). Cells with the ability to metastasize often have to rely on other 
sources of energy, mitochondrial activity and peroxide signaling (163).  
While dependence on OXPHOS seems to be characteristic for CSC, other studies report 
that the Warburg effect and reliance on glycolysis is seen in CSC population in breast, 
lung and ovarian cancer, osteosarcoma, glioblastoma (158), nasopharyngeal carcinoma 
radioresistant cells and hepatocellular carcinoma TICs (160). These contradictory 
findings, sometimes reported even in same tumor types, could be explained by different 
microenvironmental and experimental conditions, cells’ differentiation status, 
emergence of different CSCs subpopulations (epithelial- or mesenchymal-like) and 
overall tumor heterogeneity that would be reflected in engaging different metabolic 
solutions (158).  
Several studies indicate the reason why CSC population could favor glycolysis. In CSCs 
derived from human breast cancer tissues increased activity of key glycolytic enzymes 
is needed to maintain stemness phenotype and cellular redox homeostasis (164), as 
mitochondrial ROS could affect stemness through inhibition of β–catenin signaling (165). 
In stem-like spheroids obtained from ovarian cancer, glycolysis plays a role in resistance 
to apoptosis, providing survival in very hypoxic environment, making the tumor 
aggressive (166). In stem-like U87 glioblastoma cells, where mitochondrial metabolism 
is suppressed, glycolysis represents a compensatory mechanism (167). In our system, 
the favoring of glycolysis over mitochondrial respiration could be a way to keep redox 
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homeostasis, since our previous study has shown that the residual cell population copes 
with the oxidative stress as high levels of ROS come as a product of enhanced lipid 
metabolism (119). Another reason could be rooted in the need of residual cells to 
rearrange and reestablish focal adhesions and contact with ECM, as a recent study found 
glycolysis to be necessary for the cellular movement in breast and prostate cancer cells 
(168). Moreover, glycolytic intermediates are not just necessary for proliferation but also 
for generation of other important molecules such as NADPH, as seen in quiescent 
fibroblasts. Even though enhanced glycolysis was previously not considered to be a 
feature of quiescent cells, the latter study demonstrates that this is not always 
necessarily the case (169). 
Dysregulated urea cycle is another interesting pathway that emerged in both tumor and 
residual cells. This pathway is used for conversion of toxic ammonia (waste from protein 
degradation) to urea and is mainly active in the liver. The role of the urea cycle in MRD 
is unknown and only recently started to emerge as being dysregulated in cancer cells, 
where it is linked with anabolic processes through providing nitrogen (170). In the 
residual cells, enhanced urea cycle could be a cell’s way to deal with the excess products 
that might be a consequence of changed abnormal signaling, a leftover from tumor state. 
Interestingly, another enzyme involved in arginine metabolism, NOS2, catalyzing 
synthesis of nitric oxide (NO), was highly upregulated on transcriptomic level. The role 
of NOS2 in cancer is still unclear. In breast cancer lacking ER, NOS2 is found to be 
frequently upregulated and associated with poor prognosis (171). However, its role in 
MRD remains unknown. As NO is involved in many processes, it could modulate the 
tumor microenvironment, promoting tumor progression. 
Upregulated glycolysis and urea cycle, as well as Nos2 overexpression were preserved 
even 7 days after oncogene expression was switched off, hinting to a long-term effect 
rather than a reflection of a temporary state in the cell’s rewiring back to normal. This 
was confirmed by in vivo experiments performed on the mammary glands that were 
taken 9 weeks after inactivation of the oncogenes.  
Knowledge on metabolic properties of residual cells mainly comes from studies on CSCs. 
While they certainly provide important insights into characteristics and potential 
vulnerabilities of MRD, there are uncertainties revolving around CSC concept: a need for 
more specific markers, some contradictory reports on their phenotype and the results 
from xenograft transplant assays, as well as open questions about their significance in 
clinical practice (112). Since specific markers for CSCs are still not well defined, the 
existence of other residual subpopulations that have not been studied yet, is likely; the 
specific environmental conditions and different selective pressure could also drive the 
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evolution of clones with not necessarily stem-like features or stem cell origin that capable 
of surviving the treatment. In this regard, our research on the residual cell population 
obtained upon inactivation of MYC and Neu/Her2 oncogenes relevant in human breast 
cancer is unique and provides additional knowledge on MRD. 
In summary, enhanced glycolysis and urea cycle/arginine metabolism, found in tumor 
cells, seem to be preserved pathways in the residual cells and upregulated in comparison 
with normal cells. Therefore, the overexpressed genes involving key enzymes in these 
processes would be worthwhile exploring as potentially interesting therapeutic targets. 
4.3.5  Correlation with human datasets of MRD reveals potential relevance of 
these findings in the patients’ settings 
To understand the significance of upregulated glycolysis and urea cycle, as well as 
enhanced NOS2 activity in MRD in human breast cancer, two different microarray 
datasets (publicly available) were analyzed. The datasets included: tumor (pre-
treatment), residual (post-treatment) and normal (from healthy women) tissue samples. 
PCA showed that they clustered in three separate groups reflecting the general pattern 
from our in vitro data. We also saw that samples from different tumor types clustered 
together, despite differences in their molecular biology and chosen treatments. This 
indicates that the residual cell population as a whole, irrespective of the heterogeneity 
within, possesses distinct features on the transcriptional level. It could be that the 
residual cells are indeed intrinsically different, smaller subpopulation, highlighting the 
problem of tumor heterogeneity and posing the need for finding better therapeutic 
combinations, aimed not just at the bulk of the tumor, but eradication of all the cancer 
cells within. Another possibility is that the residual cell population encompasses cells that 
were able to evolve under the selective pressure of the applied therapy, adjusting and 
surviving the harsh conditions, lingering in the body in the dormant state. Overall, the 
clustering of the analyzed human samples showed that the residual cells were different 
form the primary tumor, yet still with tumorigenic potential as they were also not normal 
cells. However, it would be interesting to see if the metabolic profiles of MRD would 
exhibit the similarity to the tumor. If so, this would highlight the importance of designing 
good and selective metabolic drugs.  
Comparison of the differentially expressed genes between the residual (post-treatment) 
basal subtype and normal samples revealed the upregulation of several genes involved 
in glycolysis and urea cycle/arginine metabolism. The basal subtype group was chosen 
because it showed the closest clustering to the mouse dataset. This is in agreement with 
the studies correlating mouse and human breast tumors which show that mouse 
 117 
 
DISCUSSION 
mammary tumors with MYC overexpression are close to the human basal-like breast 
cancer subtype (143). In our analysis, mouse dataset was even closer to the particular 
basal Her2+ sample, which was not surprising since both MYC and Her2 were activated 
during tumorigenesis. In basal Her2+ sample we identified ASS1, ARG1, NOS, HK2 and 
LDH as upregulated genes matching the mouse genes involved in glycolysis and urea 
cycle/arginine metabolism. 
From the mouse genes involved in glycolysis and urea cycle that we identified as 
potential targets, upregulation of ASS1, ARG1, NOS, HK2 and LDH was found in this 
subtype. Unfortunately, basal Her2+ group was represented with only one sample in the 
dataset, which poses the need for evaluating these findings on higher number of 
samples. However, these alterations, although to a lesser extent (ASS1, GAPDH, ENO 
and LDH upregulated) were found in basal Her2 negative samples. It could be that these 
features are indeed specific for this subtype, as altered glycolysis was not found in 
luminal A and B samples. This is consistent with the findings in tumors where glycolysis 
seems to be the feature of basal-like and HER2-enriched tumors (172). 
4.4 METABOLIC TARGETS IN MINIMAL RESIDUAL DISEASE 
Inter- and intratumor heterogeneity represents a major hurdle in cancer treatment. 
Heterogeneity stems from different levels – gene mutations, different patterns of gene 
expression and different interactions with the microenvironment. While metabolic 
heterogeneity also exists, looking for the vulnerabilities on the metabolic level might 
help to reduce this immense complexity to a smaller number of metabolic solutions and 
metabolic nodes at the intersections of major metabolic pathways crucial for the survival 
of cancer cells.  
Treating the MRD on the metabolic level could eventually lead to prevention or delay of 
tumor recurrences, as some studies show success in interfering with metabolic pathways 
in the residual population:  
• metformin leads to loss of stemness traits in CSCs dependent on mitochondrial 
metabolism (158);  
• inhibition of EMT and loss of stem-like properties in breast cancer cells is achieved 
through application of a wide spectrum antibiotic, doxycycline (173);  
• another novel synthetic-lethal approach through combined therapy with 
doxycycline and vitamin C showed efficacy in targeting CSCs  (174);  
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• drugs aimed at glycolytic enzymes and transporters could be applied in treatment 
of residual cells with glycolytic profiles (175);  
• utilization of ROS scavengers lowered the DNA damage and application of 
mifepristone halted hormone-driven proliferation leading to a delay of tumor 
relapse in a mouse model (119). 
Exploring metabolic landscape of MRD in breast cancer model helped us identify several 
potential vulnerabilities of the residual cells (summarized in Figure 51), mainly enhanced 
glycolysis, urea cycle and NOS2 activity.  
 
Figure 51: Potential targets in MRD 
The identified metabolic features, characteristic for MRD, were also partly mirrored 
within the tumor cells, but different and distinct from metabolism of the normal cells. 
Therefore, this opens the possibility for selectively hitting residual and tumor cells with 
the metabolic therapy. Since increased glycolysis is also a feature of some normal cell 
types, the challenge in finding the proper therapeutic window remains. With this regard, 
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targeting HK2 could be one interesting option since this isoform is characteristic for 
cancer cells and expressed in only a few normal cell types) and inhibitors for HK2 already 
exist. Interfering with the glycolysis at its end reaction with LDH inhibitors or inhibitors 
of lactate transport could be another therapeutic option. Finally, we believe that the 
metabolites of urea cycle could be potentially significant as biomarkers (such as 
putrescine which is already used as biomarker for some cancers) for monitoring the MRD 
with the development of very sensitive methods as well as the potential targets, 
especially since it is not found in many other cell types. Still, finding a therapeutic window 
that would spare the liver as a main organ where urea cycle is very active, will pose a 
further challenge. 
4.5 IS THERE A METABOLIC MEMORY IN THE RESIDUAL CELLS? 
Since residual cells are so profoundly changed, having a distinct transcriptional and lipid 
profile and metabolic hallmarks similar to tumor cells, we refer to this phenomenon as 
“metabolic memory”. This is substantiated by the fact that we profiled these cells 7 days 
after oncogenes were inactivated in our 3D cultures and 9 weeks following oncogene 
inactivation in vivo. Moreover, in our previous study, the key features of deregulated 
lipid metabolism were also verified in mouse tissues of the regressed gland long after 
oncogene signaling and the patients’ samples after neoadjuvant treatment (119). 
Concept of metabolic memory is used to described a phenomenon observed in diabetes 
– prolonged exposure to high glucose levels leads to diabetic complications even after 
its control has been successfully achieved by therapy (176), while early and aggressive 
treatment reduces this risk. Similarly, it could be that the prolonged exposure to the 
oncogenic metabolic changes establishes the memory, preventing the cells to return to 
their normal, physiological state even in the absence of oncogene signaling.  
As metabolic reprogramming takes place during tumorigenesis, we hypothesized that 
there is a threshold, a “point of no return”, when these changes leave a profound effect 
on the cellular network. While majority of cells in our 3D culture die upon oncogene 
withdrawal, this was not the case with the cells that were exposed to oncogene action 
for a shorter time (60 hours instead of usual 5 days). Seeing this different response, we 
thought that these cells would be able to return to the normal state. We followed the 
phenotypes using IF and collected the RNA from 8 timepoints during tumorigenesis and 
9 timepoints during tumor regression, which enabled us to closely follow these 
processes. Initial analysis of the first three replicates showed us that, despite initial 
differences in the response to oncogene inactivation, 7 days after oncogene inactivation 
cells that were exposed to oncogenes for 60 hours in the end clustered together with the 
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ones from the parallel experiment (longer exposure, 5 days). Seeing this made us 
introduce another experimental condition, where the oncogenes would be switched off 
even earlier (after 36 hours). We termed the three conditions as late, mid and early 
regression (described in Chapter 3.8). In the early regression we observed the same 
response to oncogene withdrawal as in the mid regression (no apparent cell death, just 
reintegration in the existing rim). PCA plot based on the RNA-Seq data obtained from 
the many timepoints during oncogenesis and regression demonstrated that the early 
regression cells seem to eventually return to the normal state (after being exposed to 
oncogene action for 36 hours). Thus, we identified this as the “point of no return” after 
which metabolic memory is exerted.  
This opened several questions. First, what are the major metabolic events in the tumor 
progression and what could be the metabolic processes important in their survival? The 
comparison of the kinetics of oncogenesis leading to 36 hours, 60 hours and 5 days, with 
enrichment of metabolic pathways (analysis in progress), could potentially identify 
processes possibly important in leaving the “legacy”, a memory that would change these 
cells so profoundly, preventing its return to the normal state. In the same way, zooming 
in the differences between the three regression trajectories (early, mid, late) could 
reveal features or targets crucial in their survival.  
On the other hand, looking at the endpoints (residual cells 7 days after oncogene 
withdrawal only) in comparison to the normal cells and one another, would help detect 
changes important in establishing the future tumorigenic potential of residual cells; their 
ability to subsequently drive tumor recurrence. This could help filter out the noise that 
could be coming from other confounding processes causing changes with respect to the 
normal cells. 
Another relevant question remaining to be answered is if the “early regression” cells 
really restore their metabolism, as indicated in their transcriptomic profiles. To test this, 
we measured their metabolic profiles in vitro and in vivo. Analysis of this data is in 
progress and will provide an important clue about the oncogene exposure effect and 
establishment of metabolic memory.  
Nevertheless, we have first indications from our mouse colony: Kaplan-Meier curve 
showed that the mice that had been exposed shorter to the oncogene action (5-10 days 
versus 4-6 weeks) had significantly less relapse cases, indicating that these cells indeed 
have the ability to rewire to their normal state, establishing normal metabolic features. 
Overall, this highlights the need for better diagnostic tools or biomarkers able to detect 
breast tumors in the earlier stages of development. 
 121 
 
DISCUSSION 
Probably the most pressing question is: which molecular entity is the driver of metabolic 
memory? As metabolites play a part in epigenetic processes, we hypothesize that 
epigenetic changes are behind the phenomenon of metabolic memory. Interestingly, 
many genes encoding enzymes involved in epigenetic processes (such as DNA 
methyltransferases) were upregulated upon oncogene activation. This directed us to 
obtain the DNA methylation profiles from residual, tumor and normal cells. In addition, 
mechanisms explored in diabetic metabolic memory point to the DNA methylation (177). 
We obtained DNA methylation profiles by employing a new method of bisulfite-free 
sequencing. Data analysis is in progress. Comparison of the residual cells with the normal 
cells could show the extent of methylation changes, while the comparison with tumor 
cells could indicate if the specific methylation patterns were already established in the 
tumor state and preserved in residual, providing a first proof for epigenetic mechanism 
behind oncogenic memory.  
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4.6 FUTURE PERSPECTIVES 
To answer the questions raised in Chapter 4.5, the following experiments were 
performed and data was collected (summarized in Table 6). The results of the 
bioinformatic and GCMS analysis were not available at the point of this thesis submission.  
Table 6: Summary of the experiments in progress 
Data 
collection 
 
Experimental data 
 
Perspective 
Data 
analysis 
Oct 2016 
Mid-regression (60h-
7 days) kinetics: 
RNA Seq and IF 
images 
GO terms and metabolic enrichment 
to reveal important metabolic 
pathways changing along the kinetics 
of mid-regression 
Bioinformatic 
analysis 
ongoing 
Oct 2016 
- 
Nov 2017 
Early regression 
(36h-7 days) kinetics 
- RNA Seq and IF 
images 
GO terms and metabolic enrichment 
to reveal important metabolic 
pathways changing along the kinetics 
of early-regression 
Bioinformatic 
analysis 
ongoing 
Oct 2016 
- 
Nov 2017 
5d-60h-36h 
regression 
trajectories 
- RNA Seq 
comparison of late-, mid- and early 
regression trajectories to filter out 
the most important metabolic 
changes  
Bioinformatic 
analysis 
ongoing 
Oct 2016 
- 
Nov 2017 
RNA Seq 
+ GCMS 
+ untargeted MS 
+ lipidomics 
building a model based on RNA Seq 
data with measured metabolic 
constraints to predict the fluxes 
Bioinformatic 
analysis 
ongoing 
Oct 2016 
- 
Nov 2017 
RNA Seq 
+ GCMS  
+ untargeted MS  
+ lipidomics 
statistical integration of all the 
available datasets using MOFA; 
further integration at the pathway-
level; Metscape analysis 
Bioinformatic 
analysis 
ongoing 
Nov 2017 
- 
Oct 2018 
GCMS 
measurements 
obtaining metabolic picture of early 
regression endpoint/testing if there is 
a metabolic signature in vitro 
GCMS  
analysis 
ongoing 
Nov 2017 
- 
Jun 2018 
DNA methylome  
- bisulfite free 
- sequencing 
testing the concept of metabolic 
memory through analysis of DNA 
methylome 
Bioinformatic 
analysis 
ongoing 
Oct 2017 
- 
Oct 2018 
GCMS, 13C glucose 
labelling, NOS assay 
obtaining metabolic picture of early 
regression endpoint/testing if there is 
a metabolic signature in vivo 
GCMS  
analysis 
ongoing 
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The analysis of the collected data will help us to better understand the metabolic changes 
during tumor progression and their potential significance in the regression and survival 
of the residual cells. Transcriptomic and metabolomic data integration and overlay of the 
profiles of residual cells that were exposed to oncogene action for the different time 
periods, will point to processes that could be of relevance in tumor recurrence. 
Furthermore, metabolic profiles of the residual cells that were exposed to oncogene 
signaling for a short time, obtained from in vitro and in vivo experiments, will provide 
an answer about whether the transcriptomic differences observed are also reflected on 
a metabolic level, compared with other time points. Comparison of the three regression 
trajectories could highlight the pathways important for survival of these cells upon 
oncogene silencing and their potential relevance in escaping oncogene addiction. A 
model based on the RNA-sequencing data, with the constraints from metabolic 
measurements, will enable the flux predictions and improve our understanding of the 
metabolic picture in MRD. Further statistical integration of all the available datasets will 
bring another level of validation and could help to reveal other potentially interesting 
targets. DNA methylome analysis will shed a light on our hypothesis of epigenetic 
changes behind the observed metabolic memory. 
To further understand the role of enhanced glycolysis, urea cycle and NOS2 activity in 
MRD, we plan to perform the experiments where we would interfere with these features 
using the inhibitors (summarized in Table 7).  
The readout of these experiments would be:  
1) untargeted and targeted metabolomics analyses,  
2) viability assays, 
3) and cell death assays. 
Metabolomics analyses could reveal possible alterations of metabolic profiles in these 
cells as a result of interference with the targets; whether they would be able to switch 
to the alternative metabolic pathways and, if so, which routes they would engage.  
Viability and cell death assays would be used to reflect if there is an addiction of the 
residual cells to the observed processes and if targeting these pathways would eradicate 
the residual cells. After the in vitro experiments, we would eventually test the successful 
inhibitors in vivo. 
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Table 7: Planned experiments for interference with the observed targets in MRD 
Planned experiments Inhibitors Readout 
Interference with 
glycolysis 
GSK28378088 
3-bromopyruvate 
acriflavine  
1. untargeted metabolomics / GCMS 
 
2. viability assays 
 
3. cell death assays 
 
Interference with the 
urea cycle 
AIAP 
ABH Ammonium salt 
Interference with NOS2  GER 11 
Piperidine 
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CONCLUSIONS 
Using a multi-omics approach, we have characterized the refractory, residual cell 
population that was left following oncogene inactivation in the breast tumor cells. To 
model this cellular state, we employed a tractable mouse model and primary mammary 
cells derived from those mice, which were grown in a 3D cell culture system. 
Despite displaying a seemingly normal phenotype, residual cell populations exhibited a 
distinct transcriptional profile, in comparison to normal cells. Nevertheless, changes on 
the transcriptomic level also differed from the tumor state, indicating a unique nature of 
the residual cells. 
The lipidomic profile of residual cells was also unique, hinting at overall changes in the 
cell phenotype, which were also reflected in the lipid composition.  
The overall metabolic profile of residual cells bore resemblance to the tumor, in contrast 
to the differences observed on the transcriptional and lipid level. Residual cells retained 
some metabolic features that were also found pronounced in the tumor state and 
therefore seemed to be preserved long after oncogene inactivation. This reflects the 
profound and vast effect of the changes during tumor progression and alterations in the 
metabolic network, implying the existence of “metabolic memory”. This phenomenon, 
particularly its potential driver, needs to be further understood. We hypothesize that 
these features are established through an altered epigenetic landscape. 
Enhanced glycolysis, urea cycle and NOS2 activity were the most prominent features 
preserved in the residual cells. Moreover, these traits could be particularly important in 
the MRD of basal HER2 positive and HER2 negative breast cancer subtypes. The observed 
metabolic differences between the residual and normal cells should be further explored 
and could provide an interesting insight into metabolic nodes that serve as potential 
interference points against MRD. Interference of these metabolic nodes could potentially 
be used in a therapeutic setting. 
The kinetic analysis of oncogenesis and the respective phases that led to tumor 
regression indicated that the length of exposure to oncogene action could have a 
significant effect. It could equip the residual cells with a mutagenic potential, which could 
develop into a tumorigenic potential over a longer time period, enabling the cells to form 
recurrent tumors. Consequently, the detailed molecular profiles that we obtained using 
the tractable 3D culture system of MRD formation might have clinical relevance in the 
future. One possible application might be their use in further classifying tumor staging. 
This could be valuable because of the importance of early breast cancer detection, and 
the need for more sensitive diagnostic procedures.     
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6.1 ANIMALS 
Breeding and maintenance of mouse colony was done in LAR (Laboratory Animal 
Resources) facility of EMBL Heidelberg, under veterinarian supervision and in accordance 
to the guidelines of the European Commission, revised Directive 2010/63/EU and AVMA 
Guidelines 2007. Animals were kept on a 12-hour light/12-hour dark cycle, with constant 
ambient temperature (23±1°C) and humidity (60±8%), with pellet food and water ad 
libitum. Food pellets containing doxycycline (doxycycline hyclate 625 mg/kg) were 
obtained from Envigo Teklad. 
The mouse strain used was TetO-cMYC/TetO-Neu/MMTV-rtTA (121) in FVB background. 
Genotypes of the animals were determined by PCR on genomic DNA from the tail tissue, 
obtained by tail-digestion in 75 µl of digestion buffer (NaOH 25 mM + EDTA 0,2 mM) at 
98oC followed by addition of 75 µl Tris-HCl (40 mM, pH 5,5) and centrifugation at 4000 
rpm for 3 min, whereby 1 µl of the supernatant was used in the PCR reaction. Reagents 
used for PCR are summarized in the Table 8 with primer sequences provided in Table 9 
and PCR programs in Table 10. Agarose gel-electrophoresis was used for the detection 
of PCR products (MYC 630 bp, Neu 386 bp, rtTA 380 bp), which was done on the 1,5 % 
agarose (Sigma, A9539-500G) gel with Ethidium bromide solution in a final 
concentration of 0,5 µg/ml (Sigma, E1510-10ML). The products were visualized using 
Quantum-Capt1 documentation system + instrument (Peqlab). 
Table 8: PCR components for genotyping 
Reaction component Final concentration 
Primer F (Forward) 0,25 pMol/µl 
Primer R (Reverse) 0,25 pMol/µl 
dNTP mix 200 µM 
Enzyme (Taq polimerase by EMBL) 1 U/20 µl 
Dream Taq Buffer (ThermoFisher Scientific, B71) 1x 
 
Table 9: Primer sequences for genotyping of TetO-Myc/TetO-Neu/MMTV-rtTA animals 
Primer   Forward sequence Reverse sequence 
TetO-MYC  TAG TGA ACC GTC AGA TCG CCT G TTT GAT GAA GGT CTC GTC GTC C 
TetO-Neu  GACTCTCTCTCCTGCGAAGAATGG CCTCACATTGCCAAAAGACGG 
CMV-rtTA 
 
GTGAAGTGGGTCCGCGTACAG GTACTCGTCAATTCCAAGGGCATCG 
 
 
 129 
 
MATERIALS AND METHODS 
Table 10: PCR programs for TetO-Myc/TetO-Neu/MMTV-rtTA 
  TetO-MYC   TetO-Neu   MMTV-rtTA 
Step T T   T t   T t 
1 94oC 3 min   95oC 1 min   94oC 5 min 
2 94oC 10 s   95oC 15 s   94oC 30 s 
3 62oC 30 s   64oC 15 s   57oC 30 s 
4 68oC 1:30 min   72oC 1:30 min   72oC 30 s 
5 94oC 10 s   95oC 15 s   72oC 5 min 
6 60oC 30 s   61oC 15 s   10oC hold 
7 68oC 2 min   72oC 1:30 min       
8 72oC 10 min   95oC 15 s       
9 4oC Hold   58oC 15 s       
10       72oC 1:30 min       
11       95oC 15 s       
12       55oC 15 s       
13       72oC 1:30 min       
14       72oC 10 min       
15       10oC hold       
6.1.1  In vitro experiments 
Primary mammary epithelial cells were obtained through harvest of mammary glands 
from 8 weeks old virgin females, whereby mammary gland tissue was digested and 
epithelial cells were selected and cultured in 3D. 
6.1.2  In vivo experiments 
For induction of tumors, food pellets supplemented with doxycycline (625 mg/kg) was 
given to the mice. Animals were weekly monitored for the tumor detection and their 
overall health. Full blown tumors developed in the period of 4-6 weeks. When the tumor 
burden was too large (d=2 cm), animals were given food without doxycycline which 
resulted in the fast tumor regression to a non-palpable state. At the timepoint of the 
complete tumor regression (9 weeks after doxycycline withdrawal, i.e. oncogenes 
deactivation), mammary glands were harvested. Wild-type (non-inducible) siblings were 
given the same food in the exact same fashion. They represented age-matched controls 
and their mammary glands were collected at the same time and in the same manner. 
Before harvesting, animals were also checked for the phase of estrous cycle, by taking 
vaginal smears according to the modified protocol (178): 20-40 ul of 1x Phosphate 
Buffered Saline (PBS) was used to obtain vaginal lavage. The smears were dried on the 
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slide at room temperature and further fixed in 10 % formalin, washed in 1x PBS, stained 
with Crystal Violet solution (Sigma, V5265) washed in tap water and visualized using 
Leica Application Suite X and Leica DFC7000 T microscope (Leica Microsystems).  
To assess the effect on shorter exposure to the oncogenes on metabolic profiles of the 
regressed glands, mice were given doxycycline supplemented food for a period of 10 
days and then returned back to a normal diet. After 10-12 months, mammary glands of 
these animals and corresponding age-matched controls were harvested for the 
experiment. 
For examining if there was a difference between shorter and longer exposure to the 
oncogenes action in the occurrence and time-period of tumor relapses, animals that were 
not taken for the experiment (with their age-matched controls) were weekly monitored 
for the emergence of tumor recurrence. 
6.2 3D CELL CULTURE 
Three-dimensional cell cultures were established according to the published protocol 
(118) with some modifications. Primary mammary epithelial cells were obtained from 8 
weeks old virgin females of described mouse strains, through digestion of mammary 
glands in 5 mL of digestion media (Lonza/Amaxa DMEM/F12 1:1 Mixture with HEPES, L-
Gln, BE12-719F), supplemented with HEPES to the final concentration of 25 mM, 150 
U/mL Collagenase type 3 (Worthington, LS004183), 20 µg/mL Liberase Blendzyme 2 
(Roche, 05401020001) and 5 ml of Penicillin/Streptomycin (Gibco Life Technologies, 
15140-122). After digestion for 15-16 hours at 37oC in 5 % (vol/vol) CO2 atmopshere, 
in loosely capped 50 mL polypropylene conical tubes, washing step with 45 mL of 
phosphate-buffered saline (PBS) was performed. Upon centrifugation at room 
temperature, 1000 rpm for 5 min, interphase between upper fat layer and cell pellet was 
removed and 5 mL of 0.25 % trypsin-EDTA (Invitrogen, 25200-056) was added. 
Suspension was incubated for 40 min at 37oC, 5 % CO2 in loosely capped tubes, followed 
by the wash with 25 mL of STOP media (Lonza/Amaxa DMEM/F12 1:1 Mixture with 
HEPES, L-Gln, BE12-719F supplemented with HEPES to the final concentration of 25 mM 
and 10 % Tet System Approved Fetal Bovine Serum, Biowest, S181T) and treatment 
with 5-15 mg/mL DNase I (ThermoFisher, 18068015). After another centrifugation step 
at room temperature, 1000 rpm for 5 min, dissociated cells were resuspended in MEBM 
media (Lonza, Mammary Epithelial Cell Basal Medium CC-3151 with supplements from 
Mammary Epithelial Cell Medium BulletKit CC-3150) and plated onto collagen-coated 
plates (BD Biosciences, 356400) for selection of epithelial cells. Next day cells were 
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washed with PBS and the remaining ones treated with 500 µl of 0,25 % trypsin-EDTA 
until detachment. Trypsin was inactivated with 9 mL of STOP media (described above), 
followed by centrifugation step at room temperature, 1000 rpm for 5 min. Cell pellets 
were resuspended in PBS, counted, and mixed rapidly on ice with the prepared Matrigel-
collagen mixture – Cultrex 3D Culture Matrix Basement Membrane Extract (Biozol, TRE-
3445-005-01) and 1,5 mg/mL Cultrex 3D Collagen I rat tail (TEMA Ricerca, 3447-020-
01). Mixed droplets in volume of 100 µl containing 12 500 primary mouse mammary 
epithelial cells were dispensed into flat bottom wells (Corning CellBIND 12 Well Clear 
Multiple Well Plates, 3336) or chambered cover glass slides (ThermoFisher Scientific, 
Nunc LabTek II Chambered Cover glass, 155379). After gel solidifying for 35-40 min at 
37oC, 1.5 ml of MEBM serum-free media (supplemented with 2 mL of bovine pituitary 
extract, 0.5 mL of hEGF, 0.5 mL of hydrocortisone, 0.5 mL of GA-1000, 0.5 mL Insulin 
from Mammary Epithelial Cell Medium BulletKit CC-3150) was added to each well. 
Doxycycline (Sigma, Doxycycline hyclate, D9891) was titrated to lower concentration of 
200 ng/ml. For metabolic analyses, from the start of experiment until collection, media 
was used in volume of 1 mL and changed every day at the precise times.   
6.3 IMMUNOFLUORESCENCE 
3D culture gels for immunofluorescence staining were fixed with 4 % paraformaldehyde 
(PFA) for 7-10 min and transferred to the IF deactivated clear glass screw neck vials 
(Waters, 186000989DV). They were washed three times with PBS and once in IF buffer 
(containing NaCl, Na2HPO4, NaN3, BSA, TritonX-100, Tween-20; pH 7,4). Blocking was 
done using 1x IF buffer with 10 % goat serum (Jackson Immuno Research, 005-000-
121) for 1,5 h. Incubation at 4oC overnight was done, with the primary antibodies diluted 
in primary block as described above and washed the next day in 1x IF buffer 3x, 15 min 
each. Incubation with secondary antibodies and 4’, 6’-diamino-2-phenylindole (DAPI) 
was done in the primary block for 1 hour (dilution 1:1000) and followed by the washes 
with 1x IF buffer and 1x PBS, 3 times, 15 min each. Gels were mounted with Vectashield 
Anti-fade mounting medium (Vinci Biochem, VC-H-1500-L010) into LabTek II chamber 
slide (ThermoFisher Scientific, 50733) and imaged on a Leica SP5 confocal microscope 
using 63x water lens and LAS AF imaging software.  
The following antibodies were used for the 3D cultures: alpha-6-integrin (BD Biosciences 
25-0495-82, diluted 1:80), ZO-1 (Invitrogen 61-7300, diluted 1:500), GM-130 (BD 
Biosciences, 610823, diluted 1:100), E-cadherin (Invitrogen, 13-1900, diluted 1:200). 
Nuclei were stained with DAPI (ThermoScientific, 62248, diluted 1:1000). Anti-rabbit, 
anti-mouse, and anti-rat antibodies were purchased coupled with Alexa Fluor dyes from 
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Invitrogen (A21247, A11034, A11036). FFPE tissue sections were stained using the 
standard protocols for the following antibodies: HK2 (ThermoFisher Scientific, PA5-
29326, diluted 1:250), PDK1 (Invitrogen, MA5-15797, diluted 1:200), MCT4 (Santa Cruz 
Biotechnology, sc-376140, diluted 1:50), AK4 (ThermoFisher Scientific, PA5-49333, 
diluted 1:25), LIN28A (LifeSpan BioSciences, LS-B14215, diluted 1:100), ASS1 (Abcam, 
ab170952, diluted 1:50), ARG1 (Novus, NBP1-32731, diluted 1:250) and iNOS 
(ThermoFisher Scientific, PA1-036, diluted 1:100). 
Sections were mounted using ProLong Gold Antifade Mountant (ThermoFisher Scientific, 
P36930) and scanned using TissueFAXS Slides system (TissueGnostics). Quantification 
was done using StrataQuest Analysis Software (TissueGnostics). 
6.4 IMMUNOHISTOCHEMISTRY 
Dissected mammary glands were fixed in 10 % formalin solution, neutral buffered 
(Sigma, HT501128-4L) and subsequently washed with PBS. Tissue sections from FFPE 
samples were obtained by sectioning at 5 µm with RM 2135 microtome (Leica) and 
placing on the Superfrost slides (VWR, 630-0954). If frozen tissue was used for imaging 
mass spectrometry, it was cut at 4-18 µm with cryotome (Leica, CM3050 S). Staining 
by Hematoxylin QS (Vector, H-3404), Eosin 1 % Aqueous (RA Lamb, LAMB/100-D) was 
done following the standard protocol and samples were analyzed at LMD 7000 
microscope (Leica). MT-CO1 antibody (Abcam, ab14705) staining was done on FFPE 
tissue following the standard IHC protocol: deparaffinization and rehydration of the 
samples, followed by antigen retrieval using citric acid-based Antigen unmasking solution 
(Vector, H-3300) for 30 min in a steamer and inactivation of endogenous hydrogen 
peroxidase activity with 10 % H2O2 solution (Sigma, H1009). After this, blocking was 
done using 10 % Normal goat serum (Jackson Immuno Research, 00500121) in 1x 
Phosphate Saline Buffer (PBS). Incubation with primary antibody (MT-CO1 diluted 
1:500) was done in blocking buffer at 4oC overnight, after which the slides were washed 
3x, 5 min each, using 1x PBS. Incubation with biotinylated antibody from Vectastain Elite 
ABC HRP Kit (Peroxidase, Rabbit IgG; Vector Laboratories, PK-6101) was for 30 min, 
followed by washing and incubation with Horse Radish Peroxidase (HRP) conjugated 
antibody and detection using DAB Peroxidase (HRP) Substrate Kit (Vector, SK-4100). 
Counter-staining was done using hematoxylin, after which the sections were dehydrated, 
mounted with DPX Mountant for histology (Sigma, 06522) and analyzed using LMD 7000 
microscope (Leica) equipped with Leica CD310 digital camera and LASV3.7 (Leica) 
software. 
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6.5 QUANTITATIVE REAL-TIME PCR 
Total RNA from the 3D culture gels was extracted using Trizol (Invitrogen, 15596026). 
Complementary DNA (cDNA) was prepared from 200 ng of RNA, using Super Script® III 
Reverse Transcriptase kit (Invitrogen, 18080093). Real-Time PCR reaction was done 
using SYBR Green PCR Master Mix (Applied Biosystems, 4309155), 2 ng of DNA per 
reaction and 10 µM primers. Primer sequences and PCR program is shown in Table 11. 
Runs were performed on a StepOne (Applied Biosystems) machine with technical 
triplicates. The fold changes in gene expression were calculated using the ∆∆Ct method. 
Actin-beta (Actb) was used as a reference. 
Table 11: Primer sequences and program for Real-Time qPCR 
Primer  Forward sequence Reverse sequence 
Actb ATGCCCTGAGGCTCTTTTCC ACGGATGTCAACGTCACACT 
TetO-MYC GCGACTCTGAGGAGGAACAAGA CCAGCAGAAGGTGATCCAGACT 
TetO-Neu CGTTTTGTGGTCATCCAGAACG CTTCAGCGTCTACCAGGTCACC 
      
Program steps Temperature (T) Time (t) 
1 95oC 5 min 
2 95oC 30 s 
3 60oC 1 min 
Repeating steps 2 and 3 for 40 cycles, followed by Melting curve analysis. 
 
6.6 WESTERN BLOT 
3D culture gels were treated for 1,5 hours with collagenase and liberase for Matrigel 
disintegration. The disintegrated gels were collected in 15 ml Falcon tubes, shortly 
centrifuged at 1000 rpm for 5 min and washed in cold 1x PBS (two times; centrifuged 
at 1400 rpm for 4 min at 4oC), followed by pellet resuspension in protein lysis buffer 
(0,5 % sodium deoxycholate, 25 mm Hepes, pH 7,5; 150 mm NaCl, 1% Triton-X-100; 
0,1 % SDS; 5 % glycerol, 2 mm EGTA) prepared with cOmplete protease inhibitor 
cocktail tablets (Roche, 11697498001) and PhosSTOP (Roche, 4906845001). After 20 
min long incubation on ice, samples were centrifuged at 14 000 rpm for 15-30 min at 
4oC. Supernatants were collected and protein concentration measured using Bradford 
assay and BSA standard curve. Protein lysates (volumes corresponding to 30-40 µg of 
protein per well) were mixed with 5 µl of Laemmli buffer (6x) and loaded onto wells for 
SDS-PAGE. Denaturation of protein for MT-CO1 was done at 60oC, in accordance with 
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manufacturer’s instructions. Proteins were separated by SDS-PAGE and blotted onto 
PVDF membrane and stained with MT-CO1 antibody (diluted 1:500 in TBS-Tween 0,3%) 
at 4oC overnight. Beta-tubulin (Cell Signaling, #2146) was used as a reference antibody 
(in dilution 1:1000). The next day, membrane was washed with 0,3 % TBS-Tween and 
incubated with HRP-conjugated secondary antibody (Goat Anti-Mouse IgG, diluted 
1:5000 in TBS-Tween 0,3%) for 1,5 hours at room temperature, followed by washes in 
0,3 % TBS-Tween. The development was done using Amersham ECL Western Blotting 
Detection Reagent (GE Healthcare, RPN2106) and detection using ChemiDocTM Touch 
Imaging System (BioRad). The images were processed in Image J.  
6.7 TRANSCRIPTOMICS 
6.7.1  RNA collection and extraction 
RNA was harvested from a pool of two 3D gels per condition, using 900 µl of mirVana 
lysis buffer, and subsequently extracted using mirVana miRNA Isolation Kit, with phenol 
(Ambion, AM1560). After assessing RNA quality and concentration on Bioanalyzer 
(Agilent 2100, G2939BA), RNA was sequenced in the Genomics Core Facility at EMBL on 
Illumina NextSeq 500 platform, read length NextSeqHigh 75 bp.  
6.7.2  RNA-Seq data analysis 
After assessing the quality of the raw RNA sequencing reads by FastQC version 0.11.3 
(179), adapter trimming using cutadapt version 1.9.1 (180) with default options 
providing the standard Illumina TrueSeq Index adapters was done. FaQCs version 1.34 
(181) was used for subsequent quality trimming and filtering, applying following 
parameters: -q 20 -min L 25 -n 5 -discard 1. This resulted in 34,1 to 52 million total 
reads per sample. Reads were further aligned to the reference genome (mouse-
GRCm38.p4) (182) using Tophat2 version 2.0.10 (183) with the following parameter: -
G -T -x 20 -M - -microexon-search - - nocoverage-search - -no-novel-juncs-mate-std-
dev 100-r 50 -min-segment-intron 20 -I 30 -a6. For differential expression analysis, only 
reads with unique mappings were considered. The count HTSeq python library version 
0.6.1.pl. script (184) with default options was used to obtain gene level count tables. All 
reads mapped in total to 19500-20800 genes and the statistical analysis was done with 
Bioconductor package DESeq2 version 1.12.4 (185). Normalization was done based on 
size-factor to control for batch effects and inter-sample variability. Package defaults were 
used for dispersion estimation and differential expression analysis, which include 
multiple testing correction, independent filtering and cooks cutoff (186) for outlier 
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detection. For comparison of gene expression between residual versus normal cells, 
DESeq2 raw p-values were used as input to fdrtool version 1.2.15 (187) to compute q-
values. Genes with q-value<0,05 were considered as significantly differentially 
expressed. For comparison of gene expression between tumor versus normal cells, 
Bonferroni correction was used for multiple testing correction and genes with padj<0,1 
were considered as significantly differentially expressed. R V.3.3.1. (R Development Core 
Team) was used for conducting biostatistical analyses. For performing dimensionality 
reduction with Principal Component analysis (PCA) and hierarchical clustering rlog 
DESeq2 [109] transformed transcript counts were utilized. For the calculation of the 
ellipses on the PCA plots the “stat ellipse” function from the R package ggplot2 was used 
[66]. 
6.7.3  Enrichment analysis 
1925 of differentially expressed genes in residual cells (compared to never induced 
control; FDR-tool (188) q-value<0,05) and 5274 differentially expressed genes in tumor 
(compared to never induced, padj<0,1, Bonferroni correction for multiple testing)  were 
taken for the GO enrichment analysis. GO enrichment analysis was performed using 
Fisher’s exact test with a foreground of all respective differentially expressed genes and 
a background, which was composed of a unique set of 5 randomly picked genes per 
foreground gene exhibiting a similar expression mean over all samples. The chosen p-
value cutoff was 0,01. Genes, whose transcript levels significantly changed (differentially 
expressed genes) were mapped to biochemical reactions according to the KEGG 
annotation of their encoding enzymes. In case there are multiple enzymes annotated to 
the same reaction, which have a conflicting sign of change, the sign of the gene with the 
strongest log2 fold change is depicted. 
6.7.4  Reporter Metabolite Analysis  
Reporter Metabolite Analysis was done using non-directional class, the distinct-
directional class and the mixed-directional class, using improved model based on the 
HMR2 model (127). Reporter metabolite algorithm, the “piano” R package (128) with 
genes as keys and metabolites as values, was used to identify the metabolic reactions 
likely to be altered. The respective p-value/q-value and log2 FC of the differentially 
expressed genes were used to calculate p-values from a theoretical null distribution 
(10,000 permutations). Multiple testing adjustment was applied using the Benjamini-
Hochberg procedure. The threshold for significance was padj<0,1, but maximally 5 % of 
the total list of tested metabolites. A pathway enrichment was calculated for gene sets 
of 1 gene per group or bigger. 
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6.7.5  Analysis of MRD datasets from patients  
Microarray gene expression datasets from breast cancer patients pre- and post-
treatment (132) and control breast tissue from healthy women (133) were downloaded 
from Gene Expression Omnibus (GEO) (189). Each dataset was first prepared 
independently – filtered for outliers and normalized. Background correction was done 
using “rma” function of the R package “oligo” filtering genes for minimal intensity filtering 
and gene annotation of probe set IDs with the removal of multiple mappings of transcript 
cluster identifiers. Two datasets were then combined and processed (normalized, 
checked for outliers, with genes with low intensities filtered). In order to address the 
batch effect of the joined data stemming from the two experimental settings which 
largely influenced the gene expression, the PC1 was removed from PCA. In addition, due 
to the poorly defined diagnostic category and high biological variability, the “normal-
like” tumor subtype of the patients’ dataset was removed.  
6.8 METABOLOMICS 
6.8.1  Collection and extraction of intracellular and extracellular metabolites 
6.8.1.1  In vitro experiments  
Before proceeding with intracellular metabolites collection, 150 µl of extracellular media 
was taken from the wells of each condition, snap-frozen and stored at -80oC until 
analysis. Organoid structures were then freed from Matrigel upon digestion for 1,5 h at 
37oC with 3 µl of liberase and 3 µl of collagenase added to the media. 3 wells were pooled 
per condition/technical replicate, washed three times with PBS, centrifuged shortly (1000 
rpm, 2 min, room temperature) and quenched by 200 µl cold (-80oC) HPLC-grade 
methanol (Biosolve Chimie, 136841). Validation of effective cell washing before 
quenching was done by comparison of metabolic profiles with 50 µl of the used MEBM 
growth medium of each well and the last washing solution of each sample (quenched 
with 100 µl of cold -80oC HPLC-grade methanol). Extraction of metabolites was done by 
1:1 methanol-water protocol (190–192), with ribitol (Alfa Aesar, 488-81-3) as internal 
standard. For Flow Injection Q-Exactive MS extracellular metabolites were measured in 
extracellular media diluted 1:10. 
6.8.1.2 In vivo experiments  
For glucose labeling experiment, mammary glands were dissected, minced and digested 
for 2 hours at 37oC using collagenase and liberase enzymes, then were cultured for 8 
hours at 37oC in 5 % (vol/vol) CO2 atmopshere, in DMEM glucose- and pyruvate-free 
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media (ThermoFisher Scientific, 11966025) supplemented with 4,5 g/L labeled D-
Glucose U-13C, 99% (Cambridge Isotope Laboratories, Inc., CLM-1396-1) and 2 mL of 
bovine pituitary extract, 0.5 mL of hEGF, 0.5 mL of hydrocortisone, 0.5 mL of GA-1000, 
0.5 mL insulin from Mammary Epithelial Cell Medium BulletKit CC-3150. For non-labeled 
GCMS metabolomics experiment, mammary glands were dissected and cultured for 8 
hours at 37oC in 5 % (vol/vol) CO2 atmosphere, in DMEM, High Glucose (4,5 g/L glucose) 
GlutaMAX (Gibco, 10569044) supplemented with 2 mL of bovine pituitary extract, 0.5 
mL of hEGF, 0.5 mL of hydrocortisone, 0.5 mL of GA-1000, 0.5 mL insulin from Mammary 
Epithelial Cell Medium BulletKit CC-3150. Extracellular metabolites were collected and 
snap-frozen in liquid nitrogen; for intracellular metabolites harvesting, cells were quickly 
washed two times in PBS and quenched with cold methanol. Metabolites were extracted 
using 1:1 methanol-water protocol (190–192), with ribitol (Alfa Aesar, 488-81-3) as 
internal standard.  
6.8.2  Untargeted metabolomics by Flow Injection Q-Exactive MS 
High-throughput discovery metabolomics was modified from the method by Fuhrer et al. 
(193). The LC/MS platform used consists of liquid chromatography system 
(ThermoFisher Scientific Ultimate 3000) with autosampler temperature set to 10oC which 
is coupled to a Q-Exactive Plus Fourier transform mass spectrometer (ThermoFisher 
Scientific) equipped with a heated electrospray ion source. The machine was operated 
in negative ionization mode, with isocratic flow rate of 150 µl/min of mobile phase (60:40 
% (v/v) isopropanol:water buffered with 1mM ammonium fluoride at pH 9; with 10nM 
taurocholic acid and 20 nM homotaurine as lock masses). Recording of mass spectra was 
done in profile mode from 50 to 1000 m/z. Instrument was adjusted to the following 
settings: sheath gas 35 a.u.; aux gas 10 a.u.; aux gas heater 200oC; sweep gas 1 a.u.; 
spray voltage -3kV; capillary temperature 250oC; S-lens RF level 50 a.u.; resolution 70k 
@ 200 m/z; AGC target 3x106 ions, max. injection time 120 ms; acquisition duration 
60s. An automated pipeline in R was used for spectral data processing. Tentative 
annotation of detected ions as metabolites was done using the Human Metabolome 
Database (HMDB) as a reference, assuming [M-H] and [M-2H] as ionization options and 
the exchange of one or two 13C with the equivalent number of 13C atoms with the 
method-inherent disability to distinguish between isomers.  
6.8.3 GCMS analysis 
Upon drying, metabolite extracts were derivatized to their (MeOx) TMS-derivatives: 1) 
with 50 uL of 20 mg/mL methoxyamine hydrochloride (Alfa Aesar, 593-56-6) solution in 
pyridine (SigmaAldrich, 437611) for 90 min at 40oC, 2) with 100 ul N-methyl-
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trimethylsilyl-trifluoroacetamide (MSTFA) (Alfa Aesar, 24589-78-4), for 12 hours at 
room temperature (192,194). Upon derivatization (after 12 hours), metabolic profiles of 
samples were measured using a Shimadzu TQ8050 GCMS (triple quadrupole) system 
(Shimadzu Corp.), equipped with gas chromatograph with a 30 m x 0,25 mm x 0,25 µm 
DB-50 MS capillary column (Phenomenex, USA) and detector operated both in scan 
mode (recording in the range of 50-600 m/z) and MRM mode. Samples were normalized 
to ribitol as an internal standard and total metabolite levels (TML).  
For experiment using labelled glucose, metabolites were dried and derivatized to their 
(MeOx) TMS-derivatives: 1) with 50 µL of 20 mg/mL methoxyamine hydrochloride (Alfa 
Aesar, 593-56-6) solution in pyridine (SigmaAldrich, 437611) for 90 min at 40oC, 2) with 
100 µl N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1 % tert-
Butyldimethylchlorosilane (Sigma Aldrich, 00942) for 1 hour at 60oC and 12 hours at 
room temperature (192,194) and further processed as previously described.  
Calculations of p-values were done using Linear Models for Microarray Data (limma) 
(195) and Benjamini-Hochberg adjustment method. 
6.8.4 . Lipidomics analysis 
Modified Bligh & Dyer protocol (196) was used for lipid extraction. Samples were 
analysed by direct infusion nano-ESI MS, using Qtrap 6500 + coupled with a NanoMate 
(Sciex). Samples were normalized to 100 % (mol %) of total lipid. 
6.8.5 NOS enzymatic assay 
Mammary glands were dissected and homogenized in NOS assay buffer and further 
processed following the Nitric Oxide Synthase Activity Assay kit (Abcam, ab211083) 
protocol for measuring enzymatic activity of nitric oxide synthase (NOS). 
6.8.6 DNA methylome analysis 
Following digestion of the Matrigel with collagenase and liberase, DNA was collected from 
the 3D cultures and extracted following Qiagen protocol for cultured cells (Qiagen Blood 
& Cell Culture DNA Mini kit, 13323). Bisulfite-free sequencing was performed at the 
Genomics Core Facility at EMBL Heidelberg.  
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Figure 52: Ions detected by untargeted metabolomics Q-Exactive MS and data quality control. Top 
left: Consistency of intracellular raw ion detection across injections; Top right: Number of curated 
intracellular ions annotated as metabolites; Bottom left: Consistency of extracellular raw ion 
detection across injections; Bottom right: Number of curated intracellular ions annotated as 
metabolites 
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Figure 54: Other significantly changed metabolites measured in vivo 
Figure 53: PCA on a subset of metabolic genes 
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Figure 55: IF stains protein verification in the regressed mammary gland tissue and healthy tissues 
of the age-matched controls, for: A) Lin28A; B) AK4; C) NOS2.  
On the left side are given percentages of positive cells for the respective proteins; on the right – 
mean intensity of fluorescence in positive cells. 
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Figure 56: IF stains protein verification in the regressed mammary gland tissue and healthy tissues 
of the age-matched controls, for: A) PDK1; B) ASS1. 
On the left side are given percentages of positive cells for the respective proteins; on the right – 
mean intensity of fluorescence in positive cells. 
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Figure 57: Altered gene expression encoding enzymes involved in arginine metabolism (urea cycle, 
NO synthesis) in basal HER2 negative breast cancer subtype sample. Pathway map was adapted 
from KEGG pathway database (17). Abbreviations are explained in the List of Abbreviations. 
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Figure 58: Altered gene expression encoding enzymes involved in glycolysis in basal HER2 negative 
breast cancer subtype sample. Pathway map was adapted from KEGG pathway database (17). 
Abbreviations are explained in the List of Abbreviations. 
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Figure 59: Changes in lipid composition in measured lipid classes between tumor (DOX) and 
normal (NI) populations. Error bars represent Mean ± 1SE. Abbreviations are explained in the List 
of Abbreviations. 
 
Figure 60: Changes in lipid composition in measured lipid classes between tumor (DOX) and 
residual (OFF) populations. Error bars represent Mean ± 1SE. Abbreviations are explained in the 
List of Abbreviations. 
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Figure 61: Changes in the lipid species within the class of PE between residual and normal cells. 
Error bars represent Mean ± 1SE. Abbreviations are explained in the List of Abbreviations. 
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Figure 62: Metabolites detected by IMS. A) Comparison in number of annotations between the 
freshly frozen and PFA-treated samples, at FDR 0,2; B) Total number of annotations per class at 
FDR 0,2; C) Representation of all detected classes  
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ATP   adenosine triphosphate 
Bak   Bcl-2 homologous antagonist/killer 
Bax   BCL2 associated X, apoptosis regulator 
Bcl-2   B-cell lymphoma 2 
BGP   beta-galactosidase-like protein 
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LIST OF ABBREVIATIONS 
Bim   Bcl-2-like protein 11 
BRAF   v-raf murine sarcoma viral oncogene homolog B1 
BRCA1   breast cancer 1, early onset 
CAF-1   chromatin assembly factor 1 
CAFs   cancer associated fibroblasts 
CAV1   caveolin-1 
CDH1   E-cadherin 
CE   cholesteryl ester 
Cer   ceramide 
Chol   cholesterol 
CPS1   carbamoyl phosphate synthetase 
CPT1   carnitine palmitoyltransferase 1 
CSC-like  cancer stem cell-like 
CTCs   circulating tumor cells 
CUP   cancer of unknown primary 
DAG   diacylglycerol 
DAPI     4′,6-diamidino-2-phenylindole  
DCA   dichloroacetate 
DCIS   ductal carcinoma in situ 
ddPCR   droplet digital PCR 
DHAP   dihydroacetone phosphate acyltransferase, isoform A 
DHFR   dihydrofolate reductase gene 
DM1   emtansine 
DNA   deoxyribonucleic acid 
dNTP   deoxyribonucleotide triphosphate 
Dox   doxycycline 
DTCs   disseminated tumor cells 
ECM   extracellular matrix 
EGFL7   epidermal growth factor-like domain 7 
EGFR   epidermal growth factor receptor 
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LIST OF ABBREVIATIONS 
EMT   epithelial-mesenchymal transition 
ENO   enolase  
ER   estrogen receptor 
ERK   extracellular signal–regulated kinase 
ETC   electron-transport chain 
F6P   fructose 6-phosphate 
FADH   reduced flavin adenine dinucleotide 
FADH2   reduced flavin adenine dinucleotide, hydroquinone form 
FAO   fatty acid oxidation 
FASN   fatty acid synthase 
FBP   fructose-1,6-bisphosphate 
FDG-PET   2-[18F] fluoro-2-deoxy-D-glucose positron-emission tomography 
FDR   false discovery rate 
FFPE   formalin-fixed paraffin-embedded  
FH   fumarate hydratase 
G6P   glucose 6-phosphate 
G6PD   glucose-6-phosphate dehydrogenase 
G6PGLD  6-phosphogluconate dehydrogenase 
GABA   gamma-aminobutyric acid 
GAP   glyceraldehyde 3-phopshate 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GCK   glucokinase 
GCMS   gas chromatography-mass spectrometry 
GDH   glutamate dehydrogenase  
 
TIC   tumor initiating cells 
GER 11  aminoguanidine hydrochloride 
GL   glycerolipids 
GLB1   galactosidase beta 1 
GLS   glutaminase 
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LIST OF ABBREVIATIONS 
Glu   glutamine 
Glucose-6-P  glucose-6-phosphate 
GLUD   glutamate dehydrogenase 
GLUL   glutamate-ammonia ligase 
GLUT   glucose transporter 
GM-130  Golgi matrix protein 
GO    Gene Ontology 
GOT   aspartate aminotransferase, cytoplasmic 
GP   glycerophospholipids 
HBV   hepatitis B virus 
HCV   hepatitis C virus 
HER2    human epidermal growth factor receptor 2  
Hex2Cer  dihexosylceramide 
HexCer  hexosylceramide 
Hexose-P  hexose-phosphate 
HGF   hepatocyte growth factor 
HIF1   hypoxia-inducible factor 
HIPCs   hormone-independent prostate cancer 
HK2   hexokinase 2 
HMR2   Human Metabolic Atlas 2 
HPV   human papillomavirus 
IDC   invasive ductal carcinoma 
IDH1   isocitrate dehydrogenase 1 
IDH2   isocitrate dehydrogenase 1 
IF   immunofluorescence  
IGF1R   the insulin-like growth factor 1 receptor 
IHC   immunohistochemistry 
IMS   imaging mass spectrometry 
iNOS   inducible nitric oxide synthase 
ITGA6   alpha-6 integrin 
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LIST OF ABBREVIATIONS 
JHDMS  Jumonji-C domain histone demethylases 
KEGG   Kyoto Encyclopedia of Genes and Genomes 
Ki67   marker of proliferation Ki67 
LAT1   large neutral amino acids transporter small subunit 1 
LCIS   lobular carcinoma in situ 
LCMS   liquid chromatography-mass spectrometry 
LDH   lactate dehydrogenase 
LDHA   lactate dehydrogenase A 
LIN28A  lin28 homolog A 
LPC   lysophosphatidylcholine 
mAb   monoclonal antibody 
MCT   monocarboxylate transporte 
MCT4   monocarboxylate transporter 4 
Me   methionine 
ME1   malic enzyme 1 
MEK   mitogen-activated protein kinase kinase 
miRNAs  microRNAs 
MMTV-LTR  mouse mammary tumor virus-long terminal repeat 
MRD   minimal residual disease  
MRI   magnetic resonance imaging 
MRSI   magnetic resonance spectroscopy imaging 
MS   mass spectrometry 
MT-CO1  mitochondrial cytochrome c oxidase subunit 1 
mTOR   mammalian target of rapamycin  
MYC   V-myc avian myelocytomatosis viral oncogene homolog 
NAD+   nicotinamide adenine dinucleotide 
NADH   reduced nicotinamide adenine dinucleotide 
NADP+  nicotinamide adenine dinucleotide phosphate 
NADPH  nicotinamide adenine dinucleotide phosphate 
NAGS   N-acetylglutamate synthase 
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LIST OF ABBREVIATIONS 
nano-ESI MS  nano-electrospray ionization mass spectrometry 
NO   nitric oxide 
NOS2   nitric oxide synthase 2 
NSCLC   non-small-cell lung carcinoma 
Nt5e   5'-nucleotidase 
ORA   Over Representation Analysis 
ORNT1   ornithine transporter, mitochondrial 
OTC   ornithine transcarbamylase 
OXPHOS  oxidative phosphorylation 
p16   p16 protein; cyclin-dependent kinase inhibitor 2A 
p21   p21 protein; cyclin-dependent kinase inhibitor 1 
p27   p27 protein; cyclin-dependent kinase inhibitor 1B 
p53   p53 protein 
PA   phosphatidic acid 
PanIN   pancreatic intraepithelial neoplasia 
PARP   poly ADP ribose polymerase 
PC   phosphatidylcholine 
PC   principal component 
PCA   Principal Component Analysis 
PCR   polymerase chain reaction  
PDAC   pancreatic ductal adenocarcinoma 
PDH (PD)  pyruvate dehydrogenase 
PDHK (PDK)  pyruvate dehydrogenase kinase 
PEP   phopshoenolpyruvic acid 
PFA   paraformaldehyde 
PFK   phosphofructokinase 
PFKFB3  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
PG   phosphatidylglycerol 
PGAM1  phosphoglycerate mutase 1 
PGI   phosphoglucose isomerase 
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LIST OF ABBREVIATIONS 
PGK   phosphoglycerate kinase 1  
PGM   phosphoglycerate mutase 
PI   phosphatidylinositol 
PI3K   phosphoinositide 3-kinase 
PI3KCA  phosphatidylinositol 3-kinase 
piano   Platform for Integrative Analysis of Omics Data 
PK   pyruvate kinase 
PKM2   pyruvate kinase muscle isozyme M2 
PPP   pentose phosphate pathway 
PR   progesteron receptor 
PS   phosphatidylserine 
ptDNA   plasma tumor DNA 
qPCR   quantitative polymerase chain reaction 
RAF   rapidly accelerated fibrosarcoma 
RAS   rat sarcoma  
Ribose-5-P  ribose-5-phosphate 
RNA   ribonucleic acid 
ROS   reactive oxygen species 
rtTA   reverse tetracycline transactivator 
SAH   S-adenosyl homocysteine 
SAM   S-adenosylmethionine 
SCD   stearoyl-CoA desaturase-1 
SCO2   supercritical carbon dioxide cytochrome c oxidase assembly protein 
SDH   succinate dehydrogenase 
SERM   selective estrogen receptor modulators 
SHD   succinate dehydrogenase 
SIRT1   sirtuin 1 
SLC1A5  solute carrier family 1 member 5 
Slc25A13  citrin 
SM   sphingomyelin 
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LIST OF ABBREVIATIONS 
SN2   system N transporter 2 
SP   sphingolipids 
ST   sterol lipids 
TAG   triacylglycerol 
TCA   tricarboxylic acid 
TDLU   terminal ductal lobular unit 
T-DM1   trastuzumab emtansine 
TET   Ten-eleven translocation 
TKI   tyrosine kinase inhibitor 
TME   tumor microenvironment 
TNBC   triple negative breast cancer 
TPI   triosephosphate isomerase 
UCP2   uncoupling protein 2 
UCP3   uncoupling protein 3 
VDAC   voltage-dependent anion channel protein 
VEGF   vascular endothelial growth factor 
WHO   World Health Organization 
ZO-1   Zonula Occludens 1 
 
